PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
37767068,IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.,2023,"Aoki, Ken-Ichi","Chugai Pharmaceutical Ltd., Tokyo, Japan.",None
37650342,Development of a model to predict antidepressant treatment response for depression among Veterans.,2023,"Leung, Lucinda B; Oslin, David W","Center for the Study of Healthcare Innovation, Implementation, and Policy, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.; VISN 4 Mental Illness Research, Education, and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.",None
37503959,Hetnet connectivity search provides rapid insights into how biomedical entities are related.,2022/Dec/28,"Kloster, Kyle; Nagle, Michael W","Carbon, Inc., Redwood City, CA 94063, USA.; Integrative Biology, Internal Medicine Research Unit, Worldwide Research, Development, and Medicine, Pfizer Inc, Cambridge, MA 02139, USA.",None
37484062,Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.,2022,"Wunder, Frank; Dietz, Lisa; Sandner, Peter","Bayer AG, R&D Pharmaceuticals, Wuppertal, Germany.; Bayer AG, R&D Pharmaceuticals, Wuppertal, Germany.; Bayer AG, R&D Pharmaceuticals, Wuppertal, Germany.",None
37082098,Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.,2022,"Xu, Yingxin; Quek, Ruben G W; Kuznik, Andreas; Pouliot, Jean-Francois; Gullo, Giuseppe; Rietschel, Petra","Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.",None
36970056,"Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study.",2022,"Lu, Vickie; Zhou, Xiaofei; Niu, Huifeng; Yanai, Tomoko; Garcia-Ribas, Ignacio","Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.; Oncology Therapeutic Area Unit for Japan and Asia, Takeda Pharmaceutical Company Limited, Osaka, Japan.; Oncology Early Development, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, United States.",None
36970055,A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.,2022,"Shields, David J","Centers for Therapeutic Innovation, Pfizer Inc, New York, New York.",None
36970050,Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.,2022,"Hunneyball, Ian; Whittaker, Mark","Evotec Ltd, Oxfordshire, United Kingdom.; Evotec Ltd, Oxfordshire, United Kingdom.",None
36923307,"A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.",2022,"Bobba, Suresh; Senderowicz, Adrian M; Efuni, Sergey; Rippley, Ronda; Colak, Gozde; Trojer, Patrick","Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.; Constellation Pharmaceuticals (a Morphosys Company), Boston, Massachusetts.",None
36923305,"Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.",2022,"Wang, Yan; Niland, Katie; Arbeit, Robert D; Parasuraman, Sudha; Gan, Lu","X4 Pharmaceuticals, Boston, Massachusetts.; X4 Pharmaceuticals, Boston, Massachusetts.; X4 Pharmaceuticals, Boston, Massachusetts.; X4 Pharmaceuticals, Boston, Massachusetts.; X4 Pharmaceuticals, Boston, Massachusetts.",None
36923281,Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.,2022,"Sax, Nicolas; Yamashita, Kazuo","KOTAI Biotechnologies Inc, Osaka, Japan.; KOTAI Biotechnologies Inc, Osaka, Japan.",None
36922937,The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth ,2022,"Kretzschmar, Warren W","Vanadis Diagnostics, PerkinElmer Inc, Sollentuna, Sweden.",None
36908284,Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer.,2023,"Lux, Michael Patrick","Kooperatives Brustzentrum Paderborn, Frauen- und Kinderklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Paderborn, Germany.",None
36874402,Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.,2022,"Bentley, Trevor; Boldajipour, Bijan; Sommer, Cesar; Sasu, Barbra","Allogene Therapeutics Inc., South San Francisco, California.; Pfizer Inc., South San Francisco, California.; Allogene Therapeutics Inc., South San Francisco, California.; Allogene Therapeutics Inc., South San Francisco, California.",None
36872921,Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab.,2023,"Chen, Ethan; Ma, Ning; Li, Lindong","Product Development Safety, Roche (China) Holding Ltd, Shanghai, China.; Product Development Safety, Genentech, Inc., South San Francisco, California, USA.; Product Development, Roche (China) Holding Ltd, Shanghai, China.",None
36822130,Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.,2023,"Gilloteau, Isabelle; Le Mouhaer, Sylvie; Hampe, Marcio; Cai, Can; Chassot-Agostinho, Andrea","Novartis Services Inc, East Hanover, NJ 07936-1080, USA. Electronic address: isabelle.gilloteau@novartis.com.; Novartis Pharma S.A.S., CS 40150, 92563 Rueil Malmaison Cedex, France. Electronic address: sylvie.le_mouhaer@novartis.com.; Novartis Services Inc, East Hanover, NJ 07936-1080, USA. Electronic address: marcio.hampe@novartis.com.; Novartis Services Inc, East Hanover, NJ 07936-1080, USA. Electronic address: can.cai@novartis.com.; Novartis Pharma S.A.S., CS 40150, 92563 Rueil Malmaison Cedex, France. Electronic address: andrea.chassot_agostinho@novartis.com.",rheist@partners.org.
36798690,End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.,2022,"Izquierdo, Miguel","Novartis Pharmaceutical, Basel, Switzerland.",None
36777185,"Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous population.",2023/Jan/11,"Abbaszadeh, Fatemeh; Badii, Ramin","Hamada Medical Corporation, Doha, Qatar.; Hamada Medical Corporation, Doha, Qatar.",None
36726548,Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies.,2023,"Raval, Amit D; Tang, Yuexin","Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, New Jersey, USA.; Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, New Jersey, USA.",None
36719641,How imaging is changing prostate cancer management - Editorial: Comment l'imagerie peut révolutionner le traitement du cancer de la prostate - Éditorial.,2022,"Kleinclauss, F","CHRU de Besançon, 3 Bd Alexandre Fleming, 25000 Besançon, France. Electronic address: francois.kleinclauss@univ-fcomte.fr.",francois.kleinclauss@univ-fcomte.fr.
36703794,Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region.,2022,"Abdullah, Huda Ismail","Novocure Inc., New York, NY, United States.",None
36702070,Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.,2023,"Foruzan, Navid; DiPrimeo, Daniel; McCulloch, Leanne","Puma Biotechnology Inc., Los Angeles, CA, USA.; Puma Biotechnology Inc., Los Angeles, CA, USA.; Puma Biotechnology Inc., Los Angeles, CA, USA.",arlenechan@me.com.
36682891,Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.,2023,"Song, Yan; Freimark, Jonathan; Berman, Richard; Nguyen, Ha; Signorovitch, James; Sundaram, Murali","Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Analysis Group, Inc., Boston, MA.; Merck & Co., Inc., Kenilworth, NJ.",ejonasch@mdanderson.org.
36661676,LKB1 Loss Assessed by Immunohistochemistry as a Prognostic Marker to First-Line Therapy in Advanced Non-Small-Cell Lung Cancer.,2022/Dec/26,"Avilés-Salas, Alejandro; Díaz-García, Diego A; Lara-Mejía, Luis; Orozco-Morales, Mario; Catalán, Rodrigo; Hernández-Pedro, Norma Y; Rios-Garcia, Eduardo; Ramos-Ramírez, Maritza; Arrieta, Oscar","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Personalized Medicine Laboratory, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.",None
36660210,Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database.,2022,"Bomfim, Giovanni; Saturnino, Luciana Tarbes Mattana; Goncalves, Sarah Carolina; Soler, Roberto","Medical Affairs, Astellas Pharma Brazil, Sao Paulo - SP 04583-110, Brazil.; Medical Affairs, Astellas Pharma Brazil, Sao Paulo - SP 04583-110, Brazil.; Medical Affairs, Astellas Pharma Brazil, Sao Paulo - SP 04583-110, Brazil.; Medical Affairs, Astellas Pharma Brazil, Sao Paulo - SP 04583-110, Brazil.",None
36640618,Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.,2023,"Esdar, Christina; Salmio, Satu; Schroeder, Andreas","Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: christina.esdar@merckgroup.com.; Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: satu.salmio@merckgroup.com.; Merck Healthcare KGaA, Darmstadt, Germany. Electronic address: andreas.schroeder@merckgroup.com.",jean.bourhis@chuv.ch.
36619649,"Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.",2022,"Sandström, Per","Bayer HealthCare Pharmaceuticals, Whippany, NJ, United States.",None
36618900,The iR,2023,"Ping, Jerry; Szafer-Glusman, Edith; Eckert, Karl; Neuenburg, Jutta K","Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.; Pharmacyclics LLC, an AbbVie Company, South San Francisco, CA, USA.",None
36614913,Mobocertinib (TAK-788) in ,2022/Dec/23,"Lin, Huamao M; Goodman, Erin; Mehta, Minal","Takeda Development Center Americas, Inc., Lexington, MA 02421, USA.; Takeda Development Center Americas, Inc., Lexington, MA 02421, USA.; Takeda Development Center Americas, Inc., Lexington, MA 02421, USA.",None
36612153,Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma.,2022/Dec/27,"Rathore, Richa; Sudhaman, Sumedha; George, Giby V; Malashevich, Allyson K; Malhotra, Meenakshi; Liu, Minetta C; Aleshin, Alexey","Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.; Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.; Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.; Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.; Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.; Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.; Natera Inc., 13011A McCallen Pass, Austin, TX 78753, USA.",None
36600653,"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.",2022,"Graf Finckenstein, Friedrich; Jagasia, Madan; Hari, Parameswaran; Sulur, Giri; Shi, Wen; Wu, Xiao","Iovance Biotherapeutics Inc, San Carlos, California, USA.; Iovance Biotherapeutics Inc, San Carlos, California, USA.; Iovance Biotherapeutics Inc, San Carlos, California, USA.; Iovance Biotherapeutics Inc, San Carlos, California, USA.; Iovance Biotherapeutics Inc, San Carlos, California, USA.; Iovance Biotherapeutics Inc, San Carlos, California, USA.",amod.sarnaik@moffitt.org.
36600561,"Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer.",2022,"Miller, Richard A; Hu, Shenshen; Mahabhashyam, Suresh; Jones, William B; Willingham, Stephen B","Corvus Pharmaceuticals Inc, Burlingame, California, USA rmiller@corvuspharma.com.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.; Corvus Pharmaceuticals Inc, Burlingame, California, USA.",rmiller@corvuspharma.com.
36600185,"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.",2023,"Gunay, Levent M; Sugiyama, Naonobu; Connell, Carol A; Wang, Cunshan; Wu, Joseph; Menon, Sujatha; Vranic, Ivana","Pfizer Inc, Istanbul, Turkey.; Pfizer Japan Inc, Tokyo, Japan.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Ltd, Tadworth, UK.",jrcurtis@uabmc.edu.
36591529,Post-operative ctDNA monitoring in stage I colon cancer: A case report.,2022,"Dhani, Harmeet; Palsuledesai, Charuta C; Krinshpun, Shifra; Jurdi, Adham","Natera, Inc., Austin, TX, United States.; Natera, Inc., Austin, TX, United States.; Natera, Inc., Austin, TX, United States.; Natera, Inc., Austin, TX, United States.",None
36581520,[Not Available].,2023,"Laporte, Silvy; Labruyère, Carine; Simon, Tabassome","Inserm, U 1059 Sainbiose, Mines Saint-Étienne, unité de recherche clinique, innovation, pharmacologie, université Jean Monnet, CHU de Saint-Étienne, 42023 Saint-Étienne, France.; Inserm, U 1059 Sainbiose, Mines Saint-Étienne, unité de recherche clinique, innovation, pharmacologie, université Jean Monnet, CHU de Saint-Étienne, 42023 Saint-Étienne, France.; Service de pharmacologie, plateforme de recherche clinique de l'Est parisien, Sorbonne université, Assistance publique-Hôpitaux de Paris, 75012 Paris, France.",MRoustit@chu-grenoble.fr.
36578451,Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.,2023,"Hucke, Florian; Peck-Radosavljevic, Markus","Internal Medicine and Gastroenterology (IMuG), Including Centralized Emergency Service (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.; Internal Medicine and Gastroenterology (IMuG), Including Centralized Emergency Service (ZAE), Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria.",None
36575460,"Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis.",2022/Dec/27,"Thorleifsson, Gudmar; Helgadottir, Anna; Gudbjartsson, Daniel F; Holm, Hilma; Lee, Jong Young; Reilly, Dermot F; Baras, Aris; Thorsteinsdottir, Unnur; Stefansson, Kari; Ho, Yuk-Lam; Chang, Kyong-Mi; Cho, Kelly; O'Donnell, Christopher J; Gaziano, John M","deCODE Genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland.; deCODE Genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland.; deCODE Genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland.; deCODE Genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland.; , Oneomics. Co. Ltd. 2F, Soonchunhyang Mirai Medical Center 173, Buheuyng-Ro, Bucheon-Si Gyeonggi-Do, 14585, Korea.; Genetics, Merck Sharp & Dohme Corp., Kenilworth, NJ, 07033, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; deCODE Genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland.; deCODE Genetics/Amgen, Inc. Sturlugata 8, Reykjavik, 102, Iceland.; VA Boston Healthcare System, Boston, MA, USA.; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.; VA Boston Healthcare System, Boston, MA, USA.",gpeloso@bu.edu.
36568239,Identification of ,2022,"Hicking, Christine; Ihling, Christian","Merck Healthcare KGaA, Darmstadt, Germany.; Merck Healthcare KGaA, Darmstadt, Germany.",None
36564469,"ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study.",2023,"Marschner, Jens-Peter; Alevizopoulos, Konstantinos; Otterlei, Marit","Therapim Pty Ltd, Southport, QLD, Australia. jpmarschner@apimtherapeutics.com.; Therapim Pty Ltd, Southport, QLD, Australia.; Therapim Pty Ltd, Southport, QLD, Australia.",jpmarschner@apimtherapeutics.com.
36564101,Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study.,2022,"Aaltonen, Kalle","ROB-FIN, Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland.",karin.hellgren@ki.se.
36563682,Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia.,2023/Jan/09,"Creger, Emily; McMillan, Elizabeth; Mak, Chi-Ching; Jarvis, Matthew; Bossard, Carine; Beaupre, Darrin M","Biosplice Therapeutics Inc., San Diego, CA, USA.; Biosplice Therapeutics Inc., San Diego, CA, USA.; Biosplice Therapeutics Inc., San Diego, CA, USA.; Biosplice Therapeutics Inc., San Diego, CA, USA.; Biosplice Therapeutics Inc., San Diego, CA, USA.; Biosplice Therapeutics Inc., San Diego, CA, USA.",abdelwao@mskcc.org.
36563604,Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.,2023,"Tonikian, Raffi; Poehlein, Christian","Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ 07065, USA.; Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ 07065, USA.",herzogtj@ucmail.uc.edu.
36563490,Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.,2023,"Foch, Caroline; Esser, Regina; Lamy, Francois-Xavier; Zhang, Aimar","Merck Healthcare KGaA, Darmstadt, Germany.; Merck Healthcare KGaA, Darmstadt, Germany.; Merck Healthcare KGaA, Darmstadt, Germany.; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd, Beijing, China.",stefan.kasper@uk-essen.de.
36562609,Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.,2022/Dec/23,"Doyle, Jana; Greenberg, Jon","Daiichi Sankyo Incorporated, Newark, United States.; Daiichi Sankyo Incorporated, Newark, United States.",None
36562446,CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.,2022/Aug/29,"Cronin, Maureen; Fredriksson, Martin; Sundgren, Mats","Vifor Pharma, Glattbrugg, Switzerland and Ava AG, Zurich, Switzerland.; Late Clinical Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals RD, AstraZeneca, Gothenburg, Sweden.; Data Science AI, Biopharmaceuticals RD, AstraZeneca, Gothenburg, Sweden.",None
36560672,Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).,2022/Nov/29,"Sbarigia, Urbano","Janssen Pharmaceuticals NV, 2340 Beerse, Belgium.",None
36555876,Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas.,2022/Dec/07,"Mardiros, Armen; Xu, Han; Ng, Eric W; Go, William Y; Welch, John S","A2 Biotherapeutics, Agoura Hills, CA 91301, USA.; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.; A2 Biotherapeutics, Agoura Hills, CA 91301, USA.",None
36554068,Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany.,2022/Dec/15,"Jeck, Julia; Franz, Jennifer; Baltin, Christoph T; Kron, Anna; Kron, Florian","VITIS Healthcare Group, Am Morsdorfer Hof 12, 50933 Cologne, Germany.; VITIS Healthcare Group, Am Morsdorfer Hof 12, 50933 Cologne, Germany.; VITIS Healthcare Group, Am Morsdorfer Hof 12, 50933 Cologne, Germany.; VITIS Healthcare Group, Am Morsdorfer Hof 12, 50933 Cologne, Germany.; VITIS Healthcare Group, Am Morsdorfer Hof 12, 50933 Cologne, Germany.",None
36551632,Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.,2022/Dec/13,"Penrod, John R","Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, 3551 Lawrenceville, Princeton Rd, Princeton, NJ 002627, USA.",None
36550413,"Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.",2022/Dec/22,"Niyazov, Alexander","Pfizer Inc, 235 42nd St, New York, NY, 10017, USA.",rmahtani@baptisthealth.net.
36549781,Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.,2022,"Jiang, Ruiyun","Division of Biostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.",brian.rini@vumc.org.
36548927,"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.",2023/Apr/20,"Kilavuz, Nurgul; Chiu, Christopher; Chen, Menghui; Sacchi, Mariana; Elliott, Brian; Ahmadi, Tahamtan","Genmab, Princeton, NJ.; Genmab, Princeton, NJ.; Genmab, Princeton, NJ.; Genmab, Princeton, NJ.; Genmab, Princeton, NJ.; Genmab, Princeton, NJ.",None
36547985,"Estimated Prevalence of Metastatic Breast Cancer in England, 2016-2021.",2022/Dec/01,"Owide, Joshua; Fryer, Kirsty","Wilmington Healthcare Ltd, London, United Kingdom.; Wilmington Healthcare Ltd, London, United Kingdom.",None
36547809,Developing Artificial Intelligence Models for Extracting Oncologic Outcomes from Japanese Electronic Health Records.,2023,"Togo, Kanae; Yonemoto, Naohiro; Ohki, Emiko; Xu, Linghua; Hasegawa, Yoshiyuki; Satoh, Daisuke; Takemoto, Ryota","Health & Value, Pfizer Japan Inc., Tokyo, Japan. kanae.togo@pfizer.com.; Health & Value, Pfizer Japan Inc., Tokyo, Japan.; Oncology Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.; Health & Value, Pfizer Japan Inc., Tokyo, Japan.; Manufacturing IT Innovation Sector, NTT DATA Corporation, Tokyo, Japan.; Research and Development Headquarters, NTT DATA Corporation, Tokyo, Japan.; Manufacturing IT Innovation Sector, NTT DATA Corporation, Tokyo, Japan.",kanae.togo@pfizer.com.
36545310,Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework.,2022,"Leete, Jessica C; Zager, Michael G; Musante, Cynthia J; Shtylla, Blerta; Qiao, Wenlian","Clinical Pharmacology, Early Clinical Development, Pfizer Inc., Cambridge, MA, United States.; Translational Modeling and Simulation, BioMedicine Design, Pfizer Inc., La Jolla, CA, United States.; Quantitative Systems Pharmacology, Early Clinical Development, Pfizer Inc., Cambridge, MA, United States.; Quantitative Systems Pharmacology, Early Clinical Development, Pfizer Inc., La Jolla, CA, United States.; Clinical Pharmacology, Early Clinical Development, Pfizer Inc., Cambridge, MA, United States.",None
36542825,NOHA: A Promising Biomarker for Determining Estrogen Receptor Status Among Patients With Breast Cancer in Resource-Constrained Settings.,2022,"Jones, Michael","Pathology Services, Spectrum Healthcare Partners, South Portland, ME.",None
36539672,Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States.,2023,"Hackshaw, Michelle D; Recchia, Tamy; Kwong, Winghan J","Daiichi Sankyo Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.; Daiichi Sankyo Inc., Basking Ridge, NJ, USA.",neelima.denduluri@astrazeneca.com.
36539415,Dynamic partitioning of branched-chain amino acids-derived nitrogen supports renal cancer progression.,2022/Dec/20,"Masid, Maria; Hatzimanikatis, Vassily","Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne (EPFL), 1015, Lausanne, Switzerland.; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne (EPFL), 1015, Lausanne, Switzerland.",christian.frezza@uni-koeln.de.
36536472,Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape.,2022/Dec/19,"Golkaram, Mahdi; Salmans, Michael L; Vijayaraghavan, Raakhee; Zhao, Chen; Mehio, Rami; Zhang, Shile; Godsey, Jim; Pawlowski, Traci; Liu, Li","Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.; Illumina, Inc., 5200 Illumina Way, San Diego, CA, 92122, USA. lliu3@illumina.com.",hakimia@mskcc.org.
36535703,Paging the Clinical Informatics Community: Respond STAT to Dobbs v. Jackson's Women's Health Organization.,2023,"Graham, Justin V; Ozeran, Larry","GYANT, Inc, Oakland, California, United States.; Clinical Informatics, Inc., Yuba City, California, United States.",None
36535566,"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial.",2023,"Swaby, R F; Saraf, S; Yuan, J","Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.",anthonytcchan@cuhk.edu.hk.
36535565,"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.",2023,"Dvorkin, M","Budgetary Institution of Healthcare, Omsk Regional Oncology Dispensary, Omsk, Russian Federation.",tseiwert@jhmi.edu.
36534263,Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study.,2023,"Yoshimoto, Takuya; Nakagawa, Yuki; Fukuyama, Tamaki","Clinical Development Division, Chugai Pharmaceutical Co, Ltd, 1-1 Nihonbashi-Muromachi, 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.; Clinical Development Division, Chugai Pharmaceutical Co, Ltd, 1-1 Nihonbashi-Muromachi, 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.; Clinical Development Division, Chugai Pharmaceutical Co, Ltd, 1-1 Nihonbashi-Muromachi, 2-Chome Chuo-Ku, Tokyo, 103-8324, Japan.",nono@uro.med.osaka-u.ac.jp.
36534262,"Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.",2023,"Ratajczak, Christine K; Xiong, Hao","AbbVie Inc., North Chicago, IL, USA.; AbbVie Inc., North Chicago, IL, USA.",mizunomizuno@kufm.kagoshima-u.ac.jp.
36529559,Platform trials.,2023,"Laporte, Silvy; Labruyère, Carine; Simon, Tabassome","Inserm, U 1059 Sainbiose, Mines Saint-Étienne, unité de recherche clinique, innovation, pharmacologie, université Jean Monnet, CHU de Saint-Étienne, 42023 Saint-Étienne, France.; Inserm, U 1059 Sainbiose, Mines Saint-Étienne, unité de recherche clinique, innovation, pharmacologie, université Jean Monnet, CHU de Saint-Étienne, 42023 Saint-Étienne, France.; Service de pharmacologie, plateforme de recherche clinique de l'Est parisien, Sorbonne université, Assistance publique-Hôpitaux de Paris, 75012 Paris, France.",MRoustit@chu-grenoble.fr.
36528035,"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.",2023,"Pescosta, Norbert","Reparto Ematologia, Ospedale Provinciale Bolzano, Bolzano, Italy.",francesca.gay@unito.it.
36527133,"Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study.",2022/Dec/16,"Treuner, Kai; Zhang, Yi; Salunga, Ranelle; Schnabel, Catherine A","Biotheranostics, A Hologic Company, San Diego, CA, USA.; Biotheranostics, A Hologic Company, San Diego, CA, USA.; Biotheranostics, A Hologic Company, San Diego, CA, USA.; Biotheranostics, A Hologic Company, San Diego, CA, USA.",dsgroi@mgh.harvard.edu.
36526260,Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.,2023,"Hasabou, Nahla; Nuthethi, Rishita; Tiu, Ramon","Astellas Pharma US, Inc., Northbrook, Illinois.; Astellas Pharma US, Inc., Northbrook, Illinois.; Astellas Pharma US, Inc., Northbrook, Illinois.",alexander.perl@pennmedicine.upenn.edu.
36525150,"Patients' self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study.",2022/Dec/16,"Kim, Young-Joo; Kim, Sang-Hee; Lee, Jee-Sun","Medical Division, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea.; Medical Division, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea.; Medical Division, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Republic of Korea.",cjs5225@ncc.re.kr.
36517634,Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.,2023,"Hong, Agnes; El-Chaar, Nader; Ramaswamy, Krishnan; Nimke, David","Astellas Pharma Inc., Northbrook, IL, USA.; Astellas Pharma Inc., Northbrook, IL, USA.; Pfizer Inc., New York, NY, USA.; Astellas Pharma Inc., Northbrook, IL, USA.",stephen.freedland@cshs.org.
36514034,Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.,2022/Dec/13,"Becker, Claus; Shi, Kelvin; Meade, Julie; Ruiz-Soto, Rodrigo","Deciphera Pharmaceuticals, LLC, 200 Smith St., 02451, Waltham, MA, USA.; Deciphera Pharmaceuticals, LLC, 200 Smith St., 02451, Waltham, MA, USA.; Deciphera Pharmaceuticals, LLC, 200 Smith St., 02451, Waltham, MA, USA.; Deciphera Pharmaceuticals, LLC, 200 Smith St., 02451, Waltham, MA, USA.",patrick.schoffski@uzleuven.be.
36503527,Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier.,2022/Dec/12,"Jeck, Julia; Kron, Anna; Kron, Florian","VITIS Healthcare Group, Cologne, Germany.; VITIS Healthcare Group, Cologne, Germany.; VITIS Healthcare Group, Cologne, Germany. florian.kron@uk-koeln.de.",florian.kron@uk-koeln.de.
36497316,Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.,2022/Nov/26,"Gaillard, Vincent E","F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.",None
36495879,"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.",2023/Jan/14,"Hegg, Roberto","Clinica de Pesquisas e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paolo, Brazil.",shurvitz@mednet.ucla.edu.
36495188,Validation of safety outcomes in routinely collected data: Lessons learned from a multinational postapproval safety study.,2023,"Arena, Patrick J; Huang, Kui; Mo, Jingping; Schachterle, Stephen E; Nunes, Anthony P","Global Medical Epidemiology, Pfizer Inc., New York, New York, USA.; Global Medical Epidemiology, Pfizer Inc., New York, New York, USA.; Safety Surveillance Research, Pfizer Inc., New York, New York, USA.; Global Medical Epidemiology, Pfizer Inc., New York, New York, USA.; Optum Inc., Boston, Massachusetts, USA.",None
36494725,"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.",2022/Dec/10,"Dong, Jinghui; Adhikary, Sabina; Zhou, Lang; Schuberth, Petra C; Faghmous, Imi; Masouleh, Behzad Kharabi","Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.",bijal.shah@moffitt.org.
36494601,Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.,2022/Dec/09,"Lee, Jessica K; Sivakumar, Smruthy; Schrock, Alexa B; Madison, Russell; Fabrizio, David; Gjoerup, Ole; Ross, Jeffrey S; Frampton, Garrett M; Napalkov, Pavel; Montesion, Meagan; Schutzman, Jennifer L; Ye, Xin; Hegde, Priti S; Oxnard, Geoffrey R; Sokol, Ethan S; Shi, Zhen","Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Foundation Medicine Inc., Cambridge, MA, USA.; Genentech, Inc., South San Francisco, CA, USA. shi.zhen@gene.com.",shi.zhen@gene.com.
36493958,Quality Assurance in Clinical Trials Requiring Radiation Therapy in Sub-Saharan Africa.,2023/Jun/01,"Wirth, Meg","Emmes Company, Rockville, Maryland.",LLLin@mdanderson.org.
36493792,"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.",2023,"Wei, Ran; André, Valérie","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",Loxo@Lilly
36493599,"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.",2022,"Palcza, J; Jha, S; Chaney, M; Abraham, A K; Healy, J","Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.; Clinical Research, Merck & Co., Inc., Rahway.",egarralda@vhio.net.
36484171,Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.,2023/Feb/15,"Arroyo-Hernández, Marisol; Arrieta, Oscar","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",None
36483582,Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy.,2022,"Montesion, Meagan","Cancer Genomics Research, Foundation Medicine Inc., Cambridge, MA, USA.",None
36482193,"Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.",2023,"Borrow, Jennifer; Lin, Kevin K; Goble, Sandra; Maloney, Lara","Clinical Operations, Clovis Oncology, Inc., Boulder, CO, USA.; Molecular Diagnostics, Clovis Oncology, Inc., Boulder, CO, USA.; Biostatistics, Clovis Oncology, Inc., Boulder, CO, USA.; Clinical Development, Clovis Oncology, Inc., Boulder, CO, USA.",Rebecca.kristeleit@gstt.nhs.uk.
36479470,Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.,2022,"Sloane, Hillary; Starus, Anna; Fredebohm, Johannes; Jones, Frederick","Sysmex Inostics, Inc., Baltimore, MD, USA.; Sysmex Inostics, Inc., Baltimore, MD, USA.; Sysmex Inostics, Inc., Baltimore, MD, USA.; Sysmex Inostics, Inc., Baltimore, MD, USA.",None
36478334,Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.,2023,"Nakanishi, Yuka; Furuki, Satomi; Fukuda, Musashi; Ueno, Yoko; Raizer, Jeffrey; Arozullah, Ahsan","Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Inc., Tokyo, Japan.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.",None
36478297,The alternative renin-angiotensin-system (RAS) signalling pathway in prostate cancer and its link to the current COVID-19 pandemic.,2023,"Büttner, Hartwig","Takeda Pharma Vertrieb GmbH und Co. KG, Jägerstrasse 27, 10117, Berlin, Germany.",axel.merseburger@uksh.de.
36473143,Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.,2023/Apr/20,"Roberts, Mustimbo; Khan, Tariq Aziz; Miller-Moslin, Karen; Wei, Li","Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",None
36472839,"Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.",2022,"Lopes, Jared E; Losey, Heather C; Winquist, Raymond J","Research, Alkermes Inc, Waltham, Massachusetts, USA.; Research, Alkermes Inc, Waltham, Massachusetts, USA.; Research, Alkermes Inc, Waltham, Massachusetts, USA.",hua.zhang@nyulangone.org
36472728,Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.,2023,"Brown, Gordon","New Jersey Urology, A Summit Health Company, 136 Route 73 N, Suites A&B, Voorhees, NJ, 08043, USA. gbrown@njurology.com.",gbrown@njurology.com.
36470258,Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy.,2023,"Kim, Sang-Hee","Oncology Medical Affair, Pfizer Pharmaceuticals Korea Ltd., Seoul, Korea.",None
36469316,Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in Japan.,2022/Dec/01,"Kohsaka, Shinji","Section of Knowledge Integration, Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center, Tokyo, Japan.",None
36467816,Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.,2022,"Buckley, Sarah; Roman-Torres, Karisse",CTI BioPharma Seattle Washington USA.; CTI BioPharma Seattle Washington USA.,None
36467802,Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.,2022,"Masih-Khan, Esther; Reece, Donna",Princess Margaret Cancer Centre Toronto Ontario Canada.; Princess Margaret Cancer Centre Toronto Ontario Canada.,None
36467792,Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.,2022,"Chen, Christine I; DeCastro, Andrew; Van Domelen, Dane R; Zhang, Chris; Shah, Jatin J; Shacham, Sharon; Kauffman, Michael G; Bentur, Ohad S",Princess Margaret Cancer Centre Toronto Ontario Canada.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.; Karyopharm Therapeutics Inc. Newton Massachusetts USA.,None
36467355,Classical ,2022,"Qin, Tian","Burning Rock Biotech, Guangzhou, China.",None
36465931,Transferability of real-world data across borders for regulatory and health technology assessment decision-making.,2022,"Jaksa, Ashley; Arena, Patrick J; Ben-Joseph, Rami H; Campbell, Ulka B","Scientific Research and Strategy, Aetion, Inc., New York, NY, United States.; Scientific Research and Strategy, Aetion, Inc., New York, NY, United States.; Big Data Real World Evidence, Jazz Pharmaceuticals, Palo Alto, CA, United States.; Scientific Research and Strategy, Aetion, Inc., New York, NY, United States.",None
36464853,"Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.",2023,"Pan, Jie Janice; Binder, Terri A; Sauter, Nicholas; Xie, Ran","Global Value and Access (GV&A), Oncology, Eisai Inc., New Jersey, Nutley, USA.; Oncology Clinical Research, Eisai Inc., New Jersey, Nutley, USA.; Oncology Clinical Research, Eisai Inc., New Jersey, Nutley, USA.; Biostatistics, Eisai Inc., New Jersey, Nutley, USA.",None
36463643,Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.,2022,"Kim, Sindy; Huang, Xin; Bananis, Eustratios","Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121, USA. Electronic address: Sindy.Kim@pfizer.com.; Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121, USA. Electronic address: Xin.Huang@pfizer.com.; Pfizer Inc, 235 E 42nd St, New York, NY, 10017, USA. Electronic address: stratis.bananis@pfizer.com.",v.dieras@rennes.unicancer.fr.
36462464,Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.,2022,"Murugesan, K; Burn, T C; Gjoerup, O; Greenstein, R; López, J A; Montesion, M; Nimeiri, H; Schwemmers, S; Silverman, I M","Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA.; Translational and Data Sciences, Incyte Corporation, Wilmington.; Scientific and Medical Publications, Foundation Medicine, Inc., Cambridge, USA.; Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA.; Integrated Healthcare Solutions, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Cancer Genomics Research, Foundation Medicine, Inc., Cambridge, USA.; Global Clinical Development Lead Oncology, Foundation Medicine, Inc., Cambridge, USA.; Integrated HealthCare Solutions PDMA (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Clinical Bioinformatics, Incyte Corporation, Wilmington.",Vogel.Arndt@mh-hannover.de.
36460017,Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF,2023,"Ascierto, Paolo A; McArthur, Grant A","Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy. Electronic address: p.ascierto@istitutotumori.na.it.; Melanoma and Skin Service and Cancer Biology and Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.",p.ascierto@istitutotumori.na.it.
36459768,"Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).",2023,"Ding, Lieming; Wang, Yang; Yuan, Xiaobin","Betta Pharmaceuticals Co., Ltd., Hangzhou, China.; Betta Pharmaceuticals Co., Ltd., Hangzhou, China.; Betta Pharmaceuticals Co., Ltd., Hangzhou, China.",guoj307@126.com.
36459673,Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.,2023/Apr/01,"Meyers, Michael L; Qamoos, Hope; Ordentlich, Peter; Kumar, Vinit; Quaranto, Christine; Schmitt, Aaron; Gu, Yu; Jagasia, Madan","Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Syndax Pharmaceuticals, Inc, Waltham, MA.; Iovance Biotherapeutics, San Carlos, CA.",None
36459284,Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.,2023,"Ge, Ruimin; Zhu, Zhaoyin; Zhang, Wa","Clinical Development, BeiGene Ltd, Beijing, China.; BeiGene USA Inc, Ridgefield Park, NJ, USA.; Clinical Development, BeiGene Ltd, Beijing, China.",xubinghe@csco.org.cn.
36459136,Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions.,2022/Dec/01,"Bougacha, Omar; Gantzer, Laurène; Lekens, Béranger","Research and Development, Cegedim Healthcare Solutions, Boulogne-Billancourt, Paris, France.; Research and Development, Cegedim Healthcare Solutions, Boulogne-Billancourt, Paris, France.; Research and Development, Cegedim Healthcare Solutions, Boulogne-Billancourt, Paris, France.",None
36458420,Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System.,2023,"DuMontier, Clark; Driver, Jane A","New England Geriatrics Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.; New England Geriatrics Research, Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.",None
36457273,Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.,2023,"Perini, Rodolfo; Narita, Tomoyuki","Merck & Co., Inc., Rahway, New Jersey, USA.; Lenvima Alliance Management, Eisai Co., Ltd., Tokyo, Japan.",None
36456850,"Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea.",2023,"Molife, Cliff; Cho, Jae Min; Lapthorn, Jennifer; Kang, Min Ju; Kim, Sangmi; Colman, Sam; Kim, Saerom; Szende, Agota; Taipale, Kaisa-Leena","Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. molife_cliff@lilly.com.; Eli Lilly and Company, Seoul, Republic of Korea.; Labcorp Drug Development, Gaithersburg, MD, USA.; Eli Lilly and Company, Seoul, Republic of Korea.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA.; Labcorp Drug Development, Sydney, Australia.; Eli Lilly and Company, Seoul, Republic of Korea.; Labcorp Drug Development, Leeds, United Kingdom.; Eli Lilly and Company, Helsinki, Finland.",nobelg@yuhs.ac.
36456573,Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.,2022/Dec/01,"Asare, Smita M; Wilson, Amy; Asare, Adam L","Quantum Leap Healthcare Collaborative, San Francisco, USA.; Quantum Leap Healthcare Collaborative, San Francisco, USA.; Quantum Leap Healthcare Collaborative, San Francisco, USA.",LANGJ2@ccf.org.
36455505,Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.,2022,"Kahatt, C; Luepke-Estefan, X E; Siguero, M; Fernandez-Teruel, C; Cullell-Young, M","PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.",jtabernero@vhio.net.
36455396,Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study.,2023,"Leighl, Natasha B","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",janakiraman.subramanian@inova.org.
36455193,"Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an ",2022,"Deegan, Maegan; Jansen, Valerie M","Elevation Oncology, Inc, New York, NY.; Elevation Oncology, Inc, New York, NY.",None
36450379,Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer.,2022,"Alatorre-Alexander, Jorge; Höglander, Elen; Kaul, Monika; Tolson, Jonathan; Hu, Youyou; Vollan, Hans Kristian","Thoracic Oncology Clinic, Health Pharma Professional Research, Mexico City, Mexico.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, California, USA.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; F Hoffmann-La Roche Ltd, Basel, Switzerland.",andrea.ardizzoni@aosp.bo.it.
36446869,CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma.,2022/Nov/29,"Morishita, Daisuke; Sugiyama, Midori","Chordia Therapeutics, Fujisawa, Kanagawa, Japan.; Chordia Therapeutics, Fujisawa, Kanagawa, Japan.",kshimoda@med.miyazaki-u.ac.jp.
36445410,A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.,2023,"Fein, Seymour; Wu, Cai; Guerreiro, Leslie; Ren, Yixin; Shafren, Darren; Grose, Mark","CNF Pharma, LLC, New City, NY, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; ImmvirX Pty Ltd, New Lambton Heights, NSW, Australia.; Viralytics Limited, a Wholly Owned Subsidiary of Merck & Co., Inc., Rahway, NJ, USA.",janice.mehnert@nyulangone.org.
36442099,Tumor-targeted delivery of a STING agonist improvescancer immunotherapy.,2022/Dec/06,"Wu, You-Tong; Wei, Qi; Shi, Heping; Tan, Huiling; Qiu, Jian; Sun, Lijun","ImmuneSensor Therapeutics, Dallas, TX 75235.; ImmuneSensor Therapeutics, Dallas, TX 75235.; ImmuneSensor Therapeutics, Dallas, TX 75235.; ImmuneSensor Therapeutics, Dallas, TX 75235.; ImmuneSensor Therapeutics, Dallas, TX 75235.; ImmuneSensor Therapeutics, Dallas, TX 75235.",None
36441552,Mortality Among Pediatric Patients With Acute Lymphoblastic Leukemia in Sweden From 1988 to 2017.,2022/Nov/01,"Olsson, Daniel S","Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.",None
36439104,Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.,2022,"De Groot, Eleanor; Cooper, Laurence J N","Alaunos Therapeutics, Boston, MA, United States.; Alaunos Therapeutics, Boston, MA, United States.",None
36434156,Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.,2023,"Cooper, Alison M; Buckland, Sean W","The Association of the British Pharmaceutical Industry, London, UK.; Pfizer Ltd, Walton Oaks, Tadworth, Surrey, UK.",sarah.blagden@oncology.ox.ac.uk.
36427183,PERFORM: a non-interventional study assessing the patients' treatment starting with 1L palbociclib in HR+/HER2- ABC.,2022,"Runkel, Eva Diana; Glastetter, Esther","Pfizer Pharma GmbH, Linkstr. 10, Berlin, 10785, Germany.; Pfizer Pharma GmbH, Linkstr. 10, Berlin, 10785, Germany.",None
36425873,"An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).",2022,"Li, Ang","Bristol Myers Squibb Company, Princeton, NJ, USA.",None
36424660,Whole-exome sequencing of BRCA-negative breast cancer patients and case-control analyses identify variants associated with breast cancer susceptibility.,2022/Nov/23,"Tay, Ru Jin; Tan, Min-Han","Lucence Diagnostics Pte Ltd, 211 Henderson Road, Singapore, 159552, Singapore.; Lucence Diagnostics Pte Ltd, 211 Henderson Road, Singapore, 159552, Singapore.",gmslimsg@nus.edu.sg.
36424033,Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis.,2022,"White, Andrew; Bailey, Michael; Warren, Sarah","NanoString Technologies Inc, Seattle, Washington, USA.; NanoString Technologies Inc, Seattle, Washington, USA.; NanoString Technologies Inc, Seattle, Washington, USA.",paolo.ascierto@gmail.com.
36423446,"Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.",2023,"Shah, Jatin","Karyopharm Therapeutics, Inc, Newton, MA, USA.",swestin@mdanderson.org.
36418472,Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.,2023,"Ruggiero, Ciro F; Ascierto, Paolo A","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131, Naples, Italy.; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131, Naples, Italy.",gennaro.ciliberto@ifo.it.
36415537,Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy.,2022,"Ge, Wenzhen; Wu, Ning; Jalbert, Jessica J; Quek, Ruben G W; Rietschel, Petra; Pouliot, Jean-Francois; Harnett, James","Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",None
36414795,"Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.",2023,"Huang, Yu-Jing","Global Patient Safety, Eli Lilly and Company, Indianapolis, IN, USA.",tanizawa_yoshinori@lilly.com.
36414192,Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.,2023,"Memaj, A; Nathan, F","Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.; OneClinical, Bristol Myers Squibb, Princeton.",hossein.borghaei@fccc.edu.
36411391,A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins.,2023,"Stephens, Tyler; Tsybovsky, Yaroslav","Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Vaccine Research Center Electron Microscopy Unit, Cancer Research Technology Program, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.",zchen4@tamu.edu.
36410210,Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.,2022,"Iadeluca, Laura; Reisman, Arlene; Thurm, Holger; Polli, Anna M","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, Milan, Italy.",mazieres.j@chu-toulouse.fr.
36410207,Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.,2023,"Liu, Haiying; Aguila, Christian; Macharia, Harrison; Yang, Ke; Restuccia, Eleonora","Product Development Oncology, Genentech, Inc., 94080 - South San Francisco, USA.; Product Development Oncology, F. Hoffmann-La Roche Ltd, 4058 - Basel, Switzerland.; Data Sciences, F. Hoffmann-La Roche Ltd, 4058 - Basel, Switzerland.; Portfolio Clinical Safety, F. Hoffmann-La Roche Ltd, 010, Beijing, China.; Product Development Oncology, F. Hoffmann-La Roche Ltd, 4058 - Basel, Switzerland.",sms248@georgetown.edu.
36409435,A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors.,2023,"Lu, Vickie; Zhou, Xiaofei","Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Cambridge, MA, USA. Xiaofei.Zhou@Takeda.com.",Xiaofei.Zhou@Takeda.com.
36408668,The Aetion Coalition to Advance Real-World Evidence through Randomized Controlled Trial Emulation Initiative: Oncology.,2023,"Merola, David; Campbell, Ulka; Gautam, Nileesa; Rubens, Alexa; Bruno, Amanda; Jiao, Xiaolong; Taylor, Benjamin","Aetion, Inc., New York, New York, USA.; Aetion, Inc., New York, New York, USA.; Aetion, Inc., New York, New York, USA.; Aetion, Inc., New York, New York, USA.; Bayer Pharmaceuticals, Philadelphia, Pennsylvania, USA.; Bayer Pharmaceuticals, Philadelphia, Pennsylvania, USA.; Aetion, Inc., New York, New York, USA.",None
36404878,Oncology Simulation Model: A Comprehensive and Innovative Approach to Estimate and Project Prevalence and Survival in Oncology.,2022,"Bloudek, Brian; Wirtz, Heidi S; Hepp, Zsolt; Timmons, Jack; Bloudek, Lisa; McKay, Caroline","Curta Inc., Seattle, WA, USA.; Seagen Inc., Bothell, WA, USA.; Seagen Inc., Bothell, WA, USA.; Curta Inc., Seattle, WA, USA.; Curta Inc., Seattle, WA, USA.; Astellas Pharma Global Development, Inc., Northbrook, IL, USA.",None
36404637,"Motion-robust, blood-suppressed, reduced-distortion diffusion MRI of the liver.",2023,"Guidon, Arnaud","Global MR Application and Workflow, GE Healthcare, Boston, Massachusetts, USA.",None
36404384,Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.,2023,"Takeshi, Tajima; Kawaguchi, Mayu; Tokushige, Kota","Novartis Pharma K.K, Toranomon Minato-ku, Tokyo, Japan.; Novartis Pharma K.K, Toranomon Minato-ku, Tokyo, Japan.; Novartis Pharma K.K, Toranomon Minato-ku, Tokyo, Japan.",nfukuhara@med.tohoku.ac.jp.
36403367,"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.",2023,"Voisin, Anne Laure; Messayke, Sabine; Laghouati, Salim","Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.",sami.antoun@gustaveroussy.fr.
36402993,A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.,2022/Nov/19,"Sommavilla, Roberto; Seitz, Patrick; Kulenkampff, Elisabeth; Kahn, Stefan","Novartis Pharma Schweiz, Rotkreuz, Switzerland.; Novartis Pharma Schweiz, Rotkreuz, Switzerland.; Novartis Pharma Schweiz, Rotkreuz, Switzerland.; Novartis Pharma Schweiz, Rotkreuz, Switzerland.",stefan.balabanov@usz.ch.
36401732,The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.,2023,"Cheeti, Sravanthi; Gates, Mary; Chang, Ching-Wei; Fredrickson, Jill; Spoerke, Jill M; Moore, Heather M; Giltnane, Jennifer; Friedman, Lori S; Chow Maneval, Edna; Chan, Iris","Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; ORIC Pharmaceuticals, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.",bardia.aditya@mgh.harvard.edu.
36401133,"First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).",2023,"Amaya-Chanaga, Carlos; Chen, Tian","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",kenkato@ncc.go.jp.
36400106,"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.",2022,"Elimova, Elena","Princess Margaret Cancer Centre, Toronto, ON, Canada.",fmeric@mdanderson.org.
36400018,Evaluation of cell-free DNA approaches for multi-cancer early detection.,2022/Dec/12,"Aravanis, Alexander M","Illumina, Inc., San Diego, CA 92122, USA.",ovenn@grailbio.com.
36399695,Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.,2023/Mar/20,"Tiwari, Ranjan; O'Donovan, Darragh","Novartis Healthcare Pvt Ltd, Hyderabad, India.; Novartis Pharmaceuticals Corporation, Dublin, Ireland.",None
36397080,HPV knowledge and vaccine acceptability: a survey-based study among parents of adolescents (KAPPAS study).,2022/Nov/17,"Cabeza, Inés; Raba, Reyes Mazas; Company, Patricia","Healthcare Centre Galdakao, Vizcaya, Spain.; Healthcare Centre Gama, Cantabria, Spain.; Healthcare Centre Pla, Elche, Alicante, Spain.",noelia.lopez@merck.com.
36396631,Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis.,2022/Nov/17,"Zavidij, Oksana","Constellation Pharmaceuticals a MorphoSys Company, Cambridge, MA, USA.",gadgetz@broadinstitute.org.
36395164,Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: A retrospective cohort study.,2022,"Geier, Jamie; Lemeshow, Adina R","Pfizer, Inc., New York, New York, United States of America.; Pfizer, Inc., New York, New York, United States of America.",None
36394153,"PK/PD model-informed dose selection for oncology phase I expansion: Case study based on PF-06939999, a PRMT5 inhibitor.",2023,"Guo, Cen; Liao, Kai H; Li, Meng; Wang, I-Ming; Shaik, Naveed; Yin, Donghua","Pfizer Inc., San Diego, California, USA.; Pfizer Inc., San Diego, California, USA.; Pfizer Inc., San Diego, California, USA.; Pfizer Inc., San Diego, California, USA.; Pfizer Inc., San Diego, California, USA.; Pfizer Inc., San Diego, California, USA.",None
36394119,Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment.,2023,"Aida, Kensuke; Hatayama, Tomoyoshi; Shirahase, Toru","Janssen Pharmaceutical K.K., Tokyo, Japan.; Janssen Pharmaceutical K.K., Tokyo, Japan.; Janssen Pharmaceutical K.K., Tokyo, Japan.",None
36386456,"Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.",2022,"Atz, Judith; Kaiser, Rolf","Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.; Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.",None
36379002,Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.,2023/Feb/01,"Saito, Kaku; Kawaguchi, Yoshinori; Kamio, Takahiro","Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.; Daiichi Sankyo, Inc, Basking Ridge, NJ.",None
36375739,Current nonclinical approaches for immune assessments of immuno-oncology biotherapeutics.,2023,"Grimaldi, Christine; Fuller, Claudette L; Brennan, Frank R; Regenass-Lechner, Franziska; Price, Karen D; Steeves, Meredith A; Dudal, Sherri; Kronenberg, Sven; Blanset, Diann","Boehringer Ingelheim Pharmaceuticals, Inc., United States.; Merck and Co., Inc, United States.; Novartis Pharmaceuticals UK Limited, United Kingdom.; Roche Pharmaceutical Research and Early Development, United States.; Bristol Myers Squibb Company, United States.; Eli Lilly and Company, United States.; Roche Pharmaceutical Research and Early Development, United States.; Roche Pharmaceutical Research and Early Development, United States.; Boehringer Ingelheim Pharmaceuticals, Inc., United States. Electronic address: diann.blanset@boehringer-ingelheim.com.",diann.blanset@boehringer-ingelheim.com.
36375387,Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer.,2022,"Sanglier, Thibaut; Shi, Tianlai; Mouta, João","F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Bldg 1, Floor 8, NBH 02, 4070, Basel, Switzerland. Electronic address: thibaut.sanglier@roche.com.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Bldg 1, Floor 8, NBH 02, 4070, Basel, Switzerland. Electronic address: tianlai.shi@roche.com.; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Bldg 1, Floor 8, NBH 02, 4070, Basel, Switzerland. Electronic address: joao.mouta@roche.com.",fatimacardoso@fundacaochampalimaud.pt.
36375271,Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.,2022,"Ruf, T; Cardona, A; Guerini, E; Kurtsikidze, N; Smoljanovic, V","F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.",david.planchard@gustaveroussy.fr.
36371001,A simple and robust model for enrollment projection in clinical trials.,2022,"Zhang, Xiaoxi; Huang, Bo","Statistics, Pfizer Inc., New York, NY, United States of America. Electronic address: xiaoxi.zhang@pfizer.com.; Statistics, Pfizer Inc., New York, NY, United States of America.",xiaoxi.zhang@pfizer.com.
36370742,Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.,2023,"Kelly, Patrick; Sweeney, Jennifer; Forsyth, Sanjeev; Guichard, Sylvie M; Brevard, Julie; Henrick, Patrick; Mohamed, Hesham","Forma Therapeutics, Watertown, MA, USA.; Forma Therapeutics, Watertown, MA, USA.; Forma Therapeutics, Watertown, MA, USA.; Forma Therapeutics, Watertown, MA, USA.; Forma Therapeutics, Watertown, MA, USA.; Forma Therapeutics, Watertown, MA, USA.; Forma Therapeutics, Watertown, MA, USA.",jxw401@miami.edu.
36370683,Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.,2022,"Massayke, Sabine","Pharmacovigilance Unit, Gustave Roussy, F-94800 Villejuif, France.",olivier.lambotte@aphp.fr.
36370650,Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice.,2022,"Schimke, Alexandra","Medical Affairs, Mylan Pharmaceuticals GmbH, Bad Homburg, Germany.",langer@uke.de.
36370634,"Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.",2022,"Rees, William A; Smith, Michael A; Gunsior, Michele; Yan, Li; She, Dewei; Cimbora, Daniel; Paul, Friedemann; Katz, Eliezer","Horizon Therapeutics plc, Gaithersburg, MD, USA.; Horizon Therapeutics plc, Gaithersburg, MD, USA.; Horizon Therapeutics plc, Gaithersburg, MD, USA.; Horizon Therapeutics plc, Gaithersburg, MD, USA.; Horizon Therapeutics plc, Gaithersburg, MD, USA.; Horizon Therapeutics plc, Gaithersburg, MD, USA.; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Horizon Therapeutics plc, Gaithersburg, MD, USA.",jeffrey.bennett@cuanschutz.edu.
36369901,Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.,2023,"Adachi, Noriaki; Fogelman, David; Marinello, Patricia","Merck & Co., Inc., Rahway, New Jersey, USA.; Merck & Co., Inc., Rahway, New Jersey, USA.; Merck & Co., Inc., Rahway, New Jersey, USA.",None
36369159,Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.,2023,"Nicholas, Alan; Schulze, Katja; Johnson, Ann","Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.",ruschv@mskcc.org.
36368161,"Real-world study of patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2‒Negative advanced breast cancer: Patient demographics, treatment patterns, adverse events, and physician-reported satisfaction in the United States, Europe, and Israel.",2022,"Niyazov, Alexander; Lux, Michael Patrick","Pfizer Inc, 235 42nd St, New York, NY, 10017, USA. Electronic address: Alexander.Niyazov@pfizer.com.; Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, Frauenklinik St. Josefs, Salzkotten Husener Straße 81, 33098, Paderborn, Germany. Electronic address: M.Lux@vincenz.de.",M.Lux@vincenz.de.
36366338,A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.,2022/Oct/29,"Sakai, Hironori; Hojo, Wataru","R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan.; R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan.",None
36360487,Real-World Outcomes of Systemic Therapy in Japanese Patients with Cancer (Tokushukai REAl-World Data Project: TREAD): Study Protocol for a Nationwide Cohort Study.,2022/Oct/28,"Fujimura, Yoshiaki; Hayashi, Maki; Ohtaki, Megu; Ohtani, Keiko","Tokushukai Information System Inc., Osaka 530-0001, Japan.; Mirai Iryo Research Center Inc., Tokyo 102-0083, Japan.; deCult Co., Ltd., Hatsukaichi 739-0413, Japan.; deCult Co., Ltd., Hatsukaichi 739-0413, Japan.",None
36358816,Unknown,2022/Nov/02,"Niyazov, Alexander","Patient and Health Impact, Pfizer Inc., 235 42nd St., New York, NY 10017, USA.",None
36358731,Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe.,2022/Oct/28,"Wetten, Sally","Amgen Ltd., Uxbridge UB8 1DH, UK.",None
36358725,The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets.,2022/Oct/28,"Braga, Luca; Volpe, Maria Concetta; Maiocchi, Serena","Functional Cell Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy.; Functional Cell Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy.; Functional Cell Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy.",None
36358675,The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis.,2022/Oct/26,"Nakagawa, Yuki; Fukuyama, Tamaki; Sano, Fumikazu","Clinical Development Division, Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan.; Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan.; Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan.",None
36358652,"Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Prospective, Multicenter, Phase IV Trial.",2022/Oct/25,"De Rivas, Beatriz","Medical Affairs, PharmaMar, S.A., Colmenar Viejo, 28770 Madrid, Spain.",None
36344544,Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers.,2022/Nov/07,"Llop Guevara, Alba; Serra, Violeta","Experimental Therapeutics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.; Experimental Therapeutics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.",knathans@upenn.edu.
36344294,Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.,2023,"Prabhu, Vimalanand S; Orlowski, Robert","Merck & Co., Inc., Rahway, NJ, USA. Electronic address: vimalanand.prabhu@merck.com.; Merck & Co., Inc., Rahway, NJ, USA.",vimalanand.prabhu@merck.com.
36343677,Genetically Predicted Serum Vitamin C Levels and Cutaneous Squamous Cell Carcinoma Risk.,2023,"Jorgenson, Eric","Regeneron Pharmaceuticals, Tarrytown, New York, USA.",pores@mgh.harvard.edu.
36343242,Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study.,2022/Nov/16,"Fillmore, Nathanael R; Szalat, Raphael E; La, Jennifer; Branch-Elliman, Westyn; Monach, Paul A; Nguyen, Vinh; Brophy, Mary T; Do, Nhan V","Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.; Cooperative Studies Program, Veterans Affairs Boston Healthcare System, Boston, MA 02130.",None
36343174,Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.,2023/May/04,"Huang, Bo","Pfizer Inc, Groton, CT, USA.",None
36339928,Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma.,2022,"Kovaleva, Elena","Novartis Pharmaceuticals UK LTD, England.",None
36338710,"HER2 expression in urothelial carcinoma, a systematic literature review.",2022,"Scherrer, Emilie; Kang, Ashley; Bloudek, Lisa M","Seagen, Inc., Bothell, WA, United States.; Curta, Inc., Seattle, WA, United States.; Curta, Inc., Seattle, WA, United States.",None
36336769,Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective.,2022,"McCallen, Maggie; Coughlin, Christopher","Pharmacy Clinical Practice, Mayo Clinic, Phoenix, AZ, USA.; Pharmacy Clinical Practice, Mayo Clinic, Phoenix, AZ, USA.",ginna.granroth@ctca-hope.com.
36336468,Eribulin for the treatment of advanced breast cancer: A prospective observational registry study.,2022,"Brown, Ian","Eisai, Ltd, Hatfield, UK.",None
36335780,"Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.",2022,"Gambotti, Laëtitia","Institut National Contre le Cancer (INCa), France.",marie.veron705@gmail.com.
36335217,A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.,2023,"Abdul Razak, Albiruni R","Phase 1 Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.",giuseppe.curigliano@ieo.it.
36335120,"Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study.",2022/Nov/05,"Chapman, Sonya C; Hossain, Anwar M; Chen, Yanyun","Eli Lilly and Company, Bracknell, UK.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",Hope.Rugo@ucsf.edu.
36333567,"Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.",2023,"Niyazov, Alexander; Lux, Michael P","Patient Health and Impact, Pfizer Inc, New York, NY, USA.; Klinik für Gynäkologie und Geburtshilfe Frauenklinik St. Louise, Paderborn, Frauenklinik St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Kliniken, Paderborn, Germany.",rmahtani@baptisthealth.net.
36332647,"Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE.",2022,"Schoot, Reineke A","Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.",maria.otth@kispi.uzh.ch.
36332173,IRONMAN: A Novel International Registry of Men With Advanced Prostate Cancer.,2022,"Kantoff, Philip W","Convergent Therapeutics, Cambridge, MA.",None
36331674,Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.,2023,"Kikuchi, Keiichi; Akaike, Kenichiro; Takeda, Shiho","SymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan.; SymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan.; SymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan.",sentants@wakayama-med.ac.jp.
36328784,"Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study.",2022,"Plaseska-Karanfilska, Dijana","Research Centre for Genetic Engineering and Biotechnology 'Georgi D. Efremov', MASA, Skopje, Macedonia (the former Yugoslav Republic of).",brigid.lynch@cancervic.org.au.
36327219,Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative.,2022,"Stockwell, Amy D; Przychodzen, Bartlomiej; Cai, Fang; Yaspan, Brian; Smieszek, Sandra; Dabrowski, Maciej; Zawadzki, Pawel; Sypniewski, Mateusz; Kaja, Elżbieta","Genentech Inc, South San Francisco, California, United States of America.; Vanda Pharmaceuticals, Washington, District of Columbia, United States of America.; Genentech Inc, South San Francisco, California, United States of America.; Genentech Inc, South San Francisco, California, United States of America.; Vanda Pharmaceuticals, Washington, District of Columbia, United States of America.; MNM Bioscience Inc., Cambridge, Massachusetts, United States of America.; MNM Bioscience Inc., Cambridge, Massachusetts, United States of America.; MNM Bioscience Inc., Cambridge, Massachusetts, United States of America.; MNM Bioscience Inc., Cambridge, Massachusetts, United States of America.",None
36326765,Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.,2022/Nov/01,"Ramagopalan, Sreeram V; Gupta, Alind; Lockhart, Alexandre; Hsu, Grace; Ray, Joshua","Global Access, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland.; Real-World and Advanced Analytics, Cytel Inc, Cambridge, Massachusetts.; Real-World and Advanced Analytics, Cytel Inc, Cambridge, Massachusetts.; Real-World and Advanced Analytics, Cytel Inc, Cambridge, Massachusetts.; Global Access, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland.",None
36324736,Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ,2022,"Martini, Jean-François","Pfizer Inc., San Diego, CA, USA.",None
36324586,Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices.,2022,"Hu, Xiaohan; Li, Yeran; Zhao, Bin; Burke, Thomas","Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, NJ, United States.; Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, NJ, United States.; Clinical Research, Merck & Co., Inc., Rahway, NJ, United States.; Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, NJ, United States.",None
36323612,Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.,2023,"Schueler, Andrea","Boehringer Ingelheim Pharma GmbH & Co KG, 55218 Ingelheim, Germany. Electronic address: andrea.schueler@boehringer-ingelheim.com.",e.laack@haemato-onkologie-hh.de.
36323052,Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.,2022,"Huang, Min; Haiderali, Amin; Pan, Wilbur; Hu, Peter","Merck & Co., Inc., Rahway, NJ, USA. Electronic address: min_huang@merck.com.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",min_huang@merck.com.
36319831,Epidemiological Study Regarding the Incidence of Venous Thromboembolism in Patients After Cancer Remission.,2022,"Imura, Miki; Katada, Jun","Medical Affairs, Internal Medicine, Pfizer Biopharmaceuticals Group, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-Ku, Tokyo, 151-8589, Japan. miki.imura@pfizer.com.; Medical Affairs, Internal Medicine, Pfizer Biopharmaceuticals Group, Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-Ku, Tokyo, 151-8589, Japan.",miki.imura@pfizer.com.
36318364,Epidemiology and Treatment Patterns of Venous Thromboembolism: an Observational Study of Nationwide Time-Series Trends in Japan.,2022,"Takahashi, Shoko; Imura, Miki; Katada, Jun","Medical Affairs, Internal Medicine, Pfizer Biopharmaceuticals Group, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan. shoko.takahashi@pfizer.com.; Medical Affairs, Internal Medicine, Pfizer Biopharmaceuticals Group, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan.; Medical Affairs, Internal Medicine, Pfizer Biopharmaceuticals Group, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan.",shoko.takahashi@pfizer.com.
36317162,The Burden of Metastatic Cancer-Induced Bone Pain: A Narrative Review.,2022,"Bajwa, Zahid; Dragon, Erika; Robinson, Rebecca L; Sheffield, Kristin M; Thakkar, Sheena","Medical Affairs, Eli Lilly and Company, Indianapolis, IN, USA.; Medical Affairs, Pfizer, Ltd, Budapest, Hungary.; Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA.; Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA.; Patient Health & Impact, Pfizer Inc, New York, NY, USA.",None
36316952,Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options.,2023,"Allen, Brian; Clement, Jessica; Gao, Jingjing; Hubbell, Earl","GRAIL, LLC, a subsidiary of Illumina Inc., Menlo Park, CA, USA†.; Hartford Healthcare, Hartford, CT, USA.; GRAIL, LLC, a subsidiary of Illumina Inc., Menlo Park, CA, USA†.; GRAIL, LLC, a subsidiary of Illumina Inc., Menlo Park, CA, USA†.",None
36316061,"First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.",2022,"Janik, John E; Clark, Jason; Condamine, Thomas; Pulini, Jennifer; Chen, Xuejun","Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.",janice.mehnert@nyulangone.org.
36315923,Informal Providers-Ground Realities in South Asian Association for Regional Cooperation Nations: Toward Better Cancer Primary Care: A Narrative Review.,2022,"Oswal, Kunal; Jain, Yogesh","Karkinos Healthcare, Mumbai, India.; Karkinos Healthcare, Mumbai, India.",None
36310237,Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis.,2022/Oct/30,"King, Andrew J; Eric Olson, N; Gunawan, Marvin G; Kuo, Jay J; Cox, Jennifer H","Chinook Therapeutics, Inc., Seattle, WA, USA.; Chinook Therapeutics, Inc., Seattle, WA, USA.; Chinook Therapeutics, Inc., Vancouver, BC, Canada.; Chinook Therapeutics, Inc., Vancouver, BC, Canada.; Chinook Therapeutics, Inc., Vancouver, BC, Canada.",humphreysbd@wustl.edu.
36309981,A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.,2023,"Naqvi, Kiran; Zha, Jiuhong; Cheng, Wei-Han; Zhou, Ying; Hoffman, David; Harb, Jason G; Potluri, Jalaja","Research and Development, Genentech Inc, South San Francisco, California, USA.; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.; Research and Development, AbbVie Inc, North Chicago, Illinois, USA.",None
36309837,Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors.,2023/Jan/01,"Zhou, Gongfu; Walker, Chris; Dong, Zhiwan","Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.",None
36309560,Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.,2023,"Boer, Judith M","Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.",atmanabe@med.hokudai.ac.jp.
36308296,Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.,2023/Jan/01,"Chen, Chieh-I; Harnett, James; Mastey, Vera; Li, Siyu; Gullo, Giuseppe; Rietschel, Petra","Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA.",None
36307826,"Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.",2022/Oct/28,"Damia, Giovanna; Guffanti, Federica","Laboratory of Molecular Pharmacology, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.; Laboratory of Molecular Pharmacology, Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.",anna.moretti@asst-fbf-sacco.it.
36306873,Improving skin cancer management with ARTificial intelligence: A pre-post intervention trial of an artificial intelligence system used as a diagnostic aid for skin cancer management in a real-world specialist dermatology setting.,2023,"Bowling, Adrian; Haskett, Martin","MoleMap Ltd, Melbourne, Australia.; MoleMap Ltd, Melbourne, Australia.",victoria.mar@monash.edu.
36306669,Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey.,2023,"Siddiqui, Emad; Todorova, Lora; Schultz, Neil M","Astellas Pharma Inc., Chertsey, UK.; Astellas Pharma Inc., Chertsey, UK.; Astellas Pharma, Northbrook, IL, USA.",renappi@tin.it.
36306479,Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.,2023/Apr/10,"Mukherjee, Rinee; Lin, Jianxin; Souza, Fabricio","Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.; Merck & Co, Inc, Rahway, NJ.",None
36306156,Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study.,2022/Oct/28,"Wong, Lih-Ming","Epworth Healthcare, East Melbourne, Australia.",None
36302890,Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.,2022/Oct/27,"Miller, Vincent","Foundation Medicine, Inc., Cambridge, MA, USA.",atsimber@mdanderson.org.
36302562,First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.,2022,"Forgie, Alison; Yang, Wenjing; Guo, Cen; Chou, Jeffrey","Translational Oncology, Pfizer Inc, San Francisco, California, USA.; Oncology Computational Biology, Pfizer Inc, San Diego, Calfornia, USA.; Clinical Pharmacology, Pfizer Inc, San Diego, California, USA.; Early Oncology Development and Clinical Research, Pfizer Inc, San Francisco, California, USA.",ohamid@theangelesclinic.org.
36301615,An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study.,2022/Oct/27,"Chrones, Lambros; Uddin, Sharif; McCue, Maggie","Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States.; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, United States.",None
36291835,Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.,2022/Oct/15,"Macharia, Harrison; du Toit, Yolande; Heinzmann, Dominik; Knott, Adam; Song, Chunyan; Cortazar, Patricia","F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Genentech, Inc., South San Francisco, CA 94080, USA.; F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.",None
36290876,"Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada.",2022/Oct/12,"Grewal, Simrun; Wirtz, Heidi S; Hepp, Zsolt","Seagen Inc., Bothell, WA 98021, USA.; Seagen Inc., Bothell, WA 98021, USA.; Seagen Inc., Bothell, WA 98021, USA.",None
36290837,A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.,2022/Sep/28,"Doucette, Sarah","Impact Medicom Inc., Toronto, ON M6S 3K2, Canada.",None
36290832,Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.,2022/Sep/28,"Doucette, Sarah","IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.",None
36290812,Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy.,2022/Sep/22,"Lembo, Paola M C; Fournier, Pierre-André","AbbVie Corporation, Saint-Laurent, QC H4S 1Z1, Canada.; AbbVie Corporation, Saint-Laurent, QC H4S 1Z1, Canada.",None
36288238,Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.,2022/Dec/09,"McRee, Autumn J","The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ, USA.",None
36282928,"Specialty pharmacy turnaround time impediments, facilitators, and good practices.",2022,"Gabriel, Meghan Hufstader; Kotschevar, Christopher M; Tarver, DeBran; Mastrangelo, Vittorio; Pezzullo, Lynn; Campbell, Patrick J","Pharmacy Quality Alliance, Alexandria, VA.; Pharmacy Quality Alliance, Alexandria, VA.; Pharmacy Quality Alliance, Alexandria, VA.; Pharmacy Quality Alliance, Alexandria, VA.; Pharmacy Quality Alliance, Alexandria, VA.; Merck & Co, Inc, Kenilworth, NJ.",None
36279135,Comparison of Germline Genetic Testing Before and After a Medical Policy Covering Universal Testing Among Patients With Colorectal Cancer.,2022/Oct/03,"Radford, Cristi","UnitedHealthcare, Minnetonka, Minnesota.",None
36274654,Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation.,2022,"Jackson, Pamela R","Mathematical NeuroOncology Lab, Precision Neurotherapeutics Innovation Program, Mayo Clinic Arizona, Phoenix, AZ, United States.",None
36274133,Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.,2022/Oct/24,"Rieke, Damian T; de Bortoli, Till; Lamping, Mario; Benary, Manuela; Jelas, Ivan; Rüter, Gina; Berger, Johannes; Zettwitz, Marit; Kagelmann, Niklas; Kind, Andreas; Fabian, Falk; Keilholz, Ulrich","Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany. damian.rieke@charite.de.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.; Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Chariteplatz 1, 10117, Berlin, Germany.",damian.rieke@charite.de.
36273926,Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.,2022,"Maloney, Lara; Goble, Sandra; Lin, Kevin K; Kwan, Tanya","Clinical Development, Clovis Oncology, Inc., Boulder, CO, USA.; Biostatistics, Clovis Oncology, Inc., Boulder, CO, USA.; Molecular Diagnostics, Clovis Oncology, Inc., Boulder, CO, USA.; Molecular Diagnostics, Clovis Oncology, Inc., Boulder, CO, USA.",Malley@osumc.edu.
36271487,Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.,2023,"Chang, Tiffany; Yoneyama, Koichiro","Genentech, Inc., South San Francisco, California, USA.; Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.",None
36265504,"Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.",2022,"Boysen, Gunther; Gourgioti, Georgia; Martins, Karla","Medical Affairs, Astellas Pharma Europe, Addlestone, UK.; Medical Affairs, Astellas Pharma Europe, Addlestone, UK.; Medical Affairs, Astellas Pharma Europe, Addlestone, UK.",axel.merseburger@uksh.de.
36265119,"Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples.",2022,"Das Thakur, Meghna","Genentech Inc, South San Francisco, CA.",None
36265118,Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.,2022,"Lak, Nathalie S M; Stutterheim, Janine; Tytgat, Godelieve A M","Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.",None
36265095,Activities Performed by ASCO-Sponsored Oncology Student Interest Groups in Latin America: Assessing Members' Preferences and Leaders' Challenges.,2022,"Lucio-Lozada, Jose","Personalized Medicine Laboratory, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",None
36264566,Systemic Anticancer Therapy at the End of Life-Changes in Usage Pattern in the Immunotherapy Era.,2022/Dec/01,"Wang, Xiaoliang; Ascha, Mustafa S; Miksad, Rebecca A; Calip, Gregory S","Flatiron Health, Inc, New York, New York.; Flatiron Health, Inc, New York, New York.; Flatiron Health, Inc, New York, New York.; Flatiron Health, Inc, New York, New York.",None
36264378,First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.,2022,"Gumuscu, Burak; Swaby, Ramona F","Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ, 07065, USA.; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ, 07065, USA.",matahara@east.ncc.go.jp.
36263927,"Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant.",2022,"Venturini, Alessio; Giuliano, Claudio; Bernareggi, Alberto; Spezia, Riccardo; Voisin, Daniel","Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland.; Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland.; Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland.; Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland.; Helsinn Healthcare SA, Lugano/Pazzallo, Switzerland.",None
36263922,Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.,2023,"Lamy, Francois-Xavier; Allignol, Arthur; Mahmoudpour, Seyed H","Healthcare Business of Merck KGaA, Darmstadt, Germany.; Healthcare Business of Merck KGaA, Darmstadt, Germany.; Healthcare Business of Merck KGaA, Darmstadt, Germany.",None
36259380,Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.,2022/Dec/15,"Sen, Suvajit; Oliver, Jennifer W; Banerjee, Kamalika","Exelixis, Inc., Alameda, California, USA.; Exelixis, Inc., Alameda, California, USA.; Exelixis, Inc., Alameda, California, USA.",None
36258088,Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia.,2023,"Takagi, Taiga; Tachibana, Masaya; Sumi, Hiroyuki; Kakurai, Yasuyuki; Yamashita, Tomonari","Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.",kensuke.usuki@gmail.com.
36257931,A synthetic transcription platform for programmable gene expression in mammalian cells.,2022/Oct/18,"Wroblewska, Liliana; Zhang, Lin","Pfizer Inc., Cambridge, MA, 02139, USA.; Pfizer Inc., Andover, MA, 01810, USA.",tim@lugroup.org.
36257914,Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.,2023,"Wu, James J; Siddiqi, Rubina","Kite Pharma, Santa Monica, California, USA.; Kite Pharma, Santa Monica, California, USA.",None
36257531,ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences.,2022,"Abdillah, Arif","Takeda Pharmaceuticals International AG, 8 Marina Boulevard, #15-01, Marina Bay Financial Centre, 018981, Singapore. Electronic address: arif.abdillah@takeda.com.",dryangxue2010@163.com.
36252996,Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.,2022,"Nesline, Mary K","OmniSeq, Inc, Buffalo, New York, USA.",tian.zhang@utsouthwestern.edu.
36252599,"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.",2023,"López-Vilariño, José Antonio; Cullell-Young, Martin; Nieto, Antonio; Vasco, Noelia; Gómez, Javier; Kahatt, Carmen; Zeaiter, Ali","PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.",lpazaresr@seom.org.
36251545,Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.,2023,"Shubow, Sophie; Sun, Qin; Wang, Yow-Ming","Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.",None
36251491,BLOODPAC: Collaborating to chart a path towards blood-based screening for early cancer detection.,2023,"McDole, Jeremiah","Bio-Rad Laboratories Inc, Digital Biology Group, Pleasanton, California, USA.",None
36247923,"Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.",2022,"Wang, Chunxiao; Widau, Ryan C; Zhang, Wanli; Liu, Junjun; Zhang, Qiang","Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Shanghai, China.; Eli Lilly and Company, Shanghai, China.; Eli Lilly and Company, Shanghai, China.",None
36247019,"Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ",2022,"Iadeluca, Laura; Wilner, Keith D","Pfizer Inc., New York, New York.; Pfizer Inc., San Diego, California.",None
36244398,"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.",2022,"Collins, Helen; Mitra, Siddhartha; Yang, Yingsi","Global Development, Five Prime Therapeutics, South San Francisco, CA, USA.; Global Development, Five Prime Therapeutics, South San Francisco, CA, USA.; Global Development, Five Prime Therapeutics, South San Francisco, CA, USA.",ZWainberg@mednet.ucla.edu.
36243664,How Well do Polygenic Risk Scores Identify Men at High Risk for Prostate Cancer? Systematic Review and Meta-Analysis.,2023,"Kiran, Amit","Astellas Pharma Europe Ltd, Surrey, United Kingdom.",aino.siltari@tuni.fi.
36243543,Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.,2023,"Loehr, Andrea; Despain, Darrin; Watkins, Simon; King, Charmin; Nguyen, Minh; Simmons, Andrew D","Translational Medicine, Clovis Oncology, Inc, Boulder, CO, USA.; Biostatistics, Clovis Oncology, Inc., Boulder, CO, USA.; Clinical Development, Clovis Oncology UK Ltd, Cambridge, UK.; Clinical Operations, Clovis Oncology, Inc, Boulder, CO, USA.; Translational Medicine, Clovis Oncology, Inc, Boulder, CO, USA.; Translational Medicine, Clovis Oncology, Inc, Boulder, CO, USA.",abidam@mskcc.org.
36240478,FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on ,2023/Jan/20,"Bao, Weichao; Lu, Chengxing; Sierecki, Mitchell; Nakajima, Keiko; Ishida, Tatiane Cristine","Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ.; Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ.",None
36239939,Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019.,2022/Oct/03,"Lau, S W Johnny; Huang, Yue; Hsieh, Julie; Wang, Shenggang; Liu, Qi; Schwartz, Janice B; Huang, Shiew-Mei","Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.",None
36231138,An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.,2022/Oct/10,"Ferraù, Francesco","Medical Oncology, Ospedale San Vincenzo, 98039 Taormina, Italy.",None
36230741,"Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial.",2022/Oct/01,"Clarke, Christina A; Hamilton, Stephanie A; Zhang, Nan; Kumar, Harpal","GRAIL, LLC, a Subsidiary of Illumina, Inc., Menlo Park, CA 94025, USA.; GRAIL, LLC, a Subsidiary of Illumina, Inc., London, WC1V 7HP, UK.; GRAIL, LLC, a Subsidiary of Illumina, Inc., Menlo Park, CA 94025, USA.; GRAIL, LLC, a Subsidiary of Illumina, Inc., London, WC1V 7HP, UK.",None
36230681,Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.,2022/Sep/29,"Jiménez, Natalia; Reig, Òscar; Marín-Aguilera, Mercedes; Aversa, Caterina; Ferrer-Mileo, Laura; García-Esteve, Samuel; Prat, Aleix; Mellado, Begoña","Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.",None
36226872,Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?,2022/Oct/13,"Ramaswamy, Krishnan; Russell, David; Schultz, Neil M","Pfizer Inc, New York, New York, USA.; Pfizer Inc, New York, New York, USA.; Astellas Pharma, Inc, Northbrook, Illinois, USA.",None
36226865,Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?,2022,"Steinberg, Joyce; Sugg, Jennifer; Lin, Xun; Shen, Qi","Astellas Pharma Inc, Northbrook, IL, USA.; Astellas Pharma Inc, Northbrook, IL, USA.; Pfizer Inc, San Diego, CA, USA.; Pfizer Inc, San Francisco, CA, USA.",None
36224396,A saturated map of common genetic variants associated with human height.,2022,"Devineni, Poornima; Ho, Yuk-Lam A; Huffman, Jennifer E; Sendamarai, Anoop","Center for Data and Computational Sciences, VA Boston Healthcare System, Boston, MA, USA.; Veterans Affairs Boston Healthcare System, Boston, MA, USA.; Veterans Affairs Boston Healthcare System, Boston, MA, USA.; Center for Data and Computational Sciences, VA Boston Healthcare System, Boston, MA, USA.",Joel.Hirschhorn@childrens.harvard.edu.
36224216,Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19.,2022/Oct/12,"Heming, Nicholas; Annane, Djillali","Médecine Intensive Réanimation, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris (AP-HP), Garches, France.; Médecine Intensive Réanimation, Hôpital Raymond Poincaré, Assistance Publique-Hôpitaux de Paris (AP-HP), Garches, France.",slim.fourati@aphp.fr.
36220852,Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.,2022/Oct/11,"Liu, Xianchen; Li, Benjamin; McRoy, Lynn; Chen, Connie","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.",hope.rugo@ucsf.edu.
36220816,"Whole genome sequence analysis of blood lipid levels in >66,000 individuals.",2022/Oct/11,"Kim, Ryan; Viaud-Martinez, Karine A","Psomagen, Inc. (formerly Macrogen USA), Rockville, MD, USA.; Illumina Laboratory Services, Illumina. Inc, San Diego, 92122, USA.",pnatarajan@mgh.harvard.edu.
36217496,Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.,2022,"Suzuki, Ryu","Pharmaceuticals Group, Nippon Kayaku Co., Ltd, Kita-ku, Tokyo, Japan.",None
36216931,Anti-tumor efficacy of a potent and selective non-covalent KRAS,2022,"Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M; Hargis, Lauren; Engstrom, Lars D; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; David Lawson, J; Gunn, Robin J; Smith, Christopher R; Thomas, Nicole C; Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis; Bouhana, Karyn; Winski, Shannon; Haling, Jacob R; Rahbaek, Lisa; Marx, Matthew A; Olson, Peter; Christensen, James G","Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.; Array BioPharma, Inc. (acquired by Pfizer), Boulder, CO, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA.; Mirati Therapeutics, Inc., San Diego, CA, USA. christensenj@mirati.com.",christensenj@mirati.com.
36216827,Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.,2022/Oct/10,"Martini, Jean-François; Mu, Xinmeng J; Lin, Xun; Ching, Keith A","Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA.; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA.; Global Product Development-Oncology, Pfizer Inc, La Jolla, CA, 92121, USA.; Oncology Research Unit, Pfizer Worldwide Research and Development Medicine, Pfizer Inc, La Jolla, CA, 92121, USA.",motzerr@mskcc.org.
36215989,"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.",2022,"Akram, Muhammad; Pacaud, Lida","Legend Biotech USA, Piscataway, NJ, USA.; Legend Biotech USA, Piscataway, NJ, USA.",sundar.jagannath@mountsinai.com.
36209982,Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.,2023,"Arkenau, H T","HCA Healthcare UK, London, UK.",jlgracia@unav.es.
36209764,"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.",2022,"Cheng, Yiming; Amatangelo, Michael; Chen, Min; Nguyen, Tuong Vi; Amin, Alpesh","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",sloni01@emory.edu.
36202690,Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.,2022,"Ascierto, Paolo A; Chen, Ke; Jiang, Ruixuan; Fukunaga-Kalabis, Mizuho; Krepler, Clemens","Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS ""Fondazione G. Pascale,"" Naples, Italy.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",Muhammed.Khattak@health.wa.gov.au.
36201711,Impact of an Interdisciplinary Goals-of-Care Program Among Medical Inpatients at a Comprehensive Cancer Center During the COVID-19 Pandemic: A Propensity Score Analysis.,2023/Jan/20,"Aloia, Thomas","Ascension Healthcare, Houston, TX.",None
36199494,Timely Genetic Testing and Therapy Management in Patients With g,2022,"Jones, Tiffany; Ryan, Joanne C; Barnett, Chad M; Soussou, Elpitha L","OHC/US Oncology Blue Ash, Cincinnati, Ohio.; Pfizer Inc., New York, New York.; Pfizer Inc., New York, New York.; Pfizer Inc., New York, New York.",None
36198128,Automated Ascertainment of Typhlitis From the Electronic Health Record.,2022,"Miller, Tamara P; Castellino, Sharon M","Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.",None
36197494,Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.,2023,"Poretta, Tayla; Stwalley, Brian D; Sakkal, Leon A; Du, Ella X; Wang, Travis; Chen, Yan; Wang, Yan; Betts, Keith A","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Analysis Group, Inc., Los Angeles, CA, USA.; Analysis Group, Inc., Los Angeles, CA, USA.; Analysis Group, Inc., Los Angeles, CA, USA.; Analysis Group, Inc., Los Angeles, CA, USA.; Analysis Group, Inc., Los Angeles, CA, USA.",jeffrey.weber@nyulangone.org.
36193709,Impact of frailty on mortality and quality of life in patients with a history of cancer undergoing transcatheter aortic valve replacement.,2022,"Goldwater, Deena","Welcome Health Medical Group, Welcome Health Inc, Long Beach, California, USA.",None
36192237,A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.,2022,"Credille, Kelly M; Young, Suzanne R; McNeely, Samuel; Wang, Xuejing Aimee; Lin, Aimee Bence","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",Panagiotis_Konstantinopoulos@DFCI.HARVARD.EDU.
36190331,Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.,2022/Dec/09,"Rao, Sujata; Sun, Fangfang; Wang, Chunxiao; Widau, Ryan C","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",None
36186147,AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022.,2022,"Lux, Michael Patrick","Kooperatives Brustzentrum Paderborn, Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn und St. Josefs-Krankenhaus, Salzkotten, St. Vincenz-Krankenhaus GmbH, Paderborn, Germany.",None
36183219,Patient-reported experience in lung and breast cancer through a patient journey.,2022/Jul/17,"Mareque, María; Casado, Miguel Ángel","Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid. Spain.. mmareque@porib.com.; Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid. Spain.. ma_casado@porib.com.",jignaciochacon@gmail.com.
36180872,Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.,2022/Sep/30,"Mallardo, Domenico; Simeone, Ester; Vanella, Vito; Vitale, Maria Grazia; Palla, Marco; Scarpato, Luigi; Paone, Miriam; De Cristofaro, Teresa; Sparano, Francesca; Budillon, Alfredo; Ascierto, Paolo Antonio","Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori - IRCCS - Fondazione ""G. Pascale"", Naples, Italy. p.ascierto@istitutotumori.na.it.",p.ascierto@istitutotumori.na.it.
36180795,Stroke genetics informs drug discovery and risk prediction across ancestries.,2022,"Posner, Daniel C; Cho, Kelly; Ho, Yuk-Lam; Huffman, Jennifer E","Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA.",stephanie.debette@u-bordeaux.fr.
36178256,Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States.,2022,"Ozbay, A Burak","Exact Sciences Corporation, Madison, Wisconsin, USA.",None
36175779,Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.,2023,"Garcia-Vargas, Jose; Childs, Barrett H; Yasuda, Masanobu; Masuda, Shigeo; Tsujino, Toshiaki; Terao, Yui","Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA.; Bayer Yakuhin, Ltd, Osaka, Japan.; Bayer Yakuhin, Ltd, Osaka, Japan.; Bayer Yakuhin, Ltd, Osaka, Japan.; Bayer Yakuhin, Ltd, Osaka, Japan.",nfukuhara@med.tohoku.ac.jp.
36175037,Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).,2022,"Humphrey, Rachel W","Normunity, Inc, South San Francisco, California, USA.",mba41@Georgetown.edu.
36174582,"The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA.",2022,"Paul, Shilpa","Pharmacy Division, MD Anderson Cancer Center, Houston, TX, USA.",hkantarjian@mdanderson.org.
36173619,Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.,2022/Nov/01,"Chng, Nick; Matthews, Quinn","British Columbia Cancer, Prince George, British Columbia, Canada.; British Columbia Cancer, Prince George, British Columbia, Canada.",None
38505379,Descriptive epidemiology of COVID-19 in Japan 2020: insights from a multihospital database.,2023,"Inokuchi, Shoichiro; Kimura, Takeshi","Real World Data Co., Ltd.; Real World Data Co., Ltd.",None
36170624,Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.,2022,"Wu, Hsin-Ta; Balcioglu, Mustafa; Kalashnikova, Ekaterina; Sethi, Himanshu; Aleshin, Alexey","Natera Inc, Austin, TX.; Natera Inc, Austin, TX.; Natera Inc, Austin, TX.; Natera Inc, Austin, TX.; Natera Inc, Austin, TX.",None
36169807,Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.,2022,"Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong; Park, Sijin; Ju, Hana","Celltrion, Inc., 23 Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.; Celltrion, Inc., 23 Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.; Celltrion, Inc., 23 Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.; Celltrion, Inc., 23 Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.; Celltrion, Inc., 23 Academy-ro, Yeonsu-gu, Incheon, 22014, Republic of Korea.",yohe@ncc.go.jp.
36169327,Unknown,2022/Oct/18,"Critchley, Ian; Cotroneo, Nicole","Spero Therapeutics, Cambridge, Massachusetts, USA.; Spero Therapeutics, Cambridge, Massachusetts, USA.",None
36168187,Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.,2023,"Maki, Akio; Aoki, Makoto; Allepuz, Alex","Novartis Pharma KK, Tokyo, Japan.; Novartis Pharma KK, Tokyo, Japan.; Novartis Pharma AG, Basel, Switzerland.",None
36165586,Proceedings of the 2022 National Toxicology Program Satellite Symposium.,2022,"Quist, Erin M; Choudhary, Shambhunath; Tokarz, Debra A","Charles River Laboratories, Inc., Durham, North Carolina, USA.; Pfizer, Inc., Pearl River, New York, USA.; Experimental Pathology Laboratories, Inc., Durham, North Carolina, USA.",None
36165097,Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.,2022,"Pei, Jinglan; Raut, Pranil; Raposo, Catarina; Priest, Jessica; Cabatingan, Mark; Winger, Ryan C","Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.",None
36164935,Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.,2023,"Kamio, Takahiro","Clinical Safety and Pharmacovigilance, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.",None
36163093,Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.,2022/Nov/08,"Mues, Katherine E; Kirk, Brenna; Patel, Deesha A; Gelman, Alice; Chavers, L Scott; Talarico, Carla A; Esposito, Daina B; Martin, David; Mansi, James; Chen, Xing; Gatto, Nicolle M; Van de Velde, Nicolas","Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001, USA. Electronic address: katie.mues@aetion.com.; Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001, USA.; Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001, USA.; Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.; Aetion, Inc, 5 Pennsylvania Plaza, New York, NY 10001, USA.; Moderna, Inc, 200 Technology Square, Cambridge, MA 02139, USA.",katie.mues@aetion.com.
36162037,Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).,2023/Jan/20,"Schenker, Michael; Butler, Marcus O; Re, Sandra; Bas, Tuba; de Pril, Veerle; Braverman, Julia; Tenney, Daniel J; Tang, Hao","Oncology Center Sf Nectarie Ltd, Craiova, Romania.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.; Bristol Myers Squibb Company, Princeton, NJ.",None
36156915,AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.,2022,"Lux, Michael Patrick","Kooperatives Brustzentrum Paderborn, Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn und St. Josefs-Krankenhaus, Salzkotten, St. Vincenz-Krankenhaus GmbH, Paderborn, Germany.",None
36156913,AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.,2022,"Maass, Nicolai","St. Vincenz-Krankenhaus GmbH, Paderborn, Germany.",None
36155129,EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study.,2022,"Andersen, Klaus Kaae; Aarøe, Jørgen","Medical, Biopharmaceuticals, AstraZeneca Nordic, Copenhagen, Denmark.; Medical, Biopharmaceuticals, AstraZeneca of Nordic, Oslo, Norway.",espen.enerly@kreftregisteret.no.
36155117,Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.,2022,"Wang, Xinwei; Zhao, Huadong","Pfizer (China) R&amp;D Co., Ltd., Shanghai, China.; Pfizer (China) R&amp;D Co., Ltd., Shanghai, China.",xubinghe@medmail.com.cn.
36154123,Cross-Ancestry Investigation of Venous Thromboembolism Genomic Predictors.,2022/Oct/18,"Cuellar-Partida, Gabriel; Huffman, Jennifer E; Wang, Xin","23andMe, Inc, Sunnyvale, CA (G.C.-P., X.W.).; MAVERIC (J.E.H.), Veterans Affairs Boston Healthcare System, MA.; 23andMe, Inc, Sunnyvale, CA (G.C.-P., X.W.).",None
36152478,"EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.",2022,"Syed, Iqra; Gwadry-Sridhar, Femida; Liu, Linda; Rakibuz-Zaman, Muhammad; Moldaver, Daniel; Kate Shanahan, Mary","AstraZeneca Canada Inc., 5000-1004 Middlegate Road, Mississauga, ON L4Y 1M4, Canada.; Pulse Infoframe Inc., 111-700 Collip Circle, London, ON N6G 4X8, Canada.; Pulse Infoframe Inc., 111-700 Collip Circle, London, ON N6G 4X8, Canada.; Pulse Infoframe Inc., 111-700 Collip Circle, London, ON N6G 4X8, Canada.; AstraZeneca Canada Inc., 5000-1004 Middlegate Road, Mississauga, ON L4Y 1M4, Canada.; AstraZeneca Canada Inc., 5000-1004 Middlegate Road, Mississauga, ON L4Y 1M4, Canada.",sara.kuruvilla@lhsc.on.ca.
36151699,Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.,2023,"Dan, Takashi","Renascience Inc., Tokyo, Japan.",None
36151107,Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.,2022/Sep/23,"Wang, Yuli; Shi, Manli; Tan, Weiwei; Weinrich, Scott L","Oncology Research and Development, Pfizer Inc, La Jolla, CA, USA.; Oncology Research and Development, Pfizer Inc, La Jolla, CA, USA.; Clinical Pharmacology Oncology, Global Product Development, Pfizer Inc, San Diego, CA, USA.; Oncology Research and Development, Pfizer Inc, La Jolla, CA, USA.",michor@jimmy.harvard.edu.
36149968,Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.,2022/Dec/13,"Braverman, Julia; Liu, Fei Fei; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro","Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.",None
36148739,Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.,2022,"Gaillard, Vincent E","Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland.",david.pinato@imperial.ac.uk.
36141230,"How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?",2022/Aug/25,"Ascierto, Paolo Antonio","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G. Pascale"", 80131 Naples, Italy.",None
36136395,Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.,2022/Sep/22,"Bell, Timothy; Mamolo, Carla; Neuhof, Alexander","SpringWorks Therapeutics, Stamford, CT, United States.; Pfizer Inc, Groton, CT, United States.; Pfizer Pharma GmbH, Berlin, Germany.",None
36131248,"PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.",2022/Sep/21,"Fillbrunn, Mirko; Signorovitch, James; Dua, Akanksha","Analysis Group, Inc., Boston, Massachusetts, USA.; Analysis Group, Inc., Boston, Massachusetts, USA. James.Signorovitch@analysisgroup.com.; Analysis Group, Inc., Boston, Massachusetts, USA.",James.Signorovitch@analysisgroup.com.
36127823,Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.,2023,"Martínez, Sara; Kahatt, Carmen; Fudio, Salvador; Corral, Gema; Zeaiter, Ali; Montilla, Lola","PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.; PharmaMar, Madrid, Spain.",None
36126244,Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer.,2022,"Waterhouse, David","Oncology Hematology Care, Cincinnati, OH.",None
36124924,"Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.",2022/Oct/01,"Dorff, Tanya; Chen, Hsiang-Chun; Di Santo, Nicola","Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.; Biostatistics, Pfizer Inc., La Jolla, CA, USA.; Global Product Development, Pfizer Inc., Durham, NC, USA.",None
36123383,"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.",2022/Sep/19,"O'Farrell, Marie; Duke, Greg; Crowley, Richard; Buckley, Douglas; Martins, Eduardo B; Kemble, George","Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA. marie.ofarrell@sagimet.com.; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.",marie.ofarrell@sagimet.com.
36123366,Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer.,2022/Sep/19,"Patel, Sheetal; Patel, Shilpen; Duc, Anh Nguyen; Liste-Hermoso, Mario; Chui, Stephen Y","Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.",barrios@thummi.global.
36122315,Selpercatinib in Patients With ,2023/Jan/10,"Soldatenkova, Victoria; Barker, Scott S; Puri, Tarun; Bence Lin, Aimee","Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.; Eli Lilly and Company, Indianapolis, IN.",None
36121651,"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.",2023/Feb/15,"Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian","Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",None
36119832,Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.,2022,"Jiang, Yizhou; Thomas, Martine; Kirillova, Natalia; Bridgeman, John S; Kueberuwa, Gray; Biswas, Sunetra; Velazquez, Peter; Chonzi, David; Guest, Ryan D; Roberts, Zachary J","Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.; Instil Bio, Inc. Dallas, TX, USA.",None
36119641,Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study.,2022,"Jazieh, Abdul Rahman; Kumar, Amit","Cincinnati Cancer Advisors, Cincinnati, OH, USA.; AstraZeneca Pharma India Ltd, Bangalore, Karnataka, India.",None
36117201,Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.,2022/Sep/19,"Tesarowski, David; Song, Chunyan; Lysbet de Haas, Sanne; Boulet, Thomas; Lambertini, Chiara","Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",sibylle.loibl@gbg.de.
36116480,"Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.",2022/Sep/17,"Watts, Nelson; Garner, Elizabeth","Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, USA.; Ferring Pharmaceuticals, Parsippanny, NJ, USA. Electronic address: elizabeth.garner@ferring.com.",elizabeth.garner@ferring.com.
36113895,Intratumoral administration of CD1c (BDCA-1),2022,"Vasaturo, Angela; Bagnall, Christopher","Ultivue, Inc, Cambridge, Massachusetts, USA.; Ultivue, Inc, Cambridge, Massachusetts, USA.",JuliaKatharina.Schwarze@uzbrussel.be.
36110894,Update Breast Cancer 2022 Part 3 - Early-Stage Breast Cancer.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany.",None
36110892,Axillary Staging after Neoadjuvant Chemotherapy for Initially Node-Positive Breast Carcinoma in Germany: Initial Data from the AXSANA study.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany.",None
36110891,Update Breast Cancer 2022 Part 4 - Advanced-Stage Breast Cancer.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany.",None
36108661,"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.",2022,"Soldatenkova, Victoria; Sullivan, Loretta; Wright, Jennifer","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",vsubbiah@mdanderson.org.
36108560,"Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.",2022,"Luedtke, D; He, M","Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany.; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, USA.",christophe.letourneau@curie.fr.
36108261,Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.,2022,"Martini, Jean-François; Philip, Thierry","Pfizer Inc, San Diego, CA.; Pfizer Inc, San Diego, CA.",None
36108156,Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.,2022/Dec/02,"Friedrichsen, Megan; Liu, Xin; Margolis, Matthew L; Tierno, Marni Brisson; Oxnard, Geoffrey R","Foundation Medicine, Inc., Cambridge, Massachusetts.; Foundation Medicine, Inc., Cambridge, Massachusetts.; Foundation Medicine, Inc., Cambridge, Massachusetts.; Foundation Medicine, Inc., Cambridge, Massachusetts.; Foundation Medicine, Inc., Cambridge, Massachusetts.",None
36107394,"Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.",2022,"Hanaya, Miyoko; Hirano, Satoshi; Narushima, Kazuya","Kyowa Kirin Co., Ltd., Tokyo, Japan.; Kyowa Kirin Co., Ltd., Tokyo, Japan.; Kyowa Kirin Co., Ltd., Tokyo, Japan.",teshima@med.hokudai.ac.jp.
36105914,Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10,2022,"Roussou, Pantelia; Wroclawska, Monika; Karumanchi, Divyadeep; Sinclair, Karen","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.",None
36104138,"Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.",2022/Sep/14,"Johansen, Jennifer L","US Medical Immunology and Fibrosis, Bristol Myers Squibb, Princeton, New Jersey, USA.",daniel.george@duke.edu.
36102184,Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.,2022/Nov/25,"Carlsson, Martin; Wajnrajch, Michael P","Rare Disease, Biopharmaceuticals, Pfizer, New York, NY 10017, USA.; Rare Disease, Biopharmaceuticals, Pfizer, New York, NY 10017, USA.",None
36101520,MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.,2022,"Wilson, Timothy R; Chen, David; Simmons, Brian; Turner, Kristen M; Perusse, Dean; Kasibhatla, Shailaja; Christiansen, Jason","Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Genentech, Inc., South San Francisco, California, USA.; Boundless Bio, Inc., San Diego, California, USA.; Boundless Bio, Inc., San Diego, California, USA.; Boundless Bio, Inc., San Diego, California, USA.; Boundless Bio, Inc., San Diego, California, USA.",None
36100605,Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.,2022/Sep/14,"Harding, Stephen","Binding Site Group Ltd, Birmingham, UK.",sigyngvi@hi.is.
36098654,Improving access to oncology publications for advocates and people with cancer.,2022/Nov/01,"Chari, Dheepa; Ghith, Jennifer; Ferdinand, Roxanne","Pfizer Inc., New York, New York, USA.; Pfizer Inc., New York, New York, USA.; Pfizer Inc., New York, New York, USA.",None
36097345,Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.,2022,"Hansen, Aaron R","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",None
36097216,"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.",2022,"Schulze, Katja; Nicholas, Alan; Johnson, Ann; Grindheim, Jessica; Hilz, Stephanie; Shames, David S","Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.",david.carbone@osumc.edu.
36096973,Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.,2022,"Nunes, Ana Tablante","Merck, 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ 07065, United States of America.. Electronic address: atablante1@gmail.com.",bmonk@gog.org.
36094611,Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958).,2022,"Eckl, Tanja","Roche Pharma AG, Grenzach-Wyhlen, Germany.",marc.thill@agaplesion.de.
36093741,Novel and existing flexible survival methods for network meta-analyses.,2022/Sep/12,"Roychoudhury, Satrajit; Cappelleri, Joseph Christopher","Pfizer, Inc., 235 E 42nd St, New York, NY 10017, USA.; Pfizer, Inc., 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.",None
36091159,"POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma.",2022,"Jones, Mark; Bowman, Jill; Tian, Chuan","Incyte Corporation, Wilmington, DE, United States.; Incyte Corporation, Wilmington, DE, United States.; Incyte Corporation, Wilmington, DE, United States.",None
36090051,Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics.,2022,"Hallenbeck, Paul","Seneca Therapeutics, Inc., Blue Bell, PA, United States.",None
36089110,"Discovery of MDV6058 (PF-06952229), a selective and potent TGFβR1 inhibitor: Design, synthesis and optimization.",2022/Nov/01,"Pujala, Brahmam; Ramachandran, Sreekanth A; Sonawane, Mukesh; Kamble, Maruti M; Panpatil, Dayanand; Adhikari, Swati; Soni, Sanjeev; Subbareddy, Venkata; Shinde, Bharat U; Nayak, Anjan K; Bansal, Chandni; Gupta, Ashu; Mukherjee, Kakoli; Agarwal, Anil K; Herrera, Francisco J; Bernales, Sebastian; Guha, Mausumee; Chakravarty, Sarvajit; Pham, Son M; Rai, Roopa","Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Integral BioSciences Pvt. Ltd., C-64, Hosiery Complex Phase II Extension, Noida, Uttar Pradesh 201306, India.; Medivation, Inc., 525 Market Street, 36(th) Floor, San Francisco, CA 94105, USA.; Medivation, Inc., 525 Market Street, 36(th) Floor, San Francisco, CA 94105, USA.; Medivation, Inc., 525 Market Street, 36(th) Floor, San Francisco, CA 94105, USA; Pfizer Inc., Pfizer World Wide Research & Development, Building CB-4, 10777 Science Center Dr. La Jolla, CA 92121-1111, USA.; Medivation, Inc., 525 Market Street, 36(th) Floor, San Francisco, CA 94105, USA.; Medivation, Inc., 525 Market Street, 36(th) Floor, San Francisco, CA 94105, USA.; Medivation, Inc., 525 Market Street, 36(th) Floor, San Francisco, CA 94105, USA. Electronic address: roopa.rai@hotmail.com.",roopa.rai@hotmail.com.
36087093,Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.,2022,"Davicioni, Elai","Decipher Biosciences Inc., San Diego, CA, USA.",None
36085288,In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.,2022/Sep/09,"Wang, Amber Weiching","ORIC Pharmaceuticals, San Francisco, USA.",rajadhym@mskcc.org.
36084396,Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.,2022,"Hickman, D; Gallacher, P D; Wennborg, A; Attar, E C","Aprea Therapeutics, Boston, USA.; Aprea Therapeutics, Boston, USA.; Aprea Therapeutics, Boston, USA.; Aprea Therapeutics, Boston, USA.",haeseongpark@wustl.edu.
36083121,Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.,2022/Dec/27,"Yang, Zhongming; Noonan, John","Kadmon Corporation, New York, NY.; Kadmon Corporation, New York, NY.",None
36082969,Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.,2023/Jan/20,"Oza, Amit","Princess Margaret Cancer Center, Toronto, ON, Canada.",None
36077680,Management of Cancer-Associated Thrombosis in France: A National Survey among Vascular Disease and Supportive Care Specialists.,2022/Aug/27,"Chapelle, Céline","Unité de Recherche Clinique Innovation et Pharmacologie, CHU de Saint-Etienne, 42270 Saint-Etienne, France.",None
36077617,"BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.",2022/Aug/23,"Das, Sharmila; Apfel, Abraham; Xu, Ke; Kozicki, Martin; Ünsal-Kaçmaz, Keziban; Hammell, Amy; Wang, Guan; Ravindran, Palanikumar; Kollia, Georgia; Esposito, Oriana; Coker, Shodeinde","Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.; Bristol Myers Squibb, Princeton, NJ 08648, USA.",None
36072989,The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients.,2022,"Bouvier, Catherine","International Neuroendocrine Cancer Alliance (INCA), Boston, Massachusetts, USA.",None
36071033,High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER,2022/Sep/07,"Su, Faye; Lin, Kui","Novartis Pharmaceuticals, East Hanover, NJ, USA.; Genentech, Inc., South San Francisco, California, USA.",vserra@vhio.net.
36070389,A two-step mechanism governing PARP1-DNA retention by PARP inhibitors.,2022/Sep/09,"Zhang, Lianglin; Ding, Xia; VanArsdale, Todd L","Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.; Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.; Oncology Research and Development, Pfizer Inc., La Jolla, CA 92121, USA.",None
36069821,Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.,2022/Nov/01,"Asare, Smita M","Quantum Leap Healthcare Collaborative, San Francisco.",None
36067452,Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance).,2023/Jan/20,"Innocenti, Federico","AbbVie Inc, North Chicago, IL.",None
36066725,"Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.",2023,"Kiermaier, Astrid; Macharia, Harrison; Restuccia, Eleonora","Pharmaceutical Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",jtabernero@vhio.net.
36065116,Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses.,2022/Nov/21,"Fonseca, Claudia; Taussig, Michael J","Cambridge Protein Arrays Ltd, Babraham Research Campus, Cambridge, UK.; Cambridge Protein Arrays Ltd, Babraham Research Campus, Cambridge, UK.",None
36065062,Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates.,2022,"Akama, Tsutomu; Carter, David S; Easom, Eric; Freund, Yvonne; Halladay, Jason S; Liu, Yang; Tse, Susanna; Jacobs, Robert T","Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.; Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.; Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.; Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.; Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.; Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.; Pharmacokinetics, Dynamics and Metabolism, Worldwide Research, Pfizer Inc., New York, NY, USA.; Anacor Pharmaceuticals, Inc, Palo Alto, CA, USA.",tarleton@uga.edu.
36064707,Smoldering multiple myeloma current treatment algorithms.,2022/Sep/05,"Rajkumar, S Vincent","Division of Hematology, Mayo Clinic, Rochester, MN, USA. rajkumar.vincent@mayo.edu.",rajkumar.vincent@mayo.edu.
36063830,"Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.",2022,"Redfern, Charles","Sharp HealthCare, San Diego, CA, USA.",fredsaad@videotron.ca.
36060224,Risk Factors Associated with Falls and Fractures Following Prescription of Opioids Among Privately Insured Patients with Osteoarthritis.,2022,"Schepman, Patricia; Rice, J Bradford; Beck, Craig G; Pajerowski, William; White, Alan G; Thakkar, Sheena; Robinson, Rebecca L; Emir, Birol","Pfizer Inc., New York.; Analysis Group Inc., Boston, Massachusetts.; Pfizer Inc., New York, NY.; Analysis Group Inc., Boston, MA.; Analysis Group Inc., Boston, MA.; Pfizer Inc., New York, NY.; Pfizer Inc., New York, NY.; Pfizer Inc., New York, NY.",None
36058945,"Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).",2022/Sep/04,"Ernstoff, Marc S","Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA.",paolo.ascierto@gmail.com.
36055332,"Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial.",2022,"Ajayi, Temitayo; Al-Adhami, Mohammed; Deschatelets, Pascal; Francois, Cedric; Grossi, Federico","Apellis Pharmaceuticals, Waltham, MA, USA.; Apellis Pharmaceuticals, Waltham, MA, USA.; Apellis Pharmaceuticals, Waltham, MA, USA.; Apellis Pharmaceuticals, Waltham, MA, USA.; Apellis Pharmaceuticals, Waltham, MA, USA.",regis.peffaultdelatour@aphp.fr.
36055304,"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",2022,"Burgents, Joseph E; Xu, Lei; Imai, Kentaro","Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.; Merck & Co, Inc, Rahway, NJ, USA.",thomas.powles1@nhs.net.
36054756,Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.,2022,"Lipton, Jeffrey; Rosti, Gianantonio; Srivastava, Shouryadeep; Ren, Xiaowei","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; IRST/IRCCS ""Dino Amadori"", Meldola, Province of Forlì-Cesena, Italy.; Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.; Takeda Development Center Americas, Inc., Lexington, Massachusetts, USA.",None
36053878,Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study.,2022,"Duan, Yinghui; Potluri, Jalaja; Werner, Michael","AbbVie, Inc, North Chicago, Illinois, USA.; AbbVie, Inc, North Chicago, Illinois, USA.; AbbVie, Inc, North Chicago, Illinois, USA.",None
36053834,ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.,2022/Dec/15,"Sivakumar, Smruthy; Sokol, Ethan","Cancer Genomics Research, Foundation Medicine, Inc, Cambridge, Massachusetts, USA.; Cancer Genomics Research, Foundation Medicine, Inc, Cambridge, Massachusetts, USA.",None
36052772,Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.,2023,"Xia, Jinjing; Liu, Wenxin; Shi, Jane; Yi, Jing","F. Hoffmann-La Roche Ltd, Shanghai, China.; F. Hoffmann-La Roche Ltd, Shanghai, China.; F. Hoffmann-La Roche Ltd, Shanghai, China.; Genentech Inc, South San Francisco, California, USA.",None
36052536,"Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.",2023,"Matsangou, Maria; Wu, Chunzhang; Campbell, Mary; Yamashiro, Mayumi","Astellas Pharma, Inc., Northbrook, Illinois, USA.; Astellas Pharma, Inc., Northbrook, Illinois, USA.; Seagen Inc., Bothell, Washington, USA.; Astellas Pharma, Inc., Tokyo, Japan.",None
36050448,Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.,2022,"Korde, Larissa; Wang, Yingbo","Breast Cancer Therapeutics, CTEP, NCI, Seattle, WA, USA.; Oncology, Novartis Pharmaceuticals Corporation, Basel, Switzerland.",guilherme.nadermarta@bordet.be.
36050271,CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.,2022,"Cronin, Maureen; Fredriksson, Martin; Sundgren, Mats","Vifor Pharma, Glattbrugg, Switzerland; Ava, Zurich, Switzerland.; Late Clinical Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals, AstraZeneca, Gothenburg, Sweden.; Data Science and Artificial Intelligence, Biopharmaceuticals, AstraZeneca, Gothenburg, Sweden.",d.kotecha@bham.ac.uk.
36049057,"Evaluation of EDB Fibronectin in Plasma, Patient-Derived Xenograft Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tumor Tissues Using Immunoaffinity LC-MS/MS.",2022/Oct/07,"Li, Fengping; Hooper, Andrea T; Golas, Jonathon; Chang, Chao-Pei Betty; Neubert, Hendrik; King, Lindsay","BioMedicine Design, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810, United States.; Oncology Research &amp; Development, Pfizer Inc., 401 N Middletown Rd, Pearl River, New York 10965, United States.; Oncology Research &amp; Development, Pfizer Inc., 401 N Middletown Rd, Pearl River, New York 10965, United States.; Oncology Research &amp; Development, Pfizer Inc., 401 N Middletown Rd, Pearl River, New York 10965, United States.; BioMedicine Design, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts 01810, United States.; Clinical Pharmacology, Global Product Development, Pfizer Inc. 610 Main St, Cambridge, Massachusetts 02139, United States.",None
36048457,Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.,2022/Oct/01,"Akella, Lalith; Orford, Keith","Calithera Biosciences, Inc, South San Francisco, California.; Calithera Biosciences, Inc, South San Francisco, California.",None
36045401,Clinical trial design in the era of precision medicine.,2022/Aug/31,"Kurzrock, Razelle","WIN Consortium, Villejuif, France. Razelle.kurzrock@winconsortium.org.",Razelle.kurzrock@winconsortium.org.
36044897,Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.,2022/Oct/14,"Zhou, Heyue; Zhang, Yanliang; Shaabani, Namir; Du, Na; Singh, Alok; Li, Donghui; Stegman, Karen; Cao, Xia; Lim, Reyna; Rivero-Nava, Laura; Johnson, Sachi; Pai, Chin I; Cabral, Elizabeth Paz; Healy, Laura; Kerwin, Lisa; Bresson, Damien; Fu, Yanwen; Powers, Colin; Ji, Henry; Allen, Robert","Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA. Electronic address: hji@sorrentotherapeutics.com.; Sorrento Therapeutics, Inc., San Diego, CA 92121, USA.",hji@sorrentotherapeutics.com.
36044561,Application of Immunocompetent Microphysiological Systems in Drug Development: Current Perspective and Recommendations.,2022/Aug/29,"Wang, Xiaoting; Kopec, Anna K; Collinge, Mark; David, Rhiannon; Grant, Christian; Hardwick, Rhiannon N; Navratil, Aaron","Translational Safety & Bioanalytical Sciences, Amgen Research, Amgen, Inc., South San Francisco, CA, USA.; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA.; Drug Safety Research & Development, Pfizer, Inc., Groton, CT, USA.; Safety Innovation, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Preclinical Safety, AbbVie, Inc., Worcester, MA, USA.; Translational Safety Sciences, Theravance Biopharma US, Inc., South San Francisco, CA, USA.; Biology and Pharmacology, Theravance Biopharma US, Inc., South San Francisco, CA, USA.",None
36043988,Risk factors in people with mold infections that have spread to different parts of the body: a plain language summary.,2022,"Sung, Anita H; Phan, Bryant; Benigno, Michael; Aram, Jalal A","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.",None
36041086,Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.,2023/Jan/01,"Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie","Merck & Co, Inc, Kenilworth, NJ.; Seagen Inc, Bothell, WA.; Seagen Inc, Bothell, WA.",None
36040373,High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.,2022/Nov/02,"Kim, Jaegil","GSK inc. 196 Broadway, Cambridge, Massachusetts.",None
36038629,Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.,2022,"Scholler, Nathalie; Chang, Edmund C; Kim, Jenny J; Chou, Justin; Plaks, Vicki; Wang, Zixing; Xue, Allen; Mattie, Mike; Rossi, John M; Bot, Adrian","Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.; Kite, a Gilead company, Santa Monica, CA, USA.",jerome.galon@crc.jussieu.fr.
36038003,"Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.",2022,"Styren, Scot; Brown, Mark T","Pfizer Inc., New York, NY, USA.; Pfizer Inc., New York, NY, USA.",splotkin@mgh.harvard.edu.
36037567,"Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.",2022,"Fernández, C; Kahatt, C; Alfaro, V; Siguero, M; Zeaiter, A","PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.",vsubbiah@mdanderson.org.
36037515,Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.,2022/Nov/22,"Shacham, Sharon; Landesman, Yosef","Karyopharm Therapeutics, Newton, MA.; Karyopharm Therapeutics, Newton, MA.",None
36036294,Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.,2022,"Kudou, Kentarou; Zhang, Pingkuan","Biostatistics, Japan Development Center, Takeda Pharmaceutical Company Limited, Osaka, Japan.; Takeda Development Center Americas, Inc., Lexington, MA, USA.",yohe@ncc.go.jp.
36029653,"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF",2022,"Tahiri, A; Gilberg, F; Irahara, N","F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",jtabernero@vhio.net.
36029651,Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.,2022,"Avery, E J; Sun, J; Li, D; Rosales, M K","Division of Hematology and Oncology, Nebraska Hematology-Oncology, Lincoln, USA.; MacroGenics, Inc., Rockville, USA.; MacroGenics, Inc., Rockville, USA.; MacroGenics, Inc., Rockville, USA.",DocCatenacci@catenacciconsulting.com.
36029527,"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.",2022/Nov/01,"Bueno, Orlando F; Pothacamury, Rajvineeth K; Freise, Kevin J; Yue, Susan; Ross, Jeremy A; Polepally, Akshanth R; Talati, Chetasi; Lee, Shane; Jin, Ziyi; Buelow, Ben","AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; AbbVie, Inc, North Chicago, IL.; TeneoBio, Inc, Newark, CA.",None
36028857,"Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.",2022/Aug/26,"Murru, Roberta","Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, ARNAS ""G. Brotzu"", Cagliari, Italy.",darko.antic1510976@gmail.com.
36028783,Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer.,2022,"Wang, Xiaoliang; Ascha, Mustafa; Showalter, Timothy N; Lewin, Heather G; Calip, Gregory S","Flatiron Health, Inc, 233 Spring Street 5th Floor, New York, NY, 10013, USA. wendy.wang@flatiron.com.; Flatiron Health, Inc, 233 Spring Street 5th Floor, New York, NY, 10013, USA.; Flatiron Health, Inc, 233 Spring Street 5th Floor, New York, NY, 10013, USA.; Flatiron Health, Inc, 233 Spring Street 5th Floor, New York, NY, 10013, USA.; Flatiron Health, Inc, 233 Spring Street 5th Floor, New York, NY, 10013, USA.",wendy.wang@flatiron.com.
36017743,Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.,2023,"Wolff, Frieder","Roche Pharma AG, Biometrics & Epidemiology, Grenzach-Wyhlen, Germany.",None
36011250,Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?,2022/Aug/22,"Fandel, Marie-Helene","Corporate Public Affairs, Sanofi, 1831 Diegem, Belgium.",None
36008722,"Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.",2022,"Dvorkin, Mikhail; Li, Siyu; McGuire, Kristina; Kaul, Manika; Paccaly, Anne; Quek, Ruben G W; Gao, Bo; Seebach, Frank; Weinreich, David M; Yancopoulos, George D; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra","State Budgetary Healthcare Institution of Omsk Region, Omsk, Russia.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",mirandagogishvili@yahoo.com.
36008705,Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE.,2022,"Watson, Geoffrey A; Veitch, Zachary W; Shepshelovich, Daniel; Spreafico, Anna; Abdul Razak, Albiruni R; Bedard, Philippe L; Siu, Lillian L; Hansen, Aaron R","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. aaron.hansen@uhn.ca.",aaron.hansen@uhn.ca.
36007281,Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.,2022,"Penrod, John R","Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.",Frank.Griesinger@Pius-Hospital.de.
36007218,Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.,2023/Jan/20,"Chen, Eric X","Princess Margaret Cancer Centre, Toronto, ON, Canada.",None
36006054,A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.,2022,"Ye, Xin","Global Specialty Value, Access & Pricing, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.",None
35998303,Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.,2022/Nov/20,"Reynolds, Joseph G; Zhang, Xiaosha; Attie, Kenneth M; Shetty, Jeevan K","Formerly Acceleron Pharma, Inc, Cambridge, MA.; Formerly Acceleron Pharma, Inc, Cambridge, MA.; Formerly Acceleron Pharma, Inc, Cambridge, MA.; Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.",None
35998300,"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.",2023/Jan/20,"Diede, Scott J; Anderson, James R; Treichel, Sheryl; Chan, Edward L; Bhatta, Sumita; Gansert, Jennifer","Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Amgen Inc, South San Francisco, CA.; Amgen Inc, Thousand Oaks, CA.; Amgen Inc, Thousand Oaks, CA.; Amgen Inc, Thousand Oaks, CA.",None
35998013,Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.,2022/Oct/14,"Normant, Emmanuel","TG Therapeutics, New York, New York.",None
35998004,Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.,2023,"Pico-Navarro, Cesar; Gafoor, Zarina; Perschy, Teresa","Bavarian Nordic, Inc., Morrisville, NC, USA.; Bavarian Nordic, Inc., Morrisville, NC, USA.; Bavarian Nordic, Inc., Morrisville, NC, USA.",gurup_sonpavde@dfci.harvard.edu.
35996447,Characterizing intentions to receive the COVID-19 vaccine among the general population in British Columbia based on their future intentions towards the seasonal influenza vaccine.,2022,"Ogilvie, Gina S","BC Centre for Disease Control, Provincial Health Services Authority, 655 West 12th Avenue, Vancouver, British Columbia, V5Z 4R4, Canada.",None
35995953,Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.,2022,"Mathisen, Michael S; Shagan, Sarah M; Schleifman, Erica; Wang, Jin; Yan, Mark; Mocci, Simonetta; Voong, David; Fabrizio, David A; Shames, David S; Riehl, Todd","Genentech, Inc, South San Francisco, CA, USA.; Genentech, Inc, South San Francisco, CA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; Foundation Medicine, Inc, Cambridge, MA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; Foundation Medicine, Inc, Cambridge, MA, USA.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.; F. Hoffmann La-Roche, Ltd, Basel, Switzerland.",solange.peters@chuv.ch.
35992862,Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia.,2022,"Garcia, Erwin; Connelly, Margery","Laboratory Corporation of America Holdings (Labcorp), Morrisville, NC, United States.; Laboratory Corporation of America Holdings (Labcorp), Morrisville, NC, United States.",None
35988887,Correlation between efficacy endpoints in patients with advanced biliary tract cancer treated by systemic second-line therapies: Analysis of aggregated data from a systematic literature review.,2022,"Khurana, Inderpreet Singh","BresMed Health Solutions Pvt. Ltd., India.",cindy.neuzillet@curie.fr.
35988546,"Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.",2022,"Zagadailov, Erin; Xu, Rengyi; Oluyadi, Abdulafeez; Hawkins, Peter; Gheuens, Sarah; Beynon, Vanessa","Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.",andreas.glenthoej@regionh.dk.
35987165,"Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.",2022,"Mason, W","Princess Margaret Cancer Centre, Toronto, Canada.",matteo.simonelli@hunimed.eu.
35986699,"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.",2022,"Usdan, Lisa; Tarabar, Sanela; Pradhan, Vivek; Aggarwal, Sudeepta; Banfield, Christopher; Peeva, Elena; Vincent, Michael S; Xenakis, Jason; Beebe, Jean S","CNS Healthcare, Memphis, TN, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, Cambridge, MA, USA.",None
35985941,Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.,2023,"Iadeluca, Laura","Pfizer Inc, New York, NY, USA.",monica.ines@pfizer.com.
35985511,Quantitative Pathologic Analysis of Digitized Images of Colorectal Carcinoma Improves Prediction of Recurrence-Free Survival.,2022,"Westerling-Bui, Thomas","Aiforia Inc, Cambridge, Massachusetts.",pai.rish@mayo.edu.
35984998,Communication About Fall Risk in Community Oncology Practice: The Role of Geriatric Assessment.,2022,"Bearden, James; Burnette, Brian L","Upstate Carolina NCORP, Spartanburg, SC.; Cancer Research of Wisconsin and Northern Michigan (CROWN) NCORP, Green Bay, WI.",None
35981281,"Patient, Family, and Clinician Perspectives on Location of Death for Adolescents and Young Adults With Cancer.",2022,"Buchanan, Susan","Agios Pharmaceuticals, Cambridge, MA.",None
35980612,Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial.,2022/Oct/01,"Huang, Bo","Pfizer Inc, Groton, Connecticut.",None
35978838,What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.,2022,"Watkins, Simon P; Loehr, Andrea","Clinical Science, Clovis Oncology UK, Ltd, Cambridge, United Kingdom.; Translational Medicine, Clovis Oncology, Inc., Boulder, CO, United States.",None
35978274,Phantom-based acquisition time and image reconstruction parameter optimisation for oncologic FDG PET/CT examinations using a digital system.,2022/Aug/18,"Conti, Maurizio","Siemens Medical Solutions USA, Inc., Knoxville, TN, USA.",david.kersting@uni-due.de.
35977756,Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.,2022,"McCune, Steven L","Wellstar Health System Inc, Marietta, Georgia, USA.",Karim.FIZAZI@gustaveroussy.fr.
35974414,Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.,2022/Aug/16,"Seitz, Robert S; Nielsen, Tyler J; Bailey, Daniel B; Varga, Matthew G; Ring, Brian Z; Metts, Carrie F; Schweitzer, Brock L; McGregor, Kimberly; Ross, Douglas T","Oncocyte, Inc., Irvine, California, USA. rseitz@oncocyte.com.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.; Oncocyte, Inc., Irvine, California, USA.",rseitz@oncocyte.com.
35974168,Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.,2022/Aug/16,"Zhu, Zhou; Zhang, Cathy; Cao, Joan Q; Yan, Zhengming; Lu, Dongrui R; Wei, Ping; VanArsdale, Todd L; Rejto, Paul A; Huang, Xin; Liu, Yuan","Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.; Pfizer Inc, La Jolla, CA, USA.",nick.turner@icr.ac.uk.
35973745,Neoadjuvant immunotherapy of locoregionally advanced solid tumors.,2022,"Tatard-Leitman, Valerie","The Emmes Company LLC, Rockville, Maryland, USA.",ahmad.tarhini@moffitt.org.
35973665,Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.,2022,"Smoljanovic, V; Rahman, A; Kong, S; Zalutskaya, A; Louie-Gao, M; Boral, A L","F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Genentech Inc., South San Francisco, USA.; Blueprint Medicines Corporation, Cambridge, USA.; Blueprint Medicines Corporation, Cambridge, USA.; Blueprint Medicines Corporation, Cambridge, USA.",mazieres.j@chuc-toulouse.fr.
35973192,Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.,2022/Nov/22,"Kuruvilla, John; Anjos, Carla; Chu, Jufen; Zhang, Jie; Lobetti Bodoni, Chiara","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",None
35972486,Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients.,2022/Aug/16,"Zhou, Yunping","Humana Healthcare Research Inc, Louisville, Kentucky.",None
35970977,"Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.",2022,"Rüschoff, Josef; Friedrich, Michael; Portier, Bryce; Sredni, Simone T; Schildhaus, Hans Ulrich; Jasani, Bharat; Grzelinski, Marius","Targos - A Discovery Life Sciences Company, Germaniastraße 7, 34119, Kassel, Germany. josef.rueschoff@dls.com.; Targos - A Discovery Life Sciences Company, Germaniastraße 7, 34119, Kassel, Germany.; Agilent Technologies Inc, 5301 Stevens Creek Blvd, Santa Clara, CA, 95051, USA.; Agilent Technologies Inc, 5301 Stevens Creek Blvd, Santa Clara, CA, 95051, USA.; Targos - A Discovery Life Sciences Company, Germaniastraße 7, 34119, Kassel, Germany.; Targos - A Discovery Life Sciences Company, Germaniastraße 7, 34119, Kassel, Germany.; Targos - A Discovery Life Sciences Company, Germaniastraße 7, 34119, Kassel, Germany.",josef.rueschoff@dls.com.
35970302,The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.,2022,"Snider, Julia Thornton; Vadgama, Sachin; Patel, Anik R","Kite Pharmaceuticals, Santa Monica, California.; Kite Pharmaceuticals, Santa Monica, California.; Kite Pharmaceuticals, Santa Monica, California.",peralesm@MSKCC.org.
35970241,Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts.,2022,"Moore, Matt; Williams, Craig; Riley, Tom","Information Management Services, Inc., Rockville, Maryland.; Information Management Services, Inc., Rockville, Maryland.; Information Management Services, Inc., Rockville, Maryland.",ACHAN@mgh.harvard.edu.
35965268,Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics.,2022,"Mittapalli, Rajendar K; Guo, Cen; Drescher, Stefanie K; Yin, Donghua","Clinical Pharmacology, Early Clinical Development, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA. rajendar.mittapalli@pfizer.com.; Clinical Pharmacology, Early Clinical Development, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA.; Clinical Pharmacology, Early Clinical Development, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA.; Clinical Pharmacology, Early Clinical Development, Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA.",rajendar.mittapalli@pfizer.com.
35964471,Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.,2022,"Lobo, Maurice; Askelson, Margarita; Ascierto, Paolo A","Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.; Melanoma Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.",James.Larkin@rmh.nhs.uk.
35963986,Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.,2022,"Ono, Chiho","Pfizer Japan Inc, Tokyo, Japan.",takaono@hama-med.ac.jp.
35963179,Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.,2022,"Macpherson, E; Qin, A; Singh, J; Taitt, C; Shire, N","AstraZeneca Pharmaceuticals, Gaithersburg, USA.; Daiichi Sankyo Inc., Basking Ridge, USA.; Daiichi Sankyo Inc., Basking Ridge, USA.; Daiichi Sankyo Inc., Basking Ridge, USA.; AstraZeneca Pharmaceuticals, Gaithersburg, USA.",charles.powell@mssm.edu.
35963025,CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.,2022,"Frattini, Mark G; Garton, Andrew","Cellectis, Inc., New York, NY, United States.; Cellectis, Inc., New York, NY, United States.",npemmaraju@mdanderson.org.
35962206,Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.,2022,"Zhang, Hui; Green, Jennifer; Zalutskaya, Alena","Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.",vsubbiah@mdanderson.org.
35960908,Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.,2023/Jan/20,"Popa McKiver, Mihaela; Jou, Ying-Ming; Yao, David; Das, Prianka","Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",None
35960871,Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.,2022/Oct/13,"Ugidos, Manuel; Risueño, Alberto; Chan, Esther T; Beach, C L","BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol-Myers Squibb Company, Seville, Spain.; BMS Center for Innovation and Translational Research Europe (CITRE), a Bristol-Myers Squibb Company, Seville, Spain.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",None
35958589,"The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity.",2022,"Youngblood, Bradford A","Allakos Inc., San Carlos, CA, United States.",None
35958343,Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report.,2022,"Corral de la Fuente, Elena","Early Phase Clinical Drug Development in Oncology, South Texas Accelerated Research Therapeutics (START), Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.",None
35953731,Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.,2022,"van de Wetering, Marianne","Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.",lee.dupuis@sickkids.ca.
35950899,Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.,2022,"Paccagnella, Maria Luisa; Santo, Nicola Di; Elmeliegy, Mohamed; Lin, Xun; Czibere, Akos","Pfizer Inc., Groton, CT, USA.; Pfizer Inc., Durham, NC, USA.; Pfizer Inc., La Jolla, CA, USA.; Pfizer Inc., La Jolla, CA, USA.; Pfizer Inc., Cambridge, MA, USA.",None
35950037,Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study.,2022,"Zardan, Anousheh; Osborne, Brendan; Chan, Katherine F Y",Medical Affairs Janssen Inc Toronto Ontario Canada.; Medical Affairs Janssen Inc Toronto Ontario Canada.; Medical Affairs Janssen Inc Toronto Ontario Canada.,None
35949290,First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.,2022,"Ansaldi, Christelle; Rachid, Madani; Mezouar, Soraya; Menut, Agnes; Bestion, Eloïne Nadeige; Halfon, Philippe","Genoscience Pharma, Marseille, France.; Genoscience Pharma, Marseille, France.; Genoscience Pharma, Marseille, France.; Genoscience Pharma, Marseille, France.; Genoscience Pharma, Marseille, France.; Genoscience Pharma, Marseille, France.",None
35948732,Health-related quality of life with enzalutamide versus flutamide in castration-resistant prostate cancer from the AFTERCAB study.,2022,"Saito, Atsushi; Asakawa, Keiko; Uno, Satoshi","Medical Affairs Japan, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.; Medical Affairs Japan, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.; Data Science, Development, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.",hu0428@yokohama-cu.ac.jp.
35947814,"The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions.",2022/Oct/10,"Barry, Elly; Kieran, Mark; Manlay, John","Day One Biopharmaceuticals Inc, San Francisco, CA.; Day One Biopharmaceuticals Inc, San Francisco, CA.; Pfizer Inc, New York, NY.",None
35947247,Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.,2022,"Kahatt, Carmen; Luepke-Estefan, Xarles Erik; Siguero, Mariano; Fernandez-Teruel, Carlos; Cullell-Young, Martin","PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.; PharmaMar, Colmenar Viejo, Madrid, Spain.",drilona@mskcc.org.
35947165,Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.,2023,"Ballhausen, Alexej; Ben Hamza, Amin; Welters, Carlotta; Dietze, Kerstin; Bullinger, Lars; Hansmann, Leo","Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu, Augustenburger Platz 1, 13353, Berlin, Germany. leo.hansmann@charite.de.",leo.hansmann@charite.de.
35943786,Usability Evaluation of a Noninvasive Neutropenia Screening Device (PointCheck) for Patients Undergoing Cancer Chemotherapy: Mixed Methods Observational Study.,2022/Aug/09,"Lamaj, Ganimete; Pablo-Trinidad, Alberto; Butterworth, Ian; Bell, Nolan; Benasutti, Ryan; Bourquard, Aurelien; Sanchez-Ferro, Alvaro; Castro-Gonzalez, Carlos","Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.; Leuko Labs, Inc, Boston, MA, United States.",None
35943684,Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.,2022,"Scaldaferri, Matilde; Poggiu, Marco; Cattel, Francesco","S.C. Clinical Pharmacology, A.O.U. Città Della Salute e Della Scienza, Turin, Italy.; S.C. Clinical Pharmacology, A.O.U. Città Della Salute e Della Scienza, Turin, Italy.; S.C. Clinical Pharmacology, A.O.U. Città Della Salute e Della Scienza, Turin, Italy.",Semra.Aydin@ukbonn.de.
35941190,Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC.,2022/Aug/08,"Sato, Yoshiharu","DNA Chip Research Inc, Tokyo, Japan.",kei.kunimasa@oici.jp.
35940825,"Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.",2022,"Hawthorne, Thomas R; Rawls, Tracey; Yellin, Michael; Keler, Tibor","Celldex Therapeutics Inc New Haven, New Haven, Connecticut, USA.; Celldex Therapeutics Inc, Hampton, New Jersey, USA.; Celldex Therapeutics Inc, Hampton, New Jersey, USA.; R & D, Celldex Therapeutics Inc, Hampton, New Jersey, USA.",Rachel.sanborn@providence.org.
35939431,Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.,2022,"Hibar, Derrek P; Davies, Jessica; Humblet, Olivier; Maund, Sophia L; Perez, Laura","Personalized Healthcare Analytics, Genentech, Inc., South San Francisco, California, United States of America.; Personalized Healthcare Data Science, Roche Products Ltd, Welwyn Garden City, United Kingdom.; Quantitative Sciences, Flatiron Health Inc., New York, New York, United States of America.; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, United States of America.; Personalized Healthcare Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",None
35937502,Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.,2022,"Muralidharan, Sujatha; Weiss, Glen J","SOTIO Biotech Inc., Cambridge, MA 02140, USA.; SOTIO Biotech Inc., Cambridge, MA 02140, USA.",None
35935993,Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study).,2022,"Barcza, Zsófia","Syntesia Medical Communications Ltd., Budapest, Hungary.",None
35934607,Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.,2022,"Bennett, Phil","Sarah Cannon Molecular Diagnostics, HCA Healthcare UK, London, United Kingdom. Electronic address: Philip.Bennett@hcahealthcare.co.uk.",Philip.Bennett@hcahealthcare.co.uk.
35932388,"Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.",2022,"Zhou, Xiaofei; Sedarati, Farhad; Dong, Cassie; Faller, Douglas V; Venkatakrishnan, Karthik; Gupta, Neeraj","Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. xiaofei.zhou@takeda.com.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.",xiaofei.zhou@takeda.com.
35931049,A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids.,2022/Aug/04,"Thorleifsson, Gudmar; Helgadottir, Anna; Holm, Hilma; Lee, Jong Young; Reilly, Dermot F; Baras, Aris; Ho, Yuk-Lam","deCODE genetics/Amgen, Inc., Sturlugata 8, Reykjavik 102, Iceland.; deCODE genetics/Amgen, Inc., Sturlugata 8, Reykjavik 102, Iceland.; deCODE genetics/Amgen, Inc., Sturlugata 8, Reykjavik 102, Iceland.; Oneomics. co. ltd. 2F, Soonchunhyang Mirai Medical Center 173, Buheuyng-ro, Bucheon-si Gyeonggi-do 14585, Korea.; Genetics, Merck Sharp & Dohme Corp, Kenilworth, NJ 07033, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; VA Boston Healthcare System, Boston, MA, USA.",chrbro@upenn.edu.
35931020,Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.,2022/Aug/04,"Kredo-Russo, Sharon; Matiuhin, Yulia; Silberberg, Yael; Weiner, Iddo Nadav; Khabra, Efrat; Ben-Yishai, Noa; Inbar, Dana; Ben-David, Hava; Nicenboim, Julian; Kowalsman, Noga; Kario, Edith; Cohen, Tal; Geffen, Yael Friedman; Zelcbuch, Lior; Cohen, Ariel; Rappo, Urania; Gahali-Sass, Inbar; Golembo, Myriam; Lev, Vered; Zak, Naomi; Puttagunta, Sailaja; Bassan, Merav","BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.; BiomX Ltd., 22 Einstein St., Ness Ziona, 7414001, Israel; BiomX Inc., 36 E Industrial Road, Branford, CT 06405, USA.",eran.elinav@weizmann.ac.il.
35930972,External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.,2022,"Hess, L M; Jen, M-H; Peterson, P; Li, X; Liu, H; Lai, Y; Kiiskinen, U; Vickers, A","Eli Lilly and Company, Indianapolis, USA. Electronic address: hess_lisa_m@lilly.com.; Eli Lilly and Company, Basingstoke, UK.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Helsinki, Finland.; RTI Inc., Manchester, UK.",hess_lisa_m@lilly.com.
35928820,Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.,2022,"Kanhai, Karan","Medical Affairs, EUSA Pharma, Hemel Hempstead, United Kingdom.",None
35927156,Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls.,2022,"Grewal, Simrun; Fuldeore, Rupali; Sesterhenn, Steve; Chang, Nancy; Hepp, Zsolt","Seagen Inc., Bothell, WA. Electronic address: sgrewal@seagen.com.; Astellas Pharma Inc., Northbrook, IL.; Astellas Pharma Inc., Northbrook, IL.; Seagen Inc., Bothell, WA.; Seagen Inc., Bothell, WA.",sgrewal@seagen.com.
35926813,First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.,2022,"Battelli, N","Oncologia Medica, Ospedale Generale Provinciale di Macerata, Macerata.",Roberto.iacovelli@policlinicogemelli.it.
35923927,Cabozantinib combination therapy for the treatment of solid tumors: a systematic review.,2022,"Martin, Lidia","Ipsen Pharma, Barcelona, Spain.",None
35922444,Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.,2022,"Pallaud, Celine; Gathmann, Insa","Novartis Pharmaceuticals, Basel, Switzerland.; Novartis Pharmaceuticals, Basel, Switzerland.",konstanze.doehner@uniklinik-ulm.de.
35922251,"EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.",2022,"Lisyanskaya, Alla S; Gotovkin, Evgeniy A; Li, Jingjin; Mathias, Melissa; Fury, Matthew G; Lowy, Israel; Harnett, James; Chen, Chieh-I","St Petersburg State Budgetary Institution of Healthcare, St Petersburg, Russia.; State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary, Ivanovo, Russia.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.",aoaknin@vhio.net.
35921760,"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.",2022,"Spreafico, A; Oliva, M; Hoffman, K; Hallett, R M; Maetzel, D; Giblin, P; Anido, J; Kelly, A; Vickers, P J; Wasserman, R; Siu, L L","Princess Margaret Cancer Centre, Toronto, Canada.; Princess Margaret Cancer Centre, Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Northern Biologics, Inc., Toronto, Canada.; Princess Margaret Cancer Centre, Toronto, Canada.",eborazanci@honorhealth.com.
35920189,Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.,2022,"Caserta, Justin; Baldino, Carmen M","Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA 02139, USA.; Walden Biosciences, Inc., Cambridge, MA 02139, USA.",None
35918248,Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.,2022,"Pal, Sumanta K","Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA.",Deepika.Sirohi@hsc.utah.edu.
35917453,Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.,2022/Oct/27,"Liu, Shufang; Wu, Ruishan; Philipose, Nisha; Hill, Jason E; Gill, Stanley C; Rich, Elizabeth Shima; Tiu, Ramon V","Astellas Pharma US, Northbrook, IL.; Astellas Pharma US, Northbrook, IL.; Astellas Pharma US, Northbrook, IL.; Astellas Pharma US, Northbrook, IL.; Astellas Pharma US, Northbrook, IL.; Astellas Pharma US, Northbrook, IL.; Astellas Pharma US, Northbrook, IL.",None
35915198,"An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.",2022,"van Hal, Gertjan; Chapman, Sonya C; Gable, Jonathon Colby; Chen, Yanyun; Price, Gregory L; Hossain, Anwar M; Gainford, M Corona","Eli Lilly and Company, Utrecht, Netherlands.; Eli Lilly and Company, Windlesham, Surrey, UK.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",e.lim@garvan.org.au.
35914979,Real-world treatment drop-off among recurrent or metastatic cervical cancer patients: A US community oncology-based analysis.,2022,"Ting, Jie; Zhang, Yitong J","Seagen Inc., Bothell, WA, United States of America.; Seagen Inc., Bothell, WA, United States of America.",bmonk@gog.org.
35914220,Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.,2022/Nov/10,"Saumoy, Monica","Center for Digestive Health, Penn Medicine Princeton Medical Center, Plainsboro, NJ.",None
35908558,"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.",2022,"Lin, Yong","Eli Lilly and Company, Indianapolis, IN, USA.",shunlu@sjtu.edu.cn.
35906806,Work productivity among patients with metastatic breast cancer in the United States.,2022,"Hanson, Kent; Kurosky, Samantha K","Patient & Health Impact, Pfizer Inc, New York, NY, USA.; Patient & Health Impact, Pfizer Inc, New York, NY, USA.",None
35903919,A multicentre study with real-world data of the use of palbociclib in the treatment of breast cancer: Treatment duration correlates with dose reductions.,2023,"Romagnoli, Alessia","Pharmaceutical Service, Local Health Unit of Lanciano Vasto Chieti, Chieti, Italy.",None
35903719,Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany.",None
35903715,Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Germany.",None
35902133,Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.,2022,"Darowski, Diana; Jost, Christian; Freimoser-Grundschober, Anne; Moessner, Ekkehard; Umana, Pablo; Klein, Christian","Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland.; Roche Innovation Center Zurich, Roche Pharma Research & Early Development, Schlieren, Switzerland sophia.stock@med.uni-muenchen.de sebastian.kobold@med.uni-muenchen.de christian.klein.ck1@roche.com.",sophia.stock@med.uni-muenchen.de
35896281,"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.",2022,"Sui, Yunxia; Duan, Yuanyuan; Wung, Peter K; Song, In-Ho","AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",mail@dvanderheijde.nl.
35895098,Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.,2022,"Green, Stuart; Iskold, Beata; La Rosa, Carmen; Li, Qing; Martin Nguyen, Allison; Schelfhout, Jonathan; Muccino, David","Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",Jacky.Smith@manchester.ac.uk.
35887905,Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease.,2022/Jul/16,"Galinsky, Kevin; Juarez, Julius","Gastroenterology Drug Discovery Unit, Takeda Pharmaceuticals, Cambridge, MA 02139, USA.; Gastroenterology Drug Discovery Unit, Takeda Pharmaceuticals, Cambridge, MA 02139, USA.",None
35881865,Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling.,2022/Sep/01,"Lin, Regina J; Nager, Andrew R; Park, Spencer; Sutton, Janette; Lay, Cecilia; Melton, Zea; Zhang, Yi; Boldajipour, Bijan; Blarcom, Thomas J Van; Panowski, Siler H; Sasu, Barbra J; Chaparro-Riggers, Javier","Allogene Therapeutics, Inc., San Francisco, California.; Pfizer, Inc., San Diego, California.; Pfizer, Inc., San Diego, California.; Allogene Therapeutics, Inc., San Francisco, California.; Allogene Therapeutics, Inc., San Francisco, California.; Allogene Therapeutics, Inc., San Francisco, California.; Allogene Therapeutics, Inc., San Francisco, California.; Pfizer, Inc., San Diego, California.; Allogene Therapeutics, Inc., San Francisco, California.; Allogene Therapeutics, Inc., San Francisco, California.; Allogene Therapeutics, Inc., San Francisco, California.; Pfizer, Inc., San Diego, California.",None
35881486,Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses.,2022/Sep/01,"Heeke, Darren; Mattie, Mike; Bot, Adrian","Kite, a Gilead Company, Santa Monica, California, USA.; Kite, a Gilead Company, Santa Monica, California, USA.; Kite, a Gilead Company, Santa Monica, California, USA.",None
35881043,Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study.,2022/Dec/09,"Danziger, Natalie; Lin, Douglas; Decker, Brennan; Sokol, Ethan S; Huang, Richard S P; Ross, Jeffrey S","Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.",None
35877413,Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection.,2022/Nov/01,"Robichaux, Chad","Emory Healthcare, Atlanta, Georgia, USA.",None
35870472,Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.,2022,"Lee, Judy","Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.",tamara.miller@emory.edu.
35869266,Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.,2022,"Gupta, Vikas; Huang, Mei; Strouse, Bryan; Klencke, Barbara","Princess Margaret Cancer Centre, Toronto, ON, Canada.; Sierra Oncology Inc, San Mateo, CA, USA.; Sierra Oncology Inc, San Mateo, CA, USA.; Sierra Oncology Inc, San Mateo, CA, USA.",mesar@uthscsa.edu.
35869170,Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.,2022,"Deschatelets, Pascal; Francois, Cedric G; Xu, Raymond; Al-Adhami, Mohammed; Tan, Lisa; Grossi, Federico V","Apellis Pharmaceuticals, 100 5th Avenue, Waltham, MA, 02451, USA.; Apellis Pharmaceuticals, 100 5th Avenue, Waltham, MA, 02451, USA.; Apellis Pharmaceuticals, 100 5th Avenue, Waltham, MA, 02451, USA.; Apellis Pharmaceuticals, 100 5th Avenue, Waltham, MA, 02451, USA.; Lisa Tan Pharma Consulting Ltd, Cambridge, UK.; Apellis Pharmaceuticals, 100 5th Avenue, Waltham, MA, 02451, USA. federico@apellis.com.",federico@apellis.com.
35869145,"Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.",2022,"DeLuca, Stephanie; Pedutem, Theresa","Pharmacy, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada.",Jennifer.knox@uhn.ca.
35868306,Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.,2022/Aug/08,"Dao, Kim-Hien T; Schuff, Robert","Astex Pharmaceuticals, Cambridge, CB4 0QA, UK.; Ochin Inc., Portland, OR 97228, USA.",tynerj@ohsu.edu.
35867947,Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).,2022/Dec/20,"Zoroufy, Alex J","Statistics & Data Corporation, Tempe, AZ.",None
35864202,"PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.",2022/Jul/21,"Ding, Xia; Zhu, Zhou; Lapek, John; McMillan, Elizabeth A; Zhang, Alexander; Chung, Chi-Yeh; Dubbury, Sara; Lapira, Jennifer; Firdaus, Sarah; Kang, Xiaolin; Gao, Jingjin; Oyer, Jon; Chionis, John; Rollins, Robert A; Li, Lianjie; Niessen, Sherry; Bagrodia, Shubha; Zhang, Lianglin; VanArsdale, Todd","Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA. xia.ding2@pfizer.com.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA. lianglin.zhang@pfizer.com.; Oncology Research Unit, Pfizer, Inc., San Diego, CA, 92121, USA. todd.vanarsdale@pfizer.com.",todd.vanarsdale@pfizer.com.
35863108,Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.,2022,"Benzaghou, Fawzi; Knudsen, Steen; Kauh, John; Chung, John","Ipsen Pharma, Cambridge, MA, USA.; Allarity Therapeutics, MA, USA.; HUTCHMED International Corporation, USA.; Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA.",andy1pearson@btinternet.com.
35862037,Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.,2022/Sep/01,"Mukhopadhyay, Pralay; Ye, Jiabu; Anderson, Keaven M; Roychoudhury, Satrajit; Rubin, Eric H","Otsuka America Pharmaceutical, Inc, Rockville, Maryland.; Merck & Co, Inc, Kenilworth, New Jersey.; Merck & Co, Inc, Kenilworth, New Jersey.; Pfizer Inc, New York, New York.; Merck & Co, Inc, Kenilworth, New Jersey.",None
35861789,Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis.,2023,"Arrieta, Oscar","Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Tlalpan, México.",None
35860587,Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.,2022,"Liu, Xianchen; Li, Benjamin; McRoy, Lynn","Medical Pfizer Inc, New York, NY, United States.; Medical Pfizer Inc, New York, NY, United States.; Medical Pfizer Inc, New York, NY, United States.",None
35859079,PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.,2022/Jul/20,"Wang, Yingbo","Novartis Pharma AG, Basel, Switzerland.",matteo.lambertini@unige.it.
35858533,Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study.,2022,"Thiebach, Lars","Roche Pharma AG, Grenzach-Wyhlen, Germany.",None
35857579,Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T,2022/Jul/15,"Jooss, Karin","Pfizer Inc., San Diego, CA, USA.",None
35857290,Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.,2022/Sep/01,"Bhatia, Neal; Rumage, Adam; Donini, Oreola; Haulenbeek, Andrea; Schaber, Christopher J; Straube, Richard; Pullion, Christopher","Therapeutics Clinical Research, San Diego, California.; Soligenix Inc, Princeton, New Jersey.; Soligenix Inc, Princeton, New Jersey.; Soligenix Inc, Princeton, New Jersey.; Soligenix Inc, Princeton, New Jersey.; Soligenix Inc, Princeton, New Jersey.; Soligenix Inc, Princeton, New Jersey.",None
35856081,"Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.",2022,"Mhatre, Shivani K; Li, Xiao; Li, Shi; Allen, Simon; Reyes-Rivera, Irmarie; Lenain, Christelle","Genentech, Inc., South San Francisco, CA US.; Genentech, Inc., South San Francisco, CA US.; Genentech, Inc., South San Francisco, CA US.; Genentech, Inc., South San Francisco, CA US.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",None
35852793,Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.,2022/Sep/15,"Turpuseema, Teja; Purdom, Michelle; Paskalis, Dana; Miskin, Hari P; Sportelli, Peter","TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.; TG Therapeutics, Inc., New York, New York.",None
35852004,Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.,2023,"Casadebaig, Marie-Laure; Fox, Brian; Kilavuz, Nurgul; Rettby, Nils; Dell'Aringa, Justine; Taningco, Lilia; Delarue, Richard; Czuczman, Myron","Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.",None
35849791,Venetoclax Plus Gilteritinib for ,2022/Dec/10,"Tiu, Ramon V; Brackman, Deanna; Siddani, Satya; Wang, Jing; Chyla, Brenda; Lee, Paul","Astellas Pharma US, Northbrook, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.",None
35849586,Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.,2022,"Li, Yanxia; Amaladas, Nelusha; O'Mahony, Marguerita; Manro, Jason R; Inigo, Ivan; Li, Qi; Rasmussen, Erik R; Brahmachary, Manisha; Doman, Thompson N; Hall, Gerald; Kalos, Michael; Novosiadly, Ruslan; Pytowski, Bronislaw; Schaer, David A","Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.; Lilly Research Laboratories, Eli Lilly and Company, New York City, New York, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.; Loxo Oncology at Lilly, Eli Lilly and Company, New York City, New York, United States of America.",None
35848749,Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.,2022/Aug/01,"Khaldoyanidi, Sophia K; Britten, Carolyn D","Early Development Oncology, Amgen Inc., Thousand Oaks, CA.; Early Development Oncology, Amgen Inc., Thousand Oaks, CA.",None
35848218,Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.,2022,"Beachler, Daniel C; Lamy, Francois Xavier; Dinh, Jade; Papazian, Anahit; Jamal-Allial, Aziza; Mahmoudpour, Seyed Hamidreza; Verpillat, Patrice","Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA.; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, 64293, Germany.; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA.; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA.; Safety & Epidemiology, HealthCore Inc., Wilmington, DE 19801, USA.; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, 64293, Germany.; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, 64293, Germany.",None
35847482,Cabozantinib for the treatment of solid tumors: a systematic review.,2022,"Martin, Lidia","Ipsen Pharma, Barcelona, Spain.",None
35846244,"Health-related Quality of Life in Hormone Receptor-Positive Early Breast Cancer: Analyses From the Surveillance, Epidemiology, and End Results Medicare Health Outcomes Survey.",2022,"Cueto, Jenilee; Mitra, Debanjali; Law, Ernest H","Formerly Patient & Health Impact, Pfizer, Inc., New York, NY, USA.; Patient & Health Impact, Pfizer, Inc., New York, NY, USA.; Patient & Health Impact, Pfizer, Inc., New York, NY, USA.",None
35846221,"Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.",2022,"Uttamsingh, Shailaja; Hagner, Patrick R; Gandhi, Anita K; Shen, Frank; Michelliza, Sophie; Haeske, Harald; Hege, Kristen; Pourdehnad, Michael",Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.,None
35846215,Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma.,2022,"Nair, Sandhya; Diels, Joris; Olyslager, Yunsi",Janssen Pharmaceutica NV Beerse Belgium.; Janssen Pharmaceutica NV Beerse Belgium.; Janssen Pharmaceutica NV Beerse Belgium.,None
35846031,Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.,2022,"Shen, Frank; Hagner, Patrick; Li, Yan; Dobmeyer, Juergen; Gong, Nian; Uttamsingh, Shailaja; Pourdehnad, Michael",Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Centre for Innovation and Translational Research Europe (CITRE) Bristol-Myers Squibb Company Seville Spain.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.; Bristol Myers Squibb Princeton New Jersey USA.,None
35841410,"RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.",2022,"Gao, Ling; Callies, Sophie; Zimmermann, Annamaria; Walgren, Richard","Eli Lilly and Company, Bridgewater, USA.; Eli Lilly and Company, Paris, France.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",nakagawa@med.kindai.ac.jp.
35840724,Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.,2022,"Ramaswamy, Krishnan; Mardekian, Jack; Schultz, Neil M; Lechpammer, Stanislav","Pfizer Inc., New York, NY, USA. krishnan.ramaswamy@pfizer.com.; Pfizer Inc., New York, NY, USA.; Astellas Pharma Inc., Northbrook, IL, USA.; Pfizer Inc., San Francisco, CA, USA.",krishnan.ramaswamy@pfizer.com.
35839786,"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.",2022,"Essell, James; D'Andrea, Aleco","Oncology Hematology Care, Cincinnati, OH, USA.; Celgene, a Bristol-Myers Squibb company, Boudry, Switzerland.",sehgalar@upmc.edu.
35839452,"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.",2022/Nov/24,"Snider, Julia Thornton; Cheng, Paul; To, Christina","Kite, a Gilead Company, Santa Monica, CA.; Kite, a Gilead Company, Santa Monica, CA.; Kite, a Gilead Company, Santa Monica, CA.",None
35838190,Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.,2023,"Hirai, Hiroshi","Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan.",None
35836170,An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.,2022/Jul/14,"Guan, Alice Kai Dan; Garcia, David; Zhou, Anna","CRG-EVERSANA Canada Inc., 3228 South Service Road, Suite 204, Burlington, ON, L7N 3H8, Canada.; CRG-EVERSANA Canada Inc., 3228 South Service Road, Suite 204, Burlington, ON, L7N 3H8, Canada. David.Garcia@Eversana.com.; CRG-EVERSANA Canada Inc., 3228 South Service Road, Suite 204, Burlington, ON, L7N 3H8, Canada.",David.Garcia@Eversana.com.
35835137,"Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.",2022,"Llorin-Sangalang, Judith; Li, Joanne","MEI Pharma, San Diego, CA, USA.; MEI Pharma, San Diego, CA, USA.",zeleneta@mskcc.org.
35830841,Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.,2022,"Fernández, Cristian; Kahatt, Carmen; Alfaro, Vicente; Siguero, Mariano; Zeaiter, Ali","Clinical R&amp;D, PharmaMar, Colmenar Viejo, Spain.; Clinical R&amp;D, PharmaMar, Colmenar Viejo, Spain.; Clinical R&amp;D, PharmaMar, Colmenar Viejo, Spain.; Clinical R&amp;D, PharmaMar, Colmenar Viejo, Spain.; Clinical R&amp;D, PharmaMar, Colmenar Viejo, Spain.",vsubbiah@mdanderson.org.
35829935,"nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.",2022,"Zhang, Wei; Chen, Yanyun","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",ehamilton@tnonc.com.
35829790,Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.,2023,"Cho, Helen; Binder, Joe; Weeratna, Risini; Dermyer, Michael; Dai, Stanley; Boccia, Antionio; Li, Wei; Li, Shangjin; Jooss, Karin; Merson, James; Hollingsworth, Robert E","Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Vaccines and Immunotherapeutics, 340 Terry Fox Drive, Suite 200, Ottawa, ON, Canada.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA.; Pfizer Cancer Vaccines and Immunotherapeutics, 10777 Science Center Drive, San Diego, CA, USA. rehollin1@gmail.com.",rehollin1@gmail.com.
35821820,"Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older: A Randomized Clinical Trial.",2022,"Armbrecht, Gabriele","Klinik für Radiologie, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.",None
35820087,Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.,2022,"Graf, Ryon P; Raskina, Kira; Sokol, Ethan; Jin, Dexter; Li, Gerald; Huang, Richard S P; Ross, Jeffrey S; Schrock, Alexa B; Oxnard, Geoffrey R","Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.",None
35818811,Tumor growth inhibition modeling to support the starting dose for dacomitinib.,2022,"Fostvedt, Luke K; Nickens, Dana J; Tan, Weiwei; Parivar, Kourosh","Global Product Development, Pfizer Inc., Cambridge, Massachusetts, USA.; Global Product Development, Pfizer Inc., La Jolla, California, USA.; Global Product Development, Pfizer Inc., La Jolla, California, USA.; Global Product Development, Pfizer Inc., La Jolla, California, USA.",None
35816951,A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).,2022,"Cornfeld, M; Tian, C; Catlett, M; Smith, M","Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.",Sheela.Rao@rmh.nhs.uk.
35810553,"Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.",2022,"Leighl, Natasha B; Zou, Mike; Ghebremariam, Samson; O'Sullivan-Djentuh, Leslie; Belli, Riccardo; Giovannini, Monica","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",daniel.tan.s.w@singhealth.com.sg.
35804834,Considerations for the Use of Machine Learning Extracted Real-World Data to Support Evidence Generation: A Research-Centric Evaluation Framework.,2022/Jun/22,"Estevez, Melissa; Benedum, Corey M; Jiang, Chengsheng; Cohen, Aaron B; Phadke, Sharang; Sarkar, Somnath; Bozkurt, Selen","Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.; Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.; Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.; Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.; Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.; Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.; Flatiron Health, Inc., 233 Spring Street, New York, NY 10013, USA.",None
35803702,Autologous T cell responses to primary human colorectal cancer spheroids are enhanced by ectonucleotidase inhibition.,2023,"Blery, Mathieu; Remark, Romain; Bonnafous, Cécile","Innate Pharma SA, Marseille, France.; Innate Pharma SA, Marseille, France.; In Vivo Pharmacology, Innate Pharma SA, Marseille, France.",lionel.le-bourhis@inserm.fr.
35803290,"Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.",2022,"Herman, Gary A; O'Brien, Meagan P; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Musser, Bret J; Davis, John D; Turner, Kenneth C; Mahmood, Adnan; Hooper, Andrea T; Hamilton, Jennifer D; Parrino, Janie; Subramaniam, Danise; Baum, Alina; Kyratsous, Christos A; DiCioccio, A Thomas; Stahl, Neil; Braunstein, Ned; Yancopoulos, George D; Weinreich, David M","Regeneron Pharmaceuticals, Tarrytown, NY, USA. Electronic address: gary.herman@regeneron.com.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Formerly of Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Formerly of Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.",gary.herman@regeneron.com.
35803286,"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.",2022,"Kuruvilla, John","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.",nbartlet@wustl.edu.
35800987,Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.,2022,"Prabhu, Vimalanand S; Zhang, Jingchuan","Merck & Co., Inc., Rahway, NJ, USA.; Eisai Inc., Nutley, NJ, USA.",None
35798536,Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.,2022,"Trojanello, Claudia; Ascierto, Paolo Antonio","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.",georgina.long@sydney.edu.au.
35797468,Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.,2022/Nov/17,"Shetty, Jeevan K; Ito, Rodrigo; Zhang, Jennie; Zhang, George; Ha, Xianwei; Backstrom, Jay T","Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Acceleron Pharma, Cambridge, MA.",None
35796785,"A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan.",2022,"Fukushima, Koji","SymBio Pharmaceuticals Limited, Tokyo, Japan.",kishizaw@med.id.yamagata-u.ac.jp.
35794623,"Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.",2022/Jul/07,"Laghouati, Salim","Unité Fonctionnelle de Pharmacovigilance, Villejuif, France.",aurelien.marabelle@gustaveroussy.fr.
35793872,Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.,2022,"Shoushtari, Alexander; Trojanello, Claudia; Ascierto, Paolo A","Medicine, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy.",matteo.carlino@sydney.edu.au.
35790816,Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis.,2022,"Bobbili, Priyanka J; Wang, Aolin; Norregaard, Chelsea; Dimitrijevic, Saša; Sullivan, Erin; Louie-Gao, Melinda; Chin, Andi; Sendhil, Selvam R; Duh, Mei Sheng","Analysis Group, Inc., Boston, MA, USA.; Analysis Group, Inc., Boston, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Zug, Switzerland.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Analysis Group, Inc., Boston, MA, USA.; Analysis Group, Inc., Boston, MA, USA.; Analysis Group, Inc., Boston, MA, USA.",andreas.reiter@medma.uni-heidelberg.de.
35785173,"Liquid First Is ""Solid"" in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing.",2022,"Soussan-Gutman, Lior; Dvir, Addie","Rhenium Oncotest Ltd., Modi'in, Israel.; Rhenium Oncotest Ltd., Modi'in, Israel.",None
35781099,Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.,2022,"Tu, Anny; Yang, Zhongming","Biometrics Business Unit, Hangzhou Tigermed Consulting Co, Ltd, Hangzhou, China.; Kadmon Corporation, LLC, New York, New York.",sjlee@fhcrc.org.
35777957,"The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study.",2023,"Sanders, Jason Leigh; Wang, Shuai","Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.; Pfizer Inc, New York, New York, USA.",ghunninghake@bwh.harvard.edu.
35777186,Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.,2022,"Yao, Lili; Jin, Fan; Norwood, Kevin; Hansen, Aaron R","Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Princess Margaret Cancer Centre, Toronto, ON, Canada.",Caroline.EVEN@gustaveroussy.fr.
35773363,A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma.,2022/Jun/30,"Thai, Dung; Zavodovskaya, Marianna; Liu, JieJane","Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.",kensei.yamaguchi@jfcr.or.jp.
35772961,First-in-Human Evaluation of ,2022,"Maresca, Kevin P; Chappie, Thomas A; Zhang, Lei; Hughes, Zoë A; Schmidt, Christopher J; Doran, Shawn D","Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and.; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and.; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and.; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and.; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and.; Worldwide Research, Development, and Medicine, Pfizer Inc., New York, New York; and.",robert.innis@nih.gov.
35772665,Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.,2022,"Oza, A M","Princess Margaret Cancer Centre, Toronto, Canada.",jean-sebastien.frenel@ico.unicancer.fr.
35770957,Re-irradiation in patients with progressive or recurrent brain metastases from extracranial solid tumors: A novel prognostic index.,2023,"Gutierrez Torres, Salvador; Maldonado Magos, Federico; Turcott, Jenny G; Hernandez-Martinez, Juan-Manuel; Cacho-Díaz, Bernardo; Mota-García, Aida; Lozano Ruiz, Francisco; Ramos-Ramirez, Maritza; Arrieta, Oscar","Radiotherapy Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Radiotherapy Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Neuro-Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Radiotherapy Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",None
35770744,Conceptual assessment of HRQOL among Japanese non-metastatic castration-resistant prostate cancer (nmCRPC) patients.,2023,"Ledesma, Dianne Athene","Market Access Oncology, Bayer Yakuhin, Ltd., Tokyo, Japan.",None
35768976,Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study.,2022,"Tajima, Kosei; Kajihara, Yusuke","Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.; Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.",None
35767205,First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.,2022,"Liu, Yong; Yan, Xiaohong; Christensen, Jamie; Neuteboom, Saskia; Chao, Richard","Mirati Therapeutics, Inc, San Diego, CA, USA.; Mirati Therapeutics, Inc, San Diego, CA, USA.; Mirati Therapeutics, Inc, San Diego, CA, USA.; Mirati Therapeutics, Inc, San Diego, CA, USA.; Mirati Therapeutics, Inc, San Diego, CA, USA.",tbauer@tnonc.com.
35767124,Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France.,2022,"Mokgokong, Ruth","Health Economics & Outcomes Research, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK. Ruth.mokgokong@pfizer.com.",Ruth.mokgokong@pfizer.com.
35765059,Use of algorithms for identifying patients in a German claims database: learnings from a lung cancer case.,2022/Jun/28,"Lempfert, Sebastian","HCSL Healthcare Consulting Sebastian Lempfert e.K., Bekwisch 32, 22848, Norderstedt, Germany.",peter.kaskel@msd.de.
35764368,Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.,2022,"Hakansson, Alexander; Liu, Yang","Veracyte Inc, South San Francisco, California, USA.; Veracyte Inc, South San Francisco, California, USA.",Shahneen.Sandhu@petermac.org.
35764271,Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.,2022,"Hill, A; Abdullaev, S; Memaj, A; Lei, M; Dixon, M","Medical Oncology, Tasman Oncology Research, Ltd., Southport, Australia.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.; Oncology Medical Affairs, Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, USA.; Clinical Biomarkers, Translational Medicine, Bristol Myers Squibb, Princeton, USA.; Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, USA.",thierry.andre@aphp.fr.
35759814,Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer.,2022,"Rosellini, Pietro; Amintas, Samuel; Caumont, Charline; Veillon, Rémi; Gouverneur, Amandine; Merlio, Jean-Philippe; Bezin, Julien; Girodet, Pierre-Olivier","CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France; Univ. Bordeaux, Inserm CIC1401, Inserm CR1219, Inserm U1035, F-33000 Bordeaux, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France; Univ. Bordeaux, Inserm CIC1401, Inserm CR1219, Inserm U1035, F-33000 Bordeaux, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France; Univ. Bordeaux, Inserm CIC1401, Inserm CR1219, Inserm U1035, F-33000 Bordeaux, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France; Univ. Bordeaux, Inserm CIC1401, Inserm CR1219, Inserm U1035, F-33000 Bordeaux, France.; CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France; Univ. Bordeaux, Inserm CIC1401, Inserm CR1219, Inserm U1035, F-33000 Bordeaux, France. Electronic address: pierre-olivier.girodet@u-bordeaux.fr.",pierre-olivier.girodet@u-bordeaux.fr.
35759254,Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait.,2022/Aug/01,"Verma, Anurag; Huffman, Jennifer E; Cho, Kelly; Ho, Yuk-Lam; Gorman, Bryan R; Pyarajan, Saiju; Garcon, Helene; Petersen, Jeffrey M; Gatsby, Elise; Lynch, Kristine E; Arjomandi, Mehrdad; Gelernter, Joel; Chang, Kyong-Mi; Liao, Katherine P; O'Donnell, Christopher J; Hauger, Richard L","Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.; MAVERIC, VA Boston Healthcare System, Boston, Massachusetts.; MAVERIC, VA Boston Healthcare System, Boston, Massachusetts.; MAVERIC, VA Boston Healthcare System, Boston, Massachusetts.; VA Boston Healthcare System, Boston, Massachusetts.; VA Boston Healthcare System, Boston, Massachusetts.; MAVERIC, VA Boston Healthcare System, Boston, Massachusetts.; Pathology and Laboratory Medicine, Corporal Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania.; VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Healthcare System, Salt Lake City, Utah.; VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Healthcare System, Salt Lake City, Utah.; Medicine, Pulmonary and Critical Care, San Francisco VA Healthcare System, San Francisco, California.; VA Connecticut Healthcare System, West Haven.; Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.; Medicine, Rheumatology, VA Boston Healthcare System, Boston, Massachusetts.; Medicine, Cardiology, VA Boston Healthcare System, Boston, Massachusetts.; Center of Excellence for Stress & Mental Health, VA San Diego Healthcare System, San Diego, California.",None
35758895,A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.,2022/Oct/05,"Golkaram, Mahdi","Illumina, Inc., San Diego, California.",None
35756655,The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework.,2022,"Stefaniak, Victoria; Gruver, Kristi; Lin, Yong; Ferry, David","Oncology, Eli Lilly and Company, Indianapolis, IN, United States.; Oncology, Eli Lilly and Company, Indianapolis, IN, United States.; Oncology, Eli Lilly and Company, Indianapolis, IN, United States.; Oncology, Eli Lilly and Company, Indianapolis, IN, United States.",None
35755898,Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.,2022,"Kelton, John M; Ryan, Joanne C","Pfizer Inc, New York, New York.; Pfizer Inc, New York, New York.",None
35755897,Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.,2022,"Waggoner, Matthew; Katsetos, John; Thomas, Emilee","AbbVie Inc., North Chicago, Illinois.; AbbVie Inc., North Chicago, Illinois.; AbbVie Inc., North Chicago, Illinois.",None
35753087,Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.,2022,"Jennings, J; Psoinos, C; Meade, J; Ruiz-Soto, R","Deciphera Pharmaceuticals, LLC, Waltham, USA.; Deciphera Pharmaceuticals, LLC, Waltham, USA.; Deciphera Pharmaceuticals, LLC, Waltham, USA.; Deciphera Pharmaceuticals, LLC, Waltham, USA.",fjanku@me.com.
35753086,Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors.,2022,"Arrieta, O; Zatarain-Barrón, Z L; Barrón, F","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City, México.",a_cardonaz@yahoo.com.
35750695,Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies.,2022/Jun/24,"Soong, John","Senhwa Biosciences, Inc, Taipei, Taiwan.",lseymour@ctg.queensu.ca.
35750582,Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.,2023,"Bhattacharyya, Helen; Niyazov, Alexander","Biostatistics and Data Management, Pfizer Inc, New York, NY, USA.; Patient Health and Impact, Pfizer Inc, New York, NY, USA.",fred.saad@umontreal.ca.
35747143,Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy ,2022,"Comas, Laura","Oncology and Pharmacology Units, HUMSICB-CSIC, Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain.",None
35746830,"The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.",2022,"Hakimi, Zalmai; Desgraz, Renaud","Apellis Pharmaceuticals, Zug, Switzerland.; Apellis Pharmaceuticals, Zug, Switzerland.",None
35740574,Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice.,2022/Jun/13,"Beringer, Andreas; Müller-Ohldach, Mathis; Perret, Camille; Thomas, Marlene; Gondos, Adam","Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.; PDMA Medical Alliances Operations, F. Hoffmann-La Roche Ltd., Building 663, U1.312 Hochstrasse 16, CH-4053 Basel, Switzerland.; Oncology, Personalised Healthcare, F. Hoffmann-La Roche Ltd., Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.; Global Medical Affairs/PDMA, F. Hoffmann-La Roche Ltd., Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.; Pharmaceutical Division, F. Hoffmann-La Roche Ltd., Building 1, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.",None
35740512,Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan.,2022/Jun/09,"Santorelli, Melissa L; Burke, Thomas","Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., 126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ 07065, USA.; Center for Observational & Real World Evidence (CORE), Merck & Co., Inc., 126 East Lincoln Ave., P.O. Box 2000, Rahway, NJ 07065, USA.",None
35738803,Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.,2022,"Lafourcade, Alexandre; De Rycke, Yann; Castaneda, Johann; Tubach, Florence","Centre de Pharmacoépidémiologie (Cephepi), AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France.; Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.; Centre de Pharmacoépidémiologie (Cephepi), AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France.; Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.",raphaele.seror@aphp.fr.
35738590,Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.,2022,"Albert, Daniel H; Goodwin, Neal C; Davies, Angela M; Mancini, Maria; Singh, Sanjana; Popovic, Relja; Shen, Y U; McDaniel, Keith F; Kati, Warren M; Modi, Dimple A; Motwani, Monica; Wolff, Johannes E; Frost, David J","AbbVie, Inc., North Chicago, IL, U.S.A.; daniel.h.albert@abbvie.com.; Champions Oncology, Inc., Hackensack, NJ, U.S.A.; Champions Oncology, Inc., Hackensack, NJ, U.S.A.; Champions Oncology, Inc., Hackensack, NJ, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.; AbbVie, Inc., North Chicago, IL, U.S.A.",daniel.h.albert@abbvie.com.
35737639,"Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.",2022/Sep/01,"Arias, Marina; de Alvaro, Juan; Parra-Palau, Josep L; Sánchez-Pérez, Tania; Aronchik, Ida; Filvaroff, Ellen H; Lamba, Manisha; Nikolova, Zariana","Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Bristol Myers Squibb, Princeton, New Jersey, USA.; Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Seville, Spain.",None
35737359,Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma.,2022/Aug/01,"Brody, Robert; Damrauer, Scott; Ojerholm, Eric","Corporal Michael Crescenz VA Medical Center, Philadelphia.; Corporal Michael Crescenz VA Medical Center, Philadelphia.; Corporal Michael Crescenz VA Medical Center, Philadelphia.",None
35735457,"A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.",2022/Jun/17,"Doucette, Sarah","IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.",None
35734858,Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open.,2022,"Arai, Shoko; Hoshi, Masato; Woo, Joon-Suk","Pfizer Japan Inc, Tokyo, Japan.; Pfizer Japan Inc, Tokyo, Japan.; Pfizer Korea Inc, Seoul, Korea.",None
35732748,A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.,2022,"Gawade, Prasad L; Lewis, Sandra; DeCosta, Lucy; Lawrence, Tatiana; Belani, Rajesh","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Global Biostatistical Science, Amgen Ltd, Cambridge, UK.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",Robert.Rifkin@usoncology.com.
35728875,Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with ,2022,"Brase, Jan C; Gasal, Eduard; Garrett, James; Savchenko, Alexander; Görgün, Güllü","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.",htawbi@mdanderson.org.
35728447,Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis.,2022,"Fakhouri, Walid; Vizcaya, David","Eli Lilly and Company, Windlesham, Surrey, United Kingdom.; Bayer Pharmaceuticals, Barcelona, Spain.",c.yang@erasmusmc.nl.
35725592,[Locally advanced or metastatic bladder cancer: Identification of barriers and levers of patients' pathway in France].,2022,"Pourroy, Bertrand","CHU Timone, unité Oncopharma, 264, rue Saint-Pierre, 13005 Marseille, France.",nadine.houede@chu-nimes.fr.
35724442,"Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients.",2022,"Suzzoni, Steve","Département Pharmacie, Gustave Roussy, Villejuif, France.",lambros.tselikas@gustaveroussy.fr.
35719996,Social Media Listening to Understand the Lived Experience of Individuals in Europe With Metastatic Breast Cancer: A Systematic Search and Content Analysis Study.,2022,"Aasaithambi, Sathyaraj; Chauhan, Jyoti; Sagkriotis, Alexandros","Insights and Analytics, Novartis Pharma AG, Basel, Switzerland.; Insights and Analytics, Novartis Pharma AG, Basel, Switzerland.; Insights and Analytics, Novartis Pharma AG, Basel, Switzerland.",None
35718373,Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade.,2022,"Harel, Michal; Lahav, Coren; Jacob, Eyal; Dahan, Nili; Sela, Itamar; Elon, Yehonatan; Raveh Shoval, Shani; Yahalom, Galit; Sharon, Ofer","OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.; OncoHost Ltd, Binyamina, Israel.",yshaked@technion.ac.il.
35717989,"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.",2022/Jun/18,"Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro","Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.",manali.kamdar@cuanschutz.edu.
35715627,"Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.",2022,"Patel, Darshak; Pereira, Leonardo R; Cheeti, Sravanthi; Musib, Luna; Hutchinson, Katherine E; Devlin, Clare; Bernardi, Ronald","Product Development, Biometrics, Biostatistics, F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Product Development Safety, Roche Products Ltd, Welwyn, UK.; Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, USA.; Clinical Pharmacology, Genentech, Inc., South San Francisco, CA, USA.; Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, Roche Products Ltd, Welwyn, UK.; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.",trippet1@MSKCC.ORG.
35715405,Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer.,2022/Jun/17,"Scheuer, Nicolas; Hsu, Grace G; Lockhart, Alexandre","Roche Products Ltd, Welwyn Garden City, UK.; Cytel, Inc, Waltham, MA, USA.; Cytel, Inc, Waltham, MA, USA.",vsubbiah@mdanderson.org.
35714477,Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.,2022,"Ganguli, A; Bhadauria, H; Oh, M","HEOR, Oncology, Medical Affairs, Astellas Pharma Inc., Chicago, USA.; HEOR, Oncology, Medical Affairs, Astellas Pharma Inc., Chicago, USA.; HEOR, Oncology, Medical Affairs, Astellas Pharma Inc., Chicago, USA.",bertrand.tombal@uclouvain.be.
35708696,Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.,2022/Aug/01,"Fleshner, Neil E; Silberstein, Jonathan; Siddiqui, Rizwan; Hairston, John; Elsouda, Dina; Russell, David","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Memorial Healthcare System, Hollywood, Florida.; Astellas Pharma Inc, Northbrook, Illinois.; Astellas Pharma Inc, Northbrook, Illinois.; Astellas Pharma Inc, Northbrook, Illinois.; Pfizer Inc, New York, New York.",None
35708343,Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.,2022,"Choi, Michelle; Bui, Cat N; Kapustyan, Tatyana","AbbVie Inc., North Chicago, IL.; AbbVie Inc., North Chicago, IL.; AbbVie Inc., North Chicago, IL.",None
35705558,Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma.,2022/Jun/15,"Trabucco, Sally E; Millis, Sherri Z; Lee, Jessica; Frampton, Garrett M; Venstrom, Jeffrey M; Ross, Jeffrey S; Ali, Siraj M; Jin, Dexter X","Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.",gounderm@mskcc.org.
35704974,Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.,2022,"Scott, Sophie; Faull, Iris; Kushnir, Marina; Nagy, Rebecca","Guardant Health Inc, Redwood City, CA, United States.; Guardant Health Inc, Redwood City, CA, United States.; Guardant Health Inc, Redwood City, CA, United States.; Guardant Health Inc, Redwood City, CA, United States.",sanjay.popat@rmh.nhs.uk.
35704798,Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.,2022,"Madison, Russell W; Chen, Kuei-Ting; Hopkins, Julia F; Schrock, Alexa B; Lester, Ashley; Wharton, Keith A; Danziger, Natalie; Mata, Douglas A; Ross, Jeffrey S","Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Ultivue Inc, Cambridge, MA.; Ultivue Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.",None
35704796,A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.,2022,"Walker, Christopher J; Landesman, Yosef","Karyopharm Therapeutics, Newton, MA.; Karyopharm Therapeutics, Newton, MA.",None
35702414,Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.,2022,"Procter, Marion; Eiger, Daniel; Emond, Orianne; Clark, Emma; Bines, Jose","Frontier Science Scotland Ltd, Kincraig, Kingussie, UK.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Products Ltd, Welwyn Garden City, UK.; Roche Products Ltd, Welwyn Garden City, UK.; Instituto Nacional de Câncer, INCA, Rio de Janeiro, Brazil.",None
35701070,Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.,2022,"Ascierto, Paolo Antonio","Melanoma Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy p.ascierto@istitutotumori.na.it paolo.ascierto@gmail.com.",p.ascierto@istitutotumori.na.it
35700381,Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.,2022/Dec/22,"Saumoy, Monica","Center for Digestive Health, Penn Medicine Princeton Medical Center, Plainsboro, NJ.",None
35699985,Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis.,2022/Jun/13,"Chauhan, Jyoti; Aasaithambi, Sathyaraj; Lau, Mike; Sagkriotis, Alexandros","Novartis Healthcare Pvt Ltd, Hyderabad, India.; Novartis Healthcare Pvt Ltd, Hyderabad, India.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
35699834,Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.,2022,"Jan, Yi-Hua; Chen, Shu-Jen; Tan, Kien Thiam","ACT Genomics, Co. Ltd, Taipei, Taiwan.; ACT Genomics, Co. Ltd, Taipei, Taiwan.; ACT Genomics, Co. Ltd, Taipei, Taiwan.",csilsc@nus.edu.sg.
35697829,Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals.,2022/Jun/13,"Chu, Audrey Y; Podgornaia, Anna I; Gudbjartsson, Daniel F; Reilly, Dermot F; Sveinbjornsson, Gardar; Holm, Hilma; Sulem, Patrick","Genetics, Merck & Co., Inc, Kenilworth, NJ, USA.; Genetics, Merck & Co., Inc, Kenilworth, NJ, USA.; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.; Genetics, Merck & Co., Inc, Kenilworth, NJ, USA.; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.; deCODE Genetics/Amgen, Inc., Reykjavik, Iceland.",iris.heid@ukr.de.
35696045,Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.,2022,"Huo, Stephen; Del Tejo, Viviana; Du, Ella X; Yang, Xiaoran; Betts, Keith A","Worldwide Health Economics and Outcomes Research-US Market, Bristol Myers Squibb, Princeton, NJ, USA.; US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA.; Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA.; Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA.; Health Economics and Outcomes Research, Analysis Group, Inc., Los Angeles, CA, USA.",bradley_mcgregor@dfci.harvard.edu.
35695986,"Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making.",2022,"Bell, Timothy J; Welch, Verna; Brown, Andrew; Amer, Karim","Pfizer Inc., New York, USA.; Pfizer Inc., New York, USA.; Pfizer Ltd, Tadworth, UK.; Pfizer Ltd, Tadworth, UK.",charlotte.panter@adelphivalues.com.
35695215,Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.,2022,"Leoni, Mollie; Dwyer, Karen; Ito, Takahiro; Herr, Fiona","Medical Sciences, Kyowa Kirin, Inc, Princeton, New Jersey, USA.; Medical Sciences, Kyowa Kirin, Inc, Princeton, New Jersey, USA.; Medical Sciences, Kyowa Kirin, Inc, Princeton, New Jersey, USA.; Medical Affairs, Kyowa Kirin, Inc, Bedminster, New Jersey, USA.",None
35689897,Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.,2022,"Marina, Neyssa","Five Prime Therapeutics, South San Francisco, CA, USA.",axel.budde@ukbonn.de.
35683354,Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.,2022/May/24,"Zhu, Fanfan; Zhang, Wenxin","Takeda (China) International Trading Co., Ltd., Shanghai 200124, China.; Takeda (China) International Trading Co., Ltd., Shanghai 200124, China.",None
35681616,Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.,2022/May/26,"Johnston, Amanda; Bomalaski, John S","Polaris Pharmaceuticals, Inc., San Diego, CA 92121, USA.; Polaris Pharmaceuticals, Inc., San Diego, CA 92121, USA.",None
35681574,"BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.",2022/May/24,"Eiger, Daniel; de Haas, Sanne Lysbet; Restuccia, Eleonora","Product Development Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Oncology Biomarker Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.; Product Development Oncology, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.",None
35680043,Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.,2022,"Ascierto, P A; Xu, L; Jin, F; Norwood, K","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, Italy.; Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.; Merck & Co., Inc., Rahway, USA.",maio@unisi.it.
35679540,Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.,2022,"Park, Joseph K","Global Development, Amgen Inc., Thousand Oaks, California, United States of America.",None
35679096,Convenient Access to Expert-Reviewed Health Information via an Alexa Voice Assistant Skill for Patients With Multiple Myeloma: Development Study.,2022/Jun/09,"Decker, Sarah; Probst, Leona; Joneleit, Stefan; Buettner, Hartwig","Takeda Pharma Vertrieb GmbH & Co KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co KG, Berlin, Germany.; Takeda Pharma Vertrieb GmbH & Co KG, Berlin, Germany.",None
35678616,"A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer.",2022,"Wolter, Kevin D; Jani, Darshana; Sherman, Nancy","Pfizer Inc, New York, New York, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, New York, New York, USA.",None
35678045,Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.,2022,"Becker, Michael","Experimental Pharmacology and Oncology GmbH, Berlin-Buch, Germany.",None
35676445,Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.,2022/Jun/08,"Esteva, Andre; van der Wal, Douwe; Chen, Emmalyn","Artera, Inc, Mountain View, CA, USA. aesteva@artera.ai.; Artera, Inc, Mountain View, CA, USA.; Artera, Inc, Mountain View, CA, USA.",aesteva@artera.ai.
35675470,"The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.",2022,"Ramaswamy, Krishnan; Ganguli, Arijit; Haas, Gabriel P","Global HEOR, Pfizer Inc., New York, New York, USA.; Global HEOR, Astellas Pharma Inc., Northbrook, Illinois, USA.; Global Medical Affairs, Astellas Pharma Inc., Northbrook, Illinois, USA.",None
35674125,Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).,2023,"Ng, Diane","Westat Inc, Rockville, Maryland, USA.",None
35672677,Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.,2022/Jun/07,"Reeves, John A; Fellous, Marc","Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland.",chihyang@ntu.edu.tw.
35671543,Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.,2022,"Schubert, Nil A; Dowless, Michele; Shields, David J; Stancato, Louis F; van den Boogaard, Marlinde L","Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Eli Lilly and Company, Indianapolis, IN, USA.; Pfizer Centers for Therapeutic Innovation, Pfizer Inc., New York, NY, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.",j.j.molenaar@prinsesmaximacentrum.nl.
35668384,Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.,2022/Jun/06,"Groves, L; Tsang, C; Sugrue, D; McKenna, S; Houghton, J","Health Economics & Outcomes Research Ltd, Cardiff, UK.; Health Economics & Outcomes Research Ltd, Cardiff, UK.; Health Economics & Outcomes Research Ltd, Cardiff, UK.; Health Economics & Outcomes Research Ltd, Cardiff, UK.; Health Economics & Outcomes Research Ltd, Cardiff, UK.",tom.waddell@nhs.net.
35664758,Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States.,2022,"Thomaidou, Despina; Li, Benjamin; Siu, Gordon; Levin, Rebecca; Vlahiotis, Anna; Rao, Dharanija; Zanotti, Giovanni","Pfizer Inc., Hellas, Greece.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.",None
35663832,"Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study.",2022,"Shah, Jatin","Karyopharm Therapeutics, Newton, MA, USA.",None
35662591,Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.,2022,"Williams, Kirsten M","Children's Healthcare of Atlanta/Aflac Cancer Center, Atlanta, Georgia, United States.",lgriffith@niaid.nih.gov.
35660971,Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.,2022,"Hooi Wong, Chew","Pfizer Pte Ltd, Singapore. Electronic address: chewhooi.wong@pfizer.com.",Ben.Solomon@petermac.org.
35658525,"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.",2023/Jan/20,"Peng, Weimin; Fang, Xiang; Shen, Rhine R; Siddiqi, Rubina; Kloos, Ioana","Kite, a Gilead Company, Santa Monica, CA.; Kite, a Gilead Company, Santa Monica, CA.; Kite, a Gilead Company, Santa Monica, CA.; Kite, a Gilead Company, Santa Monica, CA.; Kite, a Gilead Company, Santa Monica, CA.",None
35658002,Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A.,2022/Jul/20,"Faller, Bryan; Al Baghdadi, Tareq; Papadimitrakopoulou, Vassiliki","IHA Hematology Oncology Consultants, CRC NCORP, Ann Arbor, MI.; IHA Hematology Oncology Consultants, CRC NCORP, Ann Arbor, MI.; Pfizer, Inc, New York, NY.",None
35657653,A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer.,2022,"Pathan, Nuzhat; Ma, Wei Dong; Masters, Joanna C; Cossons, Nandini; Wilner, Keith","Translational Oncology, Pfizer Inc, San Diego, CA, USA.; Biostatistics, Pfizer Inc, New York, USA.; Translational Oncology, Pfizer Inc, San Diego, CA, USA.; Lead Study Clinician, Pfizer Inc, UK.; Translational Oncology, Pfizer Inc, San Diego, CA, USA.",None
38993370,A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma.,2022,"Takashima, Satoru; Hasegawa, Takahiro; Iguchi, Motofumi; Igarashi, Kenji","Clinical Development, Shionogi & Co., Ltd., Osaka, Japan.; Biostatistics Center, Shionogi & Co., Ltd., Osaka, Japan.; Medical Affairs, Shionogi & Co., Ltd., Osaka, Japan.; Project Management, Shionogi & Co., Ltd., Osaka, Japan.",None
35655320,A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.,2022/Jun/02,"Kakizume, Tomoyuki; Myers, Andrea","Novartis Pharma K.K, Tokyo, Japan.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",chanlam_stephen@cuhk.edu.hk.
35654659,Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.,2023,"Kopyltsov, Evgeny","State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia.",pgrivas@uw.edu.
35653981,Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.,2022,"Belani, A; Zhang, X","Pfizer Inc, New York, USA.; Pfizer Inc, New York, USA.",skopetz@mdanderson.org.
35653145,Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.,2022/Aug/01,"Wei, Ran; Forrester, Tammy; Fernandez, Maria Munoz; Zimmermann, Annamaria; Headley, Desiree","Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.; Eli Lilly and Company, Indianapolis, Indiana.",None
35650597,Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.,2022/Jun/02,"Arrieta, Oscar; Barron, Feliciano; Lara-Mejia, Luis","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",christian.rolfo@mssm.edu.
35646453,Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial.,2022,"Sapin, Christophe; Leage, Soyi Liu; McKenzie, Robert; Schuster, Christopher; Riedl, Elisabeth","Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.",None
35643868,Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.,2022,"Lipton, Jeffrey H; Leip, Eric; Purcell, Simon; Yver, Anne","Princess Margaret Cancer Centre, Toronto, ON, Canada.; Pfizer Inc, Cambridge, MA, USA.; Pfizer Ltd, London, UK.; Pfizer Inc, Paris, France.",tbruemmendorf@ukaachen.de.
35643855,Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.,2022,"Wang, Tao; Neuhof, Alexander; Vandendries, Erik","Oncology, Pfizer Inc, Cambridge, MA.; Hematology Program, Pfizer Pharma GmbH, Berlin, Germany.; Oncology, Pfizer Inc, Cambridge, MA.",Matthias.Stelljes@ukmuenster.de.
35643841,"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER.",2022,"Lin, Ping; Duggan, William; Sugg, Jennifer; Russell, David","Formerly of Pfizer Inc., San Francisco, CA, USA.; Pfizer Inc., Groton, CT, USA.; Astellas Pharma, Inc., Northbrook, IL, USA.; Pfizer Inc., New York, NY, USA.",anthony.joshua@svha.org.au.
35643771,Data mining analyses for precision medicine in acromegaly: a proof of concept.,2022/May/28,"Sardon, Teresa","Anaxomics Biotech S.L., Barcelona, Spain.",mpuigd@igtp.cat.
35643624,Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis.,2022,"Liu, Xianchen; Li, Benjamin; McRoy, Lynn","Pfizer Inc, New York, NY. Electronic address: Jasonxc.Liu@pfizer.com.; Pfizer Inc, New York, NY.; Pfizer Inc, New York, NY.",Jasonxc.Liu@pfizer.com.
35640928,Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.,2022,"Naigeon, Marie","Faculté de Pharmacie, Université Paris-Saclay, Chatenay-Malabray, France.",CHAPUT-GRAS.Nathalie@gustaveroussy.fr.
35640224,Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.,2022/Nov/08,"Lin, Hui-Min","Blueprint Medicines Corporation, Cambridge, MA.",None
35637252,Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.,2022/May/30,"Groß-Langenhoff, Marco; Hasabou, Nahla; Lu, Qiaoyang; Tiu, Ramon V","Astellas Pharma GmbH, Munich, Germany.; Astellas Pharma US, Northbrook, IL, USA.; Astellas Pharma US, Northbrook, IL, USA.; Astellas Pharma US, Northbrook, IL, USA.",alexander.perl@pennmedicine.upenn.edu.
35636789,"BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours.",2022/May/30,"Sawyer, Sarah; Krainock, Michael; Maninder, Minu; Malhotra, Meenakshi; Ensor, Joe; Gao, Ling; Ellers, Sascha; Billings, Paul; Rodriguez, Angel; Aleshin, Alexey","Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA.; VA Long Beach Healthcare, Long Beach, California, USA.; Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA.; Natera Inc, Austin, Texas, USA aaleshin@natera.com.",aaleshin@natera.com.
35635631,Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.,2022,"Henary, Haby A; Wong, Hansen; Upreti, Vijay V","Medical Affairs, Amgen Inc, Thousand Oaks, CA, USA.; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, South San Francisco, CA, USA.; Clinical Pharmacology, Modeling & Simulation, Amgen Inc, South San Francisco, CA, USA.",moschos@med.unc.edu.
35631440,"Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment.",2022/May/16,"Ekpenyong, Oscar","ADME & Discovery Toxicology, Merck & Co., Inc., South San Francisco, CA 94080, USA.",None
35626166,GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells.,2022/May/23,"Littlefield, Bruce A","Eisai Inc., Cambridge, MA 02140, USA.",None
35626082,Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA.,2022/May/18,"Yaung, Stephanie J; Woestmann, Corinna; Ju, Christine; Ma, Xiaoju Max; Gattam, Sandeep; Zhou, Yiyong; Xi, Liu; Pal, Subrata; Balasubramanyam, Aarthi; Tikoo, Nalin; Palma, John F","Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.; Roche Sequencing Solutions, Inc., 14473 Potsdam, Germany.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Alector, Inc., South San Francisco, CA 94080, USA.; Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.",None
35626072,T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer.,2022/May/17,"Sanglier, Thibaut; Flahavan, Evelyn M; Pena-Murillo, Claudia; Meyer, Anne-Marie","RWD Oncology, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.; RWD Hematology, Roche Products Ltd., Hexagon Place, Falcon Way, Shire Park, Welwyn Garden City AL7 1TW, UK.; Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.; RWD Oncology, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.",None
35623341,Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.,2022/Jun/13,"Lu, Ruixiao; Braun, Jerome; Asare, Smita M","Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.; Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.; Quantum Leap Healthcare Collaborative, San Francisco, CA 94118, USA.",laura.vantveer@ucsf.edu.
35619639,"Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study.",2022,"Friedman-Mazursky, Orr; Tirosh, Matanya",Medical Affairs Pfizer Pharmaceuticals Israel Herzliya Israel.; Medical Affairs Pfizer Pharmaceuticals Israel Herzliya Israel.,None
35612853,Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.,2022/May/02,"Scheuer, Nicolas; Gupta, Alind; Hsu, Grace G","Roche Products Ltd, Welwyn Garden City, United Kingdom.; Cytel, Inc, Waltham, Massachusetts.; Cytel, Inc, Waltham, Massachusetts.",None
35612761,Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.,2022,"Taskar, Kunal S; Yang, Xinning; Neuhoff, Sibylle; Yoshida, Kenta; Cook, Jack; Polli, Joseph W; Lai, Yurong; Zamek-Gliszczynski, Maciej","Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Stevenage, UK.; Office of Clinical Pharmacology, Center of Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.; Certara UK Ltd., Simcyp Division, Sheffield, UK.; Clinical Pharmacology, Genentech Early Research and Development, South San Francisco, California, USA.; Clinical Pharmacology, Global Product Development, Pfizer Inc., Groton, Connecticut, USA.; Global Medical Sciences, ViiV Healthcare, Research Triangle Park, North Carolina, USA.; Drug Metabolism, Gilead Sciences Inc., Foster City, California, USA.; Drug Metabolism and Pharmacokinetics, IVIVT, GlaxoSmithKline, Upper Providence, Pennsylvania, USA.",None
35610260,Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.,2022/May/24,"Mashadi-Hossein, Afshin; Brauer, Heather Ann; Warren, Sarah; Danaher, Patrick","NanoString, Inc., Seattle, WA, USA.; NanoString, Inc., Seattle, WA, USA.; NanoString, Inc., Seattle, WA, USA.; NanoString, Inc., Seattle, WA, USA.",chumsri.saranya@mayo.edu.
35606235,Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.,2022/Jun/15,"Sonoyama, Takuhiro; Kamitani, Akari; Shibata, Risa; Homma, Tomoyuki; Omoto, Shinya; Igarashi, Kenji; Ariyasu, Mari","Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.; Shionogi & Co., Ltd., Pharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.; Shionogi & Co., Ltd., Pharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan.; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan. Electronic address: mari.tatsuno@shionogi.co.jp.",mari.tatsuno@shionogi.co.jp.
35605188,Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ,2022/Nov/01,"Liu, Geoffrey; Arrieta, Oscar","Princess Margaret Cancer Centre, Toronto, Canada.; Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",None
35603849,Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials.,2022/Mar/02,"Rothenberg, Mace L","Global Product Development, Pfizer Inc, New York, NY, USA.",None
35603292,Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test.,2022,"Hinestrosa, Juan Pablo; Lewis, Jean M; Schroeder, Gregor; Perrera, Orlando; Searson, David; Rastegar, Kiarash; Hughes, Jake R; Ortiz, Victor; Clark, Iryna; Balcer, Heath I; Arakelyan, Larry; Turner, Robert; Billings, Paul R; Krishnan, Rajaram","Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.; Biological Dynamics, Inc, San Diego, CA USA.",None
35603278,Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy.,2022,"Schneider, Dina; Dropulic, Boro","Lentigen, a Miltenyi Biotec company, Gaithersburg, MD USA.; Lentigen, a Miltenyi Biotec company, Gaithersburg, MD USA.",None
35598410,Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020.,2022,"Hamed, Kamal A; Smart, Jennifer I","Basilea Pharmaceutica International Ltd., Basel, Switzerland.; Basilea Pharmaceutica International Ltd., Basel, Switzerland.",leonard-duncan@jmilabs.com.
35598359,Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.,2022,"Poehlein, Christian","Merck & Co., Inc., Kenilworth, NJ, USA.",G.Roubaud@bordeaux.unicancer.fr.
35598358,The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.,2022,"Hong, Jin-Liern; Lin, Huamao M","Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, United States.; Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, 02139, United States.",petros.christopoulos@med.uni-heidelberg.de.
35597252,"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.",2022,"Zor, Evren; Zuurman, Mike; Gilotti, Geralyn; Zhang, Yifan","Novartis Pharma, Basel, Switzerland.; Novartis Pharma, Amsterdam, Netherlands.; Novartis Pharmaceuticals, East Hanover, NJ, USA.; Novartis Pharmaceuticals, East Hanover, NJ, USA.",francesco.passamonti@uninsubria.it.
35596791,Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.,2022,"Chartash, E; Dobrenkov, K; Zhou, H; Connors, E C; Zhang, Y","Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.; Merck & Co., Inc., Rahway, NJ, USA.",victor.moreno@startmadrid.com.
35595634,Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools.,2022,"Dhanasiri, Sujith; Gallagher, James; Guillevic, Yann; Schulze-Rath, Renate","Global Medical Affairs, Celgene International - A Bristol Myers Squibb Company, Boudry, Switzerland.; Pfizer Inc, New York, NY, USA.; Global Medical Affairs, Celgene International - A Bristol Myers Squibb Company, Boudry, Switzerland.; Medical Affairs &amp; Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.",jmhr@usal.es.
35594555,Ralstonia pickettii and Pseudomonas aeruginosa Bloodstream Infections Associated With Contaminated Extracorporeal Membrane Oxygenation Water Heater Devices.,2022/Nov/14,"Huntley, Miriam; Sater, Mohamad","Day Zero Diagnostics Inc., Boston, Massachusetts, USA.; Day Zero Diagnostics Inc., Boston, Massachusetts, USA.",None
35594047,Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.,2022/May/02,"Ashok, Arya; Stoll, Jessica; Mauer, Elizabeth; Nepomuceno, Vanessa M; Blackwell, Kimberly L","Tempus Labs Inc, Chicago, Illinois.; Tempus Labs Inc, Chicago, Illinois.; Tempus Labs Inc, Chicago, Illinois.; Tempus Labs Inc, Chicago, Illinois.; Tempus Labs Inc, Chicago, Illinois.",None
35592387,Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.,2022/Jun/16,"Lee, Jack Y; Nguyen, Bianca; Mukhopadhyay, Anandaroop; Han, Mia; Zhang, Jun; Gujar, Ravindra; Salazar, Jon; Hermiz, Reneta; Svenson, Lauren; Browning, Erica; Canton, David A; Twitty, Christopher G","Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.; Oncosec Medical Incorporated, 3565 General Atomics Court, San Diego, CA 92121, USA.",None
35588692,Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.,2022,"Amonkar, Mayur M; Norquist, Josephine M; Wang, Ruixue; Norwood, Kevin","Merck & Co., Inc., Rahway NJ, USA. Electronic address: mayur.amonkar@merck.com.; Merck & Co., Inc., Rahway NJ, USA. Electronic address: josephine_norquist@merck.com.; Merck & Co., Inc., Rahway NJ, USA. Electronic address: ruixue.wang@merck.com.; Merck & Co., Inc., Rahway NJ, USA. Electronic address: kevin.norwood@merck.com.",AURELIEN.MARABELLE@gustaveroussy.fr.
35585358,Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.,2022,"Matsumura, Eiji; Ishigami, Masato; Sugihara, Masahiro","Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.; Daiichi Sankyo Co., Ltd, Tokyo, Japan.",tdoi@east.ncc.go.jp.
35584676,WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.,2022/May/17,"Kitai, Hidenori; Michel, Adam O","Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Drug Safety and Pharmacometrics, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA; Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.",sent@mskcc.org.
35584336,"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.",2022/Oct/01,"Habboubi, Nassir; Conlan, Maureen G","Stemline Therapeutics/Menarini Group, New York, NY.; Radius Health, Inc, Boston, MA.",None
35580297,AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With ,2022/Sep/20,"Sun, Changan; Wei, Hongying; Li, Chuan; Ali, Siraj M; Miller, Vincent A; Wu, Qiong","Hansoh Pharmaceutical Group Co. Ltd, Shanghai, China.; Hansoh Pharmaceutical Group Co. Ltd, Shanghai, China.; Hansoh Pharmaceutical Group Co. Ltd, Shanghai, China.; EQRx, Inc, Cambridge, MA.; EQRx, Inc, Cambridge, MA.; Hansoh Pharmaceutical Group Co. Ltd, Shanghai, China.",None
35579943,Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.,2022/Jul/01,"Ali, Siraj M","Foundation Medicine Inc., Cambridge, Massachusetts, USA.",None
35577966,Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial.,2022,"Manyonda, Isaac","St George's Healthcare NHS Trust, London, UK.",f.pesola@qmul.ac.uk.
35577503,Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.,2022,"Watson, Carl","A4P Ltd, Sandwich, UK.",gomez-roca.carlos@iuct-oncopole.fr.
35576438,"Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.",2022/Aug/02,"Parmar, Hema; Akella, Lalith; Orford, Keith","Calithera Biosciences, Inc., South San Francisco, California.; Calithera Biosciences, Inc., South San Francisco, California.; Calithera Biosciences, Inc., South San Francisco, California.",None
35572530,Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment.,2022,"Church, Sarah E","NanoString Technologies, Inc., Seatlle, WA, United States.",None
35570071,Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.,2022,"Lipton, Jeffrey H","Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: Jeff.Lipton@uhn.ca.",Jeff.Lipton@uhn.ca.
35568439,Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study.,2022,"Walther, Julia; Dory, Anne","Service de pharmacie stérilisation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.; Service de pharmacie stérilisation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.",laurent.arnaud@chru-strasbourg.fr.
35567776,Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia.,2022,"Duan, Yinghui; Mendes, Wellington; Potluri, Jalaja; Tews, Björn","US Medical Affairs, AbbVie Inc., North Chicago, Illinois, USA.; Oncology Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.; Oncology Clinical Development - Myeloid Program, AbbVie Inc., North Chicago, Illinois, USA.; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois, USA.",None
35566609,Unknown,2022/Apr/28,"Soussan-Gutman, Lior; Ben-Shitrit, Taly; Dvir, Addie","Rhenium Oncotest Ltd., Ha-Satat St. 20, Modi'in-Maccabim-Re'ut 7177704, Israel.; Rhenium Oncotest Ltd., Ha-Satat St. 20, Modi'in-Maccabim-Re'ut 7177704, Israel.; Rhenium Oncotest Ltd., Ha-Satat St. 20, Modi'in-Maccabim-Re'ut 7177704, Israel.",None
35565428,Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.,2022/May/05,"Re, Sandra; Paulucci, David; Dobler, Darin","Bristol Myers Squibb, Princeton, NJ 08543, USA.; Bristol Myers Squibb, Princeton, NJ 08543, USA.; Bristol Myers Squibb, Princeton, NJ 08543, USA.",None
35565368,Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer.,2022/Apr/29,"Yaung, Stephanie J; Ju, Christine; Gattam, Sandeep; Nicholas, Alan; Sommer, Nicolas; Hurwitz, Herbert I; Lee, John J; Casey, Fergal; Price, Richard; Palma, John F","Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Roche Molecular Systems, Inc., Pleasanton, CA 94588, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.; Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.; Genentech, Inc., South San Francisco, CA 94080, USA.; Roche Sequencing Solutions, Inc., Pleasanton, CA 94588, USA.",None
35561140,Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective.,2022,"Neuhoff, Sibylle; Yoshida, Kenta; Leeder, James Steven; Mukherjee, Dwaipayan; Varma, Manthena V S; Zhang, Xinyuan; Yang, Xinning","Certara UK Ltd., Sheffield, UK.; Clinical Pharmacology, Genentech Research and Early Development, South San Francisco, California, USA.; Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.; Clinical Pharmacology & Pharmacometrics, Research & Development, AbbVie, Inc., North Chicago, Illinois, USA.; Pharmacokinetics, Dynamics and Metabolism, Medicine Design, Worldwide R&D, Pfizer Inc, Groton, Connecticut, USA.; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.; Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.",None
35553646,Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.,2022/May/13,"Jacob, Allison","Adaptive Biotechnologies, Seattle, Washington.",None
35552673,"Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.",2022/Aug/15,"Bananis, Eustratios; Liu, Yuan; Huang, Xin; Kim, Sindy; Lechuga Frean, Maria Jose","Pfizer Inc, New York, New York.; Pfizer Inc, San Diego, California.; Pfizer Inc, San Diego, California.; Pfizer Inc, San Diego, California.; Pfizer Inc, San Diego, California.",None
35552364,Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.,2022/Jul/01,"Du, Yining; Currie, Sue L; Hoch, Ute; Tagliaferri, Mary; Hannah, Alison L","Nektar Therapeutics, San Francisco, California.; Nektar Therapeutics, San Francisco, California.; Nektar Therapeutics, San Francisco, California.; Nektar Therapeutics, San Francisco, California.; Nektar Therapeutics, San Francisco, California.",None
35552271,LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade.,2022/Jul/01,"Marathi, Upendra","7 Hills Pharma, Houston, Texas, USA.",None
35551965,Development of a core outcome set for basal cell carcinoma.,2022,"Hurst, Eva A","Distinctive Dermatology, Fairview Heights, Illinois.",m-alam@northwestern.edu.
35551307,Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation.,2022,"Steinthorsdottir, Valgerdur; Thorleifsson, Gudmar; Thorsteinsdottir, Unnur; Stefansson, Kari","deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.; deCODE Genetics, Amgen Inc., Reykjavik, Iceland.",andrew.morris-5@manchester.ac.uk.
35550641,Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.,2022,"Daniele, Patrick; Mamolo, Carla; Cappelleri, Joseph C; Bell, Timothy; Neuhof, Alexander; Tremblay, Gabriel; Musat, Mihaela; Forsythe, Anna","Purple Squirrel Economics, a Cytel Company, Montreal, Canada.; Pfizer Inc., Groton, Connecticut, United States of America.; Pfizer Inc., Groton, Connecticut, United States of America.; Pfizer Inc., New York, New York, United States of America.; Pfizer Pharma GmbH, Berlin, Germany.; Purple Squirrel Economics, a Cytel Company, Montreal, Canada.; Purple Squirrel Economics, a Cytel Company, New York, New York, United States of America.; Purple Squirrel Economics, a Cytel Company, New York, New York, United States of America.",None
35550060,"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.",2022,"Reece, Donna; Jou, Ying-Ming; Ganetsky, Alex; Popa McKiver, Mihaela","Princess Margaret Cancer Centre, Toronto, ON, Canada.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",mdimop@med.uoa.gr.
35545778,"Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.",2022/May/11,"Tsukurov, Olga; Zhou, Xiaofei; Faessel, Helene; Yuan, Ying; Sedarati, Farhad; Faller, Douglas V; Kimura, Akiko","Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Pharmaceutical Company Limited, Osaka, Japan.",wushangju@ntu.edu.tw.
35545680,Fundamental immune-oncogenicity trade-offs define driver mutation fitness.,2022,"Campitelli, Laura F; Osborne, Edward J; Klinger, Mark; Robins, Harlan S","Adaptive Biotechnologies, Seattle, WA, USA.; Adaptive Biotechnologies, Seattle, WA, USA.; Adaptive Biotechnologies, Seattle, WA, USA.; Adaptive Biotechnologies, Seattle, WA, USA.",greenbab@mskcc.org.
35544124,Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor-Induced Hand-Foot Skin Reaction.,2022/Jul/01,"Sauder, Maxwell","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",None
35538491,"The ""Great Debate"" at Melanoma Bridge 2021, December 2nd-4th, 2021.",2022/May/10,"Tawbi, Hussein A","Melanoma Medical Oncology, Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Brain Metastasis Clinic, UT MD Anderson Cancer Center, Houston, TX, USA.",paolo.ascierto@gmail.com.
35536733,Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.,2022/May/10,"Dima, Laura","Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland.",None
35535436,"The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial.",2022,"Lawrence, David","Pfizer Inc., New York, New York, USA.",None
35534504,PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients.,2022/May/09,"Church, Sarah E","NanoString Technologies, Inc., Seattle, United States.",christine.lundgren@med.lu.se.
35534063,Changes in primary care visits arising from the COVID-19 pandemic: an international comparative study by the International Consortium of Primary Care Big Data Researchers (INTRePID).,2022/May/09,"Kang, Seo Young","International Healthcare Center, Asan Medical Center, Seoul, South Korea.",k.tu@utoronto.ca.
35525184,Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer.,2022,"Kushnir, M; Odegaard, J; Faull, I","Guardant Health Inc, Redwood, USA.; Guardant Health Inc, Redwood, USA.; Guardant Health Inc, Redwood, USA.",julia.alcaide.sspa@juntadeandalucia.es.
35524239,"A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.",2022/May/06,"Berhanu, Ghimja; Brandt, Ulrike; Stefanelli, Tommaso","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",maria.pantaleo@unibo.it.
35520101,The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy.,2022,"Alqaisi, Husam A; Stecca, Carlos; Fallah-Rad, Nazanin; Jiang, Di Maria","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.",None
35513244,Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.,2022,"Asare, S M; Asare, A L","Quantum Leap Healthcare Collaborative, San Francisco, USA.; Quantum Leap Healthcare Collaborative, San Francisco, USA.",lajos.pusztai@yale.edu.
35510893,Gastric Neuroendocrine Tumors With Parietal Cell Atrophy in a Long-term Carcinogenicity Study in Rats.,2022,"Shirai, Norimitsu; Choudhary, Shambhunath; Houle, Christopher","Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, USA.; Drug Safety Research and Development, Pfizer Inc., Pearl River, New York, USA.; Drug Safety Research and Development, Pfizer Inc., Groton, Connecticut, USA.",None
35508689,Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates.,2022/May/04,"Procopio-Melino, Renée; Kotch, Frank W; Prashad, Amar S; Gomes, Jose M; Wang, Wenge; Arve, Bo; Dawdy, Andrew; Chen, Lawrence; Sperry, Justin; Rouse, Jason C","BioProcess R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 1 Burtt Road, Andover, MA, 01810, USA.; BioProcess R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 875 Chesterfield Parkway West, Chesterfield, MO, 63017, USA. Frank.W.Kotch@pfizer.com.; BioProcess R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 875 Chesterfield Parkway West, Chesterfield, MO, 63017, USA.; BioProcess R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 1 Burtt Road, Andover, MA, 01810, USA. Jose.Gomes@pfizer.com.; BioProcess R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 1 Burtt Road, Andover, MA, 01810, USA.; BioProcess R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 875 Chesterfield Parkway West, Chesterfield, MO, 63017, USA.; Analytical R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 875 Chesterfield Parkway West, Chesterfield, MO, 63017, USA. Andrew.W.Dawdy@pfizer.com.; Analytical R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 1 Burtt Road, Andover, MA, 01810, USA.; Analytical R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 875 Chesterfield Parkway West, Chesterfield, MO, 63017, USA.; Analytical R&D, Biotherapeutics Pharmaceutical Sciences, Medicinal Sciences, Pfizer Worldwide R&D, 1 Burtt Road, Andover, MA, 01810, USA.",Xiaotian.Zhong@pfizer.com.
35507638,The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.,2022,"Kanhai, Karan","Medical Affairs, EUSA Pharma, Hemel Hempstead, UK.",None
35507536,"BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.",2022,"Hickman, Taylor L; Choi, Eugene; Whiteman, Kathleen R; Muralidharan, Sujatha; Pai, Tapasya; Johnson, Tyler; Parikh, Avani; Friedman, Taylor; Gilbert, Madaline; Shen, Binzhang; Barron, Luke; McGinness, Kathleen E; Ettenberg, Seth A; Motz, Greg T; Weiss, Glen J; Jensen-Smith, Amy","Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; SOTIO Biotech Inc.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; Unum Therapeutics, Inc., Cambridge, Massachusetts, United States of America.; SOTIO Biotech Inc.",None
35507334,Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.,2022/Jun/01,"Fettiplace, James; Ngai, Yenting; Nunn, Miles A","Akari Therapeutics Plc, London, United Kingdom.; Akari Therapeutics Plc, London, United Kingdom.; Akari Therapeutics Plc, London, United Kingdom.",None
35504291,Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.,2022/Jun/07,"Sethumadhavan, Shalini; Negrón Abril, Yashira L; Goldford, Joshua; Sellers, Katherine; Pirman, David; Roddy, Thomas P; Kingsbury, Gillian","Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.; Agios Pharmaceuticals, Cambridge, MA, USA.",sutherland.k@wehi.edu.au.
35500404,Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.,2022,"Zhao, Zi-Ming; Ren, Min","Translational Science, Oncology Business Group, Eisai Inc., Nutley, NJ, USA.; Biostats, Oncology Business Group, Eisai Inc., Nutley, NJ, USA.",nmasuda@alpha.ocn.ne.jp.
35499204,"A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond.",2022,"Kim, Semmie; Van Tornout, Jan M","TYME Technologies Inc., Bedminster, New Jersey, USA.; TYME Technologies Inc., Bedminster, New Jersey, USA.",None
35493516,"A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors.",2022,"Hooper, Andrea T","Oncology Research and Development, Pfizer, Inc., Pearl River, NY, United States.",None
35487845,Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.,2022,"Gupta, Kushagra; Alexandrou, Ari; Herraez-Baranda, Luis; Tosti, Nadia; Restuccia, Eleonora","IQVIA RDS India Pvt Ltd, Bangalore, India.; F. Hoffmann-La Roche Ltd., Welwyn, United Kingdom.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.",joseph.gligorov@aphp.fr.
35485219,Bispecific antibodies for immune cell retargeting against cancer.,2022,"Chen, Rebecca P; Shinoda, Kenta; Rampuria, Pragya; Jin, Fang; Bartholomew, Tin; Zhao, Chunxia; Yang, Fan; Chaparro-Riggers, Javier","Pfizer BioMedicine Design, Pfizer Inc, San Diego, CA, USA.; Pfizer BioMedicine Design, Pfizer Inc, Cambridge, MA, USA.; Pfizer BioMedicine Design, Pfizer Inc, Cambridge, MA, USA.; Pfizer BioMedicine Design, Pfizer Inc, Cambridge, MA, USA.; Pfizer BioMedicine Design, Pfizer Inc, Andover, MA, USA.; Pfizer BioMedicine Design, Pfizer Inc, Cambridge, MA, USA.; Pfizer BioMedicine Design, Pfizer Inc, San Diego, CA, USA.; Pfizer BioMedicine Design, Pfizer Inc, San Diego, CA, USA.",None
35483398,Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.,2022,"Keating, Armand","Princess Margaret Cancer Center, Toronto, ON, Canada.",thanarajasingam.gita@mayo.edu.
35475258,"Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA).",2022,"Hunter, Bradley D; Matharu, Balpreet; Metcalf, Louis; Wildum, Steffen; Graham, Emily","Intermountain Healthcare, Salt Lake City, UT, USA.; Roche Products Ltd, Welwyn Garden City, UK.; Roche Products Ltd, Welwyn Garden City, UK.; F Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Products Ltd, Welwyn Garden City, UK.",None
35475157,Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration-resistant prostate cancer: AFTERCAB study.,2022,"Saito, Atsushi; Uno, Satoshi",Astellas Pharma Inc. Tokyo Japan.; Astellas Pharma Inc. Tokyo Japan.,None
35472249,"Burden of disease, treatment utilization, and the impact on education and employment in patients with sickle cell disease: A comparative analysis of high- and low- to middle-income countries for the international Sickle Cell World Assessment Survey.",2022,"Paulose, Jincy; Ramscar, Nicholas","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharma AG, Basel, Switzerland.",None
35472167,Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.,2022,"Peterson, Timothy; Orozco, Jennifer S","Janssen Pharmaceuticals, Beerse, Belgium.; Janssen Pharmaceuticals, Beerse, Belgium.",None
35471070,The cost impact of disease progression to metastatic castration-sensitive prostate cancer.,2022,"Chaves, Leonardo Passos; Feng, Qi; Zhu, Julia; Abbott, Thomas","Astellas Pharma Global Development, Inc., Northbrook, IL.; Astellas Pharma Global Development, Inc., Northbrook, IL.; Astellas Pharma Global Development, Inc., Northbrook, IL.; Astellas Pharma Global Development, Inc., Northbrook, IL.",None
35470385,Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.,2022/Oct/11,"Miao, Harry; Bunn, Veronica; Fenton, Keenan; Fanale, Michelle; Puhlmann, Markus","Kite Pharma, Santa Monica, CA.; Millennium Pharmaceuticals Inc., Cambridge, MA.; Seagen Inc., Bothell, WA.; Seagen Inc., Bothell, WA.; Seagen Inc., Bothell, WA.",None
35468945,Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.,2022,"Pennesi, Edoardo; Michels, Naomi; Brivio, Erica; Jiang, Yilin; Thano, Adriana; Ammerlaan, Anneke J C; Boer, Judith M; Sleight, Barbara; Chen, Ying; Vormoor-Bürger, Britta; Bautista Sirvent, Francisco J; Zwaan, Christian M","Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pfizer Inc, Groton, CT, USA.; Pfizer Inc, Groton, CT, USA.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. c.m.zwaan@prinsesmaximacentrum.nl.",c.m.zwaan@prinsesmaximacentrum.nl.
35467965,Development of a Machine Learning Model Using Limited Features to Predict 6-Month Mortality at Treatment Decision Points for Patients With Advanced Solid Tumors.,2022,"Chalkidis, George; Yui, Shuntaro","Hitachi, Ltd, Tokyo, Japan.; Hitachi, Ltd, Tokyo, Japan.",None
35467243,"Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.",2022,"Petrich, Adam; Modi, Dimple; Morgan-Lappe, Susan; Nuthalapati, Silpa; Motwani, Monica; Dunbar, Martin; Glasgow, Jaimee; Medeiros, Bruno C","AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.; AbbVie Inc, North Chicago, IL, USA.",emiliano.calvo@startmadrid.com.
35464463,Differences in SARS-CoV-2 Vaccine Response Dynamics Between Class-I- and Class-II-Specific T-Cell Receptors in Inflammatory Bowel Disease.,2022,"Elyanow, Rebecca; Gittelman, Rachel M; Chapman, Heidi; Kaplan, Ian M","Adaptive Biotechnologies, Seattle, WA, United States.; Adaptive Biotechnologies, Seattle, WA, United States.; Adaptive Biotechnologies, Seattle, WA, United States.; Adaptive Biotechnologies, Seattle, WA, United States.",None
35461522,"Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.",2022,"Folschweiller, Nicolas","GSK, Wavre, Belgium; Takeda Pharmaceuticals, Zurich, Switzerland. Electronic address: nicolas.folschweiller@takeda.com.",nicolas.folschweiller@takeda.com.
35459795,Development of an immunohistochemical assay for Siglec-15.,2022,"Niu, Shuqiong; Liu, Linda N; Cusumano, Zachary T; Langermann, Sol","NextCure Inc, Beltsville, MD, USA.; NextCure Inc, Beltsville, MD, USA.; NextCure Inc, Beltsville, MD, USA.; NextCure Inc, Beltsville, MD, USA.",david.rimm@yale.edu.
35456993,GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma.,2022/Apr/10,"West, Cameron E","Genzada Pharmaceuticals, Hutchinson, KS 67502, USA.",None
35455781,Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity.,2022/Mar/23,"Lemeshow, Adina R; Russo, Leo J; Barnes, David M; Ababio, Yaa; Habtezion, Aida","Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.; Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.; Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.; Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.; Worldwide Medical and Safety, Pfizer Inc., 235 E 42nd St., New York, NY 10017, USA.",None
35449595,Identification of Recombinant Chimpanzee Adenovirus C68 Degradation Products Detected by AEX-HPLC.,2022,"Powers, Thomas W; Mullins, Elise K; Zhang, Kun; Binder, Joseph J; Friese, Olga; Runnels, Herbert A; Thompson, Lawrence C","Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States.; Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States.; Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States.; Cancer Vaccines and Immunotherapeutics, Pfizer Inc., San Diego, CA, United States.; Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States.; Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States.; Analytical Research and Development, Biotherapeutic Pharmaceutical Sciences, Pfizer Inc., Chesterfield, MO, United States.",None
35448196,Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.,2022/Apr/13,"Christofides, Anna","IMPACT Medicom Inc., Toronto, ON M6S 3K2, Canada.",None
35448189,"The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis.",2022/Apr/11,"McConechy, Melissa K; Furman, Benjamin L S; Aguirre Hernandez, Rosalia; Feijao, Pedro; Mulder, David","Canexia Health Inc., 1-3661 West 4th Avenue, Vancouver, BC V6R 1P2, Canada.; Canexia Health Inc., 1-3661 West 4th Avenue, Vancouver, BC V6R 1P2, Canada.; Canexia Health Inc., 1-3661 West 4th Avenue, Vancouver, BC V6R 1P2, Canada.; Canexia Health Inc., 1-3661 West 4th Avenue, Vancouver, BC V6R 1P2, Canada.; Canexia Health Inc., 1-3661 West 4th Avenue, Vancouver, BC V6R 1P2, Canada.",None
35445963,Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.,2022,"Papp, Kim A; Beecker, Jennifer; Gooderham, Melinda J; Hong, Chih-Ho; Lynde, Charles W; Maari, Catherine; Vender, Ronald B","Probity Medical Research Inc., Waterloo, ON, Canada. kapapp@probitymedical.com.; Probity Medical Research Inc., Waterloo, ON, Canada.; Probity Medical Research Inc., Waterloo, ON, Canada.; Probity Medical Research Inc., Waterloo, ON, Canada.; Probity Medical Research Inc., Waterloo, ON, Canada.; Innovaderm Research Inc, Montreal, QC, Canada.; Dermatrials Research Inc., Hamilton, ON, Canada.",kapapp@probitymedical.com.
35445315,"Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.",2022,"Tsujino, Toshiaki; Sunaya, Toshiyuki; Okayama, Yutaka","Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., 2-4-9 Umeda, Kita-ku, Osaka, 530-0001, Japan.; Product Development, Bayer Yakuhin, Ltd., Osaka, Japan.; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., 2-4-9 Umeda, Kita-ku, Osaka, 530-0001, Japan. yutaka.okayama@bayer.com.",yutaka.okayama@bayer.com.
35444058,Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.,2022,"Puente, Erika; Tang, Lily; Chien, David; Hoch, Ute; Choudhury, Arkopal; Yu, Danni; Currie, Sue L; Tagliaferri, Mary A; Zalevsky, Jonathan","Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.; Nektar Therapeutics, San Francisco, California, USA.",ntannir@mdanderson.org.
35443742,Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.,2022/Apr/20,"Bui, Cat N; Benjamin, Katy; Kamalakar, Rajesh; Potluri, Jalaja; Mendes, Wellington; Devine, Jacob","AbbVie Inc., North Chicago, IL, USA.; AbbVie Inc., North Chicago, IL, USA.; AbbVie Inc., North Chicago, IL, USA.; AbbVie Inc., North Chicago, IL, USA.; AbbVie Inc., North Chicago, IL, USA.; Genentech Inc., South San Francisco, CA, USA.",keith.pratz@pennmedicine.upenn.edu.
35442707,A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.,2022/Apr/20,"Shazer, Ronald; Der-Torossian, Hirak","Mirati Therapeutics Inc., San Diego, CA 92121, USA.; Mirati Therapeutics Inc., San Diego, CA 92121, USA.",None
35441907,Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance.,2022,"Yoshizaki, Kenji; Nakao, Takafumi","Safety Management Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.; Safety Management Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., 1-5, Dosho-machi 2-chome, Chuo-ku, Osaka, 541-8526, Japan.",huemura@med.kindai.ac.jp.
35440675,GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.,2022/Apr/19,"Tirunagaru, Vijaya G; Doebele, Robert C","Rain Therapeutics Inc, Newark, CA, USA.; Rain Therapeutics Inc, Newark, CA, USA.",s.piscuoglio@unibas.ch.
35440668,Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.,2022,"Ansell, Peter; He, Lei","AbbVie Inc., North Chicago, IL, USA.; AbbVie Inc., North Chicago, IL, USA.",Cgay@mdanderson.org.
35440124,Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts.,2022/Apr/19,"Kulick, Amanda; Meneses, Maximiliano; de Stanchina, Elisa","Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA.; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA.; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA.",sent@mskcc.org.
35439371,Quantitative systems pharmacology modeling provides insight into inter-mouse variability of Anti-CTLA4 response.,2022,"Qiao, Wenlian; Lin, Lin; Young, Carissa; Narula, Jatin; Hua, Fei; Matteson, Andrew; Hooper, Andrea; Gruenbaum, Lore; Betts, Alison","BioMedicine Design, World Research, Development and Medical, Pfizer, Inc., Cambridge, Massachusetts, USA.; Formerly, Applied BioMath, Inc., Concord, Massachusetts, USA.; Formerly, Applied BioMath, Inc., Concord, Massachusetts, USA.; BioMedicine Design, World Research, Development and Medical, Pfizer, Inc., Cambridge, Massachusetts, USA.; Applied BioMath, Inc., Concord, Massachusetts, USA.; Applied BioMath, Inc., Concord, Massachusetts, USA.; Formerly, Oncology Research Unit, World Research, Development and Medical, Pfizer, Inc., Pearl River, New York, USA.; Formerly, Applied BioMath, Inc., Concord, Massachusetts, USA.; Applied BioMath, Inc., Concord, Massachusetts, USA.",None
35439028,"Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.",2022/Aug/01,"Nangia, Narinder; Whitaker, Steve","Omeros Corporation, Seattle, WA.; Omeros Corporation, Seattle, WA.",None
35438754,Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.,2022/Apr/01,"Nickols, Nicholas G; Clise, Christina E; Maraka, Spyridoula; Ambrogini, Elena; Becker, Daniel J; Makarov, Danil V; Adorno Febles, Victor; Belligund, Pooja M; Al-Ajam, Mohammad; Goetz, Matthew B; Graber, Christopher J; Bhattacharya, Debika; Soo Hoo, Guy","Radiation Oncology Service, VA Greater Los Angeles Healthcare System, Los Angeles, California.; VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico.; Medicine Service, Central Arkansas Veterans Healthcare System, Little Rock.; Medicine Service, Central Arkansas Veterans Healthcare System, Little Rock.; Division of Hematology and Oncology VA New York Harbor Healthcare System, Manhattan Campus, New York.; VA New York Harbor Healthcare System, Manhattan Campus, New York.; VA New York Harbor Healthcare System, Manhattan Campus, New York.; VA New York Harbor Healthcare System, Brooklyn Campus, Brooklyn.; VA New York Harbor Healthcare System, Brooklyn Campus, Brooklyn.; Infectious Diseases Section, VA Greater Los Angeles Healthcare System, Los Angeles, California.; Infectious Diseases Section, VA Greater Los Angeles Healthcare System, Los Angeles, California.; Infectious Diseases Section, VA Greater Los Angeles Healthcare System, Los Angeles, California.; Pulmonary, Critical Care and Sleep Section, VA Greater Los Angeles Healthcare System, Los Angeles, California.",None
35437332,Development of a clinical polygenic risk score assay and reporting workflow.,2022,"Antwi, Ashley A; Brunette, Charles A; Danowski, Morgan; Jones, Natalie E; Vassy, Jason L","Veterans Affairs Boston Healthcare System, Boston, MA, USA.; Veterans Affairs Boston Healthcare System, Boston, MA, USA.; Veterans Affairs Boston Healthcare System, Boston, MA, USA.; Veterans Affairs Boston Healthcare System, Boston, MA, USA.; Veterans Affairs Boston Healthcare System, Boston, MA, USA. jvassy@bwh.harvard.edu.",jvassy@bwh.harvard.edu.
35435472,"A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.",2022,"Manzo, Julia; Puhalla, Shannon; Appleman, Leonard; Tawbi, Hussein; Stoller, Ronald; Lee, James J; Kiesel, Brian F; Ji, Jiuping; Zhang, Yiping; Chu, Edward; Beumer, Jan H","Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. beumerj@gmail.com.",beumerj@gmail.com.
35432603,"A phase 1 study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of the selective inhibitor of nuclear export (SINE) selinexor in Asian patients with advanced or metastatic malignancies.",2022,"Xu, Hongmei; Chang, Hua; Landesman, Yosef; Shah, Jatin; Shacham, Sharon","Karyopharm Therapeutics, Newton, MA, USA.; Karyopharm Therapeutics, Newton, MA, USA.; Karyopharm Therapeutics, Newton, MA, USA.; Karyopharm Therapeutics, Newton, MA, USA.; Karyopharm Therapeutics, Newton, MA, USA.",None
35429901,"Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.",2022,"Corsaro, Massimo; Huang, Xin","Pfizer Inc., Milan, Italy.; Pfizer Inc., San Diego, USA.",mmartin@geicam.org.
35426046,A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.,2022,"Belani, Rajesh; DeCosta, Lucy; Gawade, Prasad L; Lawrence, Tatiana; Lewis, Sandra","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Ltd, Uxbridge, UK.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",rmahtani@baptisthealth.net.
35425960,Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.,2022/Apr/15,"Zhou, Yinghui","TESARO: A GSK company, Waltham, Massachusetts.",None
35422631,Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib.,2022,"Gibson, Neil","Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.",None
35422531,Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.,2022,"Yun, Cindy; Shagan, Sarah M; Hu, Sylvia; Jin, Yanling; Shames, David S; Schleifman, Erica; Fabrizio, David A; Phan, See","Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd, Mississauga ON, Canada.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; Foundation Medicine, Inc, Cambridge, MA, USA.; Genentech, Inc., South San Francisco, CA, USA.",vamsidhar.velcheti@nyulangone.org.
35420921,Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.,2022/May/20,"Rosbrook, Brad; Zohren, Fabian; Yamada, Shunsuke; Haas, Gabriel P","Pfizer Inc, New York, NY.; Pfizer Inc, New York, NY.; Astellas Pharma Inc, Northbrook, IL.; Astellas Pharma Inc, Northbrook, IL.",None
35420744,Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.,2022,"Yang, Jingyan","Pfizer Inc, 235 E 42nd St, New York, NY 10017. Email: jingyan.yang@pfizer.com.",jingyan.yang@pfizer.com.
35419649,Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.,2022,"Dominguez, Sophie","Hôpitaux Catholiques de Lille, Département d'Onco-hématologie, Université Catholique de Lille, Hôpital St Vincent de Paul, Lille, France.",alexandre.santos@novartis.com.
35419282,Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer.,2022,"Knape, Charlene","Inivata Inc, Research Triangle Park, Durham, NC, United States.",None
35418180,Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.,2022/Apr/13,"Schneider, Dina","Lentigen Technology, Inc., a Miltenyi Biotec Company, Gaithersburg, MD, USA.",Evelyn.Ullrich@kgu.de.
35416053,Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.,2022,"Kopyltsov, Evgeny","State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia.",None
35414591,Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.,2022,"Cavallo, Rosetta; Peng, Linda; Zhang, Xiaoyu; Baughman, Jan; Bonvini, Ezio; Moore, Paul A; Goldberg, Stacie M; Arnaldez, Fernanda I","MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.",charu.aggarwal@uphs.upenn.edu.
35413267,Microbial byproducts determine reproductive fitness of free-living and parasitic nematodes.,2022/Jun/08,"Park, Hyun Shin","Seegene Inc., Ogeum-ro, Songpa-Gu, Seoul 05548, Republic of Korea.",ken.cadwell@nyulangone.org.
35406808,Cytoplasmic Colocalization of RXRα and PPARγ as an Independent Negative Prognosticator for Breast Cancer Patients.,2022/Apr/06,"Sixou, Sophie","Faculté des Sciences Pharmaceutiques, Université Toulouse III-Paul Sabatier, F-31062 Toulouse, France.",None
35406577,Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany.,2022/Apr/01,"Scherrer, Emilie; Chandwani, Sheenu; Jiang, Ruixuan; Krepler, Clemens","Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Merck & Co., Inc., Kenilworth, NJ 07033, USA.; Merck & Co., Inc., Kenilworth, NJ 07033, USA.",None
35406565,Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers.,2022/Mar/31,"Keating, Karen; Fillbrunn, Mirko; Gao, Wei; Ayyagari, Rajeev","Bayer HealthCare Pharmaceuticals, Inc., Whippany, Hanover Township, NJ 07981, USA.; Analysis Group, Inc., Boston, MA 02199, USA.; Analysis Group, Inc., Boston, MA 02199, USA.; Analysis Group, Inc., Boston, MA 02199, USA.",None
35404390,CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma.,2022/May/02,"Twyman-Saint Victor, Christina; Zhao, Qihong","Bristol-Myers Squibb, Princeton, NJ.; Bristol-Myers Squibb, Princeton, NJ.",None
35403447,"A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer.",2022,"Mangeshkar, Milan; Faoro, Leonardo","Exelixis, Inc., Alameda, California, USA.; Exelixis, Inc., Alameda, California, USA.",None
35397932,Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management.,2022,"le Comte, Marianne; Kwee, Wilma; Wensveen, Brigit","Drug Information Center, Royal Dutch Pharmacists Association KNMP, the Hague, the Netherlands.; Drug Information Center, Royal Dutch Pharmacists Association KNMP, the Hague, the Netherlands.; Drug Information Center, Royal Dutch Pharmacists Association KNMP, the Hague, the Netherlands.",f.g.a.jansman@rug.nl.
35397210,Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.,2022,"Dowden, Jeff J","Provincial Cancer Care Program, Eastern Health, St John's, NL, Canada.",y.lyratzopoulos@ucl.ac.uk.
35396580,Mapping genomic loci implicates genes and synaptic biology in schizophrenia.,2022,"Kam-Thong, Tony; Rautanen, Anna; Collier, David A; Malhotra, Dheeraj","Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffman-La Roche, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffman-La Roche, Basel, Switzerland.; Eli Lilly and Company, Windlesham, UK.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffman-La Roche, Basel, Switzerland.",ODonovanMC@cardiff.ac.uk.
35393688,Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin.,2022,"Phillips, Jonathan A; Taub, Mitchell E; Bogdanffy, Matthew S; Yuan, Jing; Knight, Brian; Smith, James D; Ku, Warren W","Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.; Pfizer Inc, Cambridge, Massachusetts, USA.; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.; Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.",None
35393425,Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.,2022/Apr/07,"Goddemeier, Thomas; Grombacher, Thomas","the healthcare business of Merck KGaA, Darmstadt, Germany.; the healthcare business of Merck KGaA, Darmstadt, Germany.",Ruth.Plummer@newcastle.ac.uk.
35392186,Nurses in clinical trials: perceptions of impact on the research enterprise.,2022,"Keller, Rosemary; Purdom, Michelle","Clinician, Worldwide Research and Development/Safety, Pfizer, Inc., New York, NY, USA.; Vice President, Clinical Research and Operations, TG Therapeutics, Inc., New York, NY, USA.",None
35391496,Reimagining diversity in multiple myeloma clinical trials.,2022,"Habr, Dany","Pfizer Oncology, Pfizer Inc., New York City, New York, USA.",None
35389428,Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial.,2022/Jun/01,"Dervin, Shannon; Schulze, Katja; Darbonne, Walter C; Yun, Cindy","Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.; Genentech, Inc, South San Francisco, California.",None
35388003,Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.,2022/Apr/06,"Hozak, Rebecca R; Rasmussen, Erik R; Xia, Meng Summer; Rhodes, Ryan; Wijayawardana, Sameera; Bell-McGuinn, Katherine M; Aggarwal, Amit","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, New York, NY, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",ms.vd.heijden@nki.nl.
37435446,Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing's disease.,2022,"Stroud, Anna; Dhaliwal, Pearl; Harvey, Richard J; Alvarado, Raquel; Jonker, Benjamin P; Winder, Mark J; Grayson, Jessica W","Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.; Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.; Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.; Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.; Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.; Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.; Rhinology and Skull Base Research Group, St Vincent's Centre for Applied Medical Research, Sydney, Australia.",None
35385051,Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System.,2022/May/01,"Solano, Francis X","UPMC Community Medicine Inc, Pittsburgh, Pennsylvania.",None
35383114,"Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.",2022,"Feng, Yan; Plautz, Gregory; Lei, Ming; Chang, Han; Lin, Wen Hong; Roy, Amit; Bello, Akintunde; Sheng, Jennifer","Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Medical Safety Assessment, Bristol Myers Squibb, Princeton, New Jersey, USA.; Precision Medicine, Bristol Myers Squibb, Princeton, New Jersey, USA.; Translational Bioinformatics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA.; Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA Jennifer.Sheng@bms.com.",Jennifer.Sheng@bms.com.
35380178,Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.,2022/Jun/15,"Suzuki, Takuya; Ren, Min; Fushimi, Kazuma","Eisai Co., Ltd., Tokyo, Japan.; Eisai Inc., Nutley, NJ, USA.; Eisai Co., Ltd., Tokyo, Japan.",None
35378840,Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.,2022,"Jacobson, Dionna; Cadieux, Benoit; Bachmann, Basia A; Rehn, Marko; Saad, Hossam","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",None
35377424,Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK.,2022/Apr/01,"Song, Chao; Li, Yanli; Kreaden, Usha Seshadri","Global Health Economics and Outcome Research, Intuitive Surgical Inc, Atlanta, Georgia.; Global Health Economics and Outcome Research, Intuitive Surgical Inc, Sunnyvale, California.; Biostatistics & Global Evidence Management, Intuitive Surgical Inc, Sunnyvale, California.",None
35373356,Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.,2022,"Pithavala, Yazdi K; Martini, Jean-François; Chen, Joseph","Clinical Pharmacology, Oncology Business Unit, Pfizer Inc., La Jolla, California, USA.; Translational Oncology, Global Product Development, Pfizer Inc., San Diego, California, USA.; Clinical Pharmacology, Oncology Business Unit, Pfizer Inc., La Jolla, California, USA.",None
35371621,Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting.,2022,"Kamei, Naoki; Iyama, Teruaki; Kashiwagi, Masahide","Bio Advanced Technology Division, Corporate R&D Headquarters, Konica Minolta, Inc, Tokyo, Japan.; Bio Advanced Technology Division, Corporate R&D Headquarters, Konica Minolta, Inc, Tokyo, Japan.; Bio Advanced Technology Division, Corporate R&D Headquarters, Konica Minolta, Inc, Tokyo, Japan.",None
35368070,Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients.,2022/Jun/16,"Carlsson, Martin; Wajnrajch, Michael P","Rare Disease, Biopharmaceuticals, Pfizer, New York, NY, USA.; Rare Disease, Biopharmaceuticals, Pfizer, New York, NY, USA.",None
35367007,"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.",2022/Apr/30,"Chen, Ke; Diede, Scott J; Ahsan, Sama; Ibrahim, Nageatte","Merck & Co, Inc., Kenilworth, NJ, USA.; Merck & Co, Inc., Kenilworth, NJ, USA.; Merck & Co, Inc., Kenilworth, NJ, USA.; Merck & Co, Inc., Kenilworth, NJ, USA.",lukejj@upmc.edu.
35366963,"Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.",2022,"Ufkin, Melanie; Li, Jingjin; Zhu, Min; Ambati, Srikanth R; Chaudhry, Aafia; Lowy, Israel","Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.",bannerra@cinj.rutgers.edu.
35364421,Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.,2022,"Gurary, Ellen B; Siegel, Abby B; Wang, Anran","Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, USA. Electronic address: egurary@gmail.com.; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, USA. Electronic address: abby.siegel@merck.com.; Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, USA. Electronic address: jiang.dian.wang@merck.com.",AZHU@mgh.harvard.edu.
35363892,Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.,2022/Jul/01,"Caocci, Giovanni","Polo oncologico ""A. Businco"", Università degli studi di Cagliari, Cagliari, Italy.",None
35363053,Aggressive End-of-Life Care in the Veterans Health Administration versus Fee-for-Service Medicare among Patients with Advanced Lung Cancer.,2022,"Lorenz, Karl A; Levy, Cari R","Center for Innovation to Implementation, VA Palo Alto Healthcare System, Palo Alto, California, USA.; Eastern Colorado VA Healthcare System, Aurora, Colorado, USA.",None
35361918,Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.,2022,"You, Benoit; Tod, Michel; Freyer, Gilles; Colomban, Olivier","Univ Lyon; Université Claude Bernard Lyon 1; Faculté de médecine Lyon-Sud; EA UCBL/HCL 3738 CICLY; Pharmacie, Lyon, France. benoit.you@chu-lyon.fr.; Univ Lyon; Université Claude Bernard Lyon 1; Faculté de médecine Lyon-Sud; EA UCBL/HCL 3738 CICLY; Pharmacie, Lyon, France.; Univ Lyon; Université Claude Bernard Lyon 1; Faculté de médecine Lyon-Sud; EA UCBL/HCL 3738 CICLY; Pharmacie, Lyon, France.; Univ Lyon; Université Claude Bernard Lyon 1; Faculté de médecine Lyon-Sud; EA UCBL/HCL 3738 CICLY; Pharmacie, Lyon, France.",benoit.you@chu-lyon.fr.
35361879,Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.,2022/Mar/31,"Madonna, Gabriele; Capone, Mariaelena; Ascierto, Paolo Antonio","Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione ""G. Pascale"", Via Mariano Semmola 53, 80131, Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione ""G. Pascale"", Via Mariano Semmola 53, 80131, Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione ""G. Pascale"", Via Mariano Semmola 53, 80131, Naples, Italy.",marialuigia.carbone@idi.it.
35361487,Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.,2022,"Xu, Lei; Jin, Fan; Norwood, Kevin","Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: lei_xu2@merck.com.; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: fan.jin@merck.com.; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: kevin.norwood@merck.com.",patrick_ott@dfci.harvard.edu.
35358455,"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.",2022,"Siegel, Jonathan M; Köchert, Karl; Walter, Annette O; Childs, Barrett H; Elbi, Cem","Clinical Statistics Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Biomarker and Data Insights, Bayer AG Pharma, Berlin, Germany.; Translational Medicine Oncology, Bayer AG Pharma, Berlin, Germany.; Oncology Development, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Global Clinical Development, Oncology, Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.",df132@leicester.ac.uk.
35358441,"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.",2022,"Marks, David I","United Bristol Healthcare Trust, Bristol, UK.",a.fielding@ucl.ac.uk.
35357449,Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.,2022/Mar/01,"Weberpals, Janick","Real World Data Collaborations, Personalized Healthcare Data, Analytics and Imaging, F. Hoffmann-La Roche, Basel, Switzerland.",None
35356551,Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.,2022,"Kurt, Murat; Kotapati, Srividya; Moshyk, Andriy","Bristol Myers Squibb, Health Economics and Outcomes Research, Princeton, NJ, USA.; Bristol Myers Squibb, Worldwide Medical Affairs, Princeton, NJ, USA.; Bristol Myers Squibb, Health Economics and Outcomes Research, Princeton, NJ, USA.",None
35354304,Real-world cost-effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia.,2022/Mar/31,"Kelton, John; Yang, Jingyan","Pfizer, Inc., New York, NY 10017, USA.; Patient Health & Impact (PHI), Pfizer, Inc., New York, NY 10017, USA.",None
35354274,Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors.,2022,"Li, Dandan; Zhao, Di; Gao, Yanfei; Xu, Wenping","Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaA.; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaA.; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaA.; Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. Beijing, China, 100022, an affiliate of Merck KGaA.",None
35353549,Cancer Burden Among Arab World Males in 2020: The Need for a Better Approach to Improve Outcome.,2022,"Jazieh, Abdul-Rahman","Cincinnati Cancer Advisors, Cincinnati, OH.",None
35350106,Awareness and Availability of Routine Germline ,2022,"Runkel, Eva Diana; Niyazov, Alexander; Quek, Ruben G W","Pfizer Pharma GmbH, Berlin, Germany.; Pfizer Inc., New York, New York, USA.; Pfizer Inc., San Francisco, California, USA.",None
35349331,Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio ,2022/Jun/20,"Brodersen, Lisa Eidenschink; Loken, Michael R","Hematologics Inc, Seattle, WA.; Hematologics Inc, Seattle, WA.",None
35347493,Guidance on the need for contraception related to use of pharmaceuticals: the Japan Agency for Medical Research and Development Study Group for providing information on the proper use of pharmaceuticals in patients with reproductive potential.,2022,"Yoshida, Saori; Ohira, Takashi; Katsura, Aiko; Fujiwara, Michio","Qol Co., Ltd, 4-3-1 Toranomon, Minato-ku, Tokyo, Japan.; Takeda Pharmaceutical Company Limited, 2-1-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan.; Novartis Pharma K.K, 1-23-1 Toranomon, Minato-ku, Tokyo, Japan.; Japan Pharmaceutical Manufacturers Association, 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan.",nao@marianna-u.ac.jp.
35347238,Clinical and molecular correlates of JAK-inhibitor therapy failure in myelofibrosis: long-term data from a molecularly annotated cohort.,2022,"England, James T; McNamara, Caroline J; Huang, Jingyue; Arruda, Andrea; Nye, Taylor; Cheung, Verna; Claudio, Jaime O; Maze, Dawn; Sibai, Hassan; Bankar, Aniket; Xu, Wei; Gupta, Vikas","Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. vikas.gupta@uhn.ca.",vikas.gupta@uhn.ca.
35344649,Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis.,2023,"Amin, Khalid; Wang, Yingbo; Sen, Paramita; Slimane, Khemaies","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Pharma AG, Basel, Switzerland.",None
35344588,Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.,2022,"Vourvahis, Manoli; Byon, Wonkyung; Chang, Cheng; Le, Vu; Graham, Daniela; Tripathy, Sakambari; Raha, Nancy; Luo, Lina; Mathialagan, Sumathy; Dowty, Martin; Rodrigues, A David; Malhotra, Bimal","Pfizer Inc., New York, New York, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., New York, New York, USA.; Pfizer Inc., New York, New York, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., Cambridge, Massachusetts, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., New York, New York, USA.",None
35344524,Real-World Comparison of Isavuconazole and Voriconazole in Terms of the Need for Dosage Adjustments Guided by Clinical Pharmacological Advice During Primary Prophylaxis of Invasive Fungal Infections in Pediatric Patients with Hemato-Oncological Malignancies.,2022/Oct/01,"Cojutti, Pier Giorgio","Clinical Pharmacology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.",None
35344035,Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.,2022/Jun/01,"Kumar, Sunil; Kuperwasser, Charlotte; Stephens, Philip J","Naveris Inc., Natick, Massachusetts.; Naveris Inc., Natick, Massachusetts.; Naveris Inc., Natick, Massachusetts.",None
35342654,The Utility of Circulating Tumor DNA (ctDNA) Monitoring in Cancer Patients Who Are Pregnant or Planning to Become Pregnant.,2022,"Hook, Nicole; Krainock, Michael; Budde, Griffin; Malashevich, Allyson Koyen; Meltzer, Jeffrey; Jelsema, Russ; Olshan, Perry; Billings, Paul R; Aleshin, Alexey","Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.; Natera, Inc, Austin TX, USA.",None
35342286,Identifying and Validating Networks of Oncology Biomarkers Mined From the Scientific Literature.,2022,"Wager, Kim; Chari, Dheepa; Ho, Steffan; Rees, Tomas","Oxford PharmaGenesis, Oxford, UK.; Pfizer, Inc., New York, NY, USA.; Pfizer, Inc., New York, NY, USA.; Oxford PharmaGenesis, Oxford, UK.",None
35338679,Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.,2022,"Wang, Kun; Choeurng, Voleak; Dennis, Lucas; Skoletsky, Joel; Woodhouse, Ryan; Li, Meijuan; Chang, Ching-Wei; Simmons, Brian; Riehl, Todd","Biostatistics, Foundation Medicine Inc., Cambridge, MA, USA.; Oncology Biostatistics, Genentech, Inc., South San Francisco, CA, USA.; Franchise Development, Foundation Medicine Inc., Cambridge, MA, USA.; Companion Diagnostics Development, Foundation Medicine Inc., Cambridge, MA, USA.; Regulatory Affairs, Foundation Medicine Inc., Cambridge, MA, USA.; Biometrics and Biomarkers, Foundation Medicine Inc., Cambridge, MA, USA.; Oncology Biostatistics, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.",None
35337972,Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.,2022,"San Antonio, B; Shahir, A; Hulstijn, M; Brown, J; Zimmermann, A; Wei, R","Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.",Hope.Rugo@ucsf.edu.
35337365,Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.,2022/Mar/25,"Liu, Fei Fei; Hasskarl, Jens; Li, Daniel; Kuruvilla, John","Bristol Myers Squibb, Princeton, NJ, USA.; Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Bristol Myers Squibb, Princeton, NJ, USA.; Princess Margaret Cancer Centre, Toronto, ON, Canada.",g-cartron@chu-montpellier.fr.
35333599,Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.,2022/Jul/20,"Ge, Joy; Swaby, Ramona F; Gumuscu, Burak","Merck & Co Inc, Kenilworth, NJ.; Merck & Co Inc, Kenilworth, NJ.; Merck & Co Inc, Kenilworth, NJ.",None
35332383,Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.,2022/Mar/25,"Green, George; Neely, Jaclyn; Nelson, David M","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",nwi@nordicbio.com.
35332278,"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.",2022,"Strulev, Vadim; Nesheiwat, Tonia","Janssen Pharmaceutica NV, Beerse, Belgium.; Legend Biotech USA Inc, Piscataway, NJ, USA.",mvmateos@usal.es.
35332062,"IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.",2022,"Duncan, Meghan","Xilio Therapeutics, Waltham, Massachusetts, USA.",TYap@mdanderson.org.
35331946,"Impact of COVID-19 pandemic on oncology clinical trial design, data collection and analysis.",2022,"Tang, Rui Sammi; Zhu, Jian; Liu, Fang; Jiang, Xun; Huang, Bo","Servier Pharmaceuticals, Boston, MA, USA.; Servier Pharmaceuticals, Boston, MA, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.; Amgen Inc., Thousand Oaks, CA, USA.; Pfizer Inc., Groton, CT, USA.",tai-tsang.x.chen@gsk.com.
35331214,Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.,2022/Mar/25,"Du, Pan; Yu, Jianjun; Jia, Shidong","Predicine, Inc., Hayward, CA, USA.; Predicine, Inc., Hayward, CA, USA.; Predicine, Inc., Hayward, CA, USA.",lisa.horvath@lh.org.au.
35330444,"Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease.",2022/Mar/11,"Yamamoto, Yuichi; Kanayama, Norihiro; Nakayama, Yusuke; Matsushima, Nobuko","Clinical Evaluation Sub-Committee, Medicinal Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11, Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Clinical Evaluation Sub-Committee, Medicinal Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11, Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Clinical Evaluation Sub-Committee, Medicinal Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11, Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.; Clinical Evaluation Sub-Committee, Medicinal Evaluation Committee, Japan Pharmaceuticals Manufacturers Association, 2-3-11, Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023, Japan.",None
35329077,Factors Associated with Polyp Detection Rate in European Colonoscopy Practice: Findings of The European Colonoscopy Quality Investigation (ECQI) Group.,2022/Mar/13,"Staines, Harry","Sigma Statistical Services Ltd., Saint Andrews KY16 0BD, UK.",None
35327433,Isolation of Functional SARS-CoV-2 Antigen-Specific T-Cells with Specific Viral Cytotoxic Activity for Adoptive Therapy of COVID-19.,2022/Mar/09,"Lanzarot, Diego","MiltenyiBiotech, 28223 Madrid, Spain.",None
35324270,"Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.",2022,"Lago, Nestor","Gema Biotech SAU, CABA, Argentina.",None
35323332,Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.,2022/Mar/02,"Masih-Khan, Esther; Reece, Donna","Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.; Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada.",None
35322232,Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.,2022,"Elimova, Elena; Poulart, Valerie; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",janjigiy@mskcc.org.
35319967,Landscape of ,2022,"El-Refai, Sherif M; O'Neil, Bert; Barrett, Alexander S","Tempus Labs Inc, Chicago, IL.; Tempus Labs Inc, Chicago, IL.; Tempus Labs Inc, Chicago, IL.",None
35317841,A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.,2022/Mar/22,"Liu, Y","Veracyte, Inc., San Diego, CA, USA.",claire.fletcher07@imperial.ac.uk.
35315874,Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.,2022/Apr/05,"Hunt, Beverley J","Kings Healthcare Partners, London, England.",None
35314842,Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.,2022,"Lui, Christine; Milletti, Francesca; Dong, Jinghui; Xu, Hairong","Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.; Kite, a Gilead Company, Santa Monica, CA, USA.",sneelapu@mdanderson.org.
35313167,Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.,2022,"Kiermaier, Astrid; Procter, Marion; Restuccia, Eleonora","Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland. Electronic address: astrid.kiermaier@roche.com.; Frontier Science Scotland Ltd., Kincraig, Kingussie, UK. Electronic address: marion.procter@frontier-science.co.uk.; Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic address: eleonora.restuccia@roche.com.",martine.piccart@bordet.be.
35313048,Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.,2022,"Gaillard, Vincent E",F. Hoffmann-La Roche Ltd.BaselSwitzerland.,None
35307611,Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.,2022,"Peltz, Gerson","Pfizer Inc., Cambridge, Massachusetts.",syylwu@live.cn.
35306859,Real-world treatment patterns of palbociclib and blood count monitoring in patients with advanced breast cancer in Japan.,2022,"Muramatsu, Yasuaki; Togo, Kanae; Laurent, Thomas","Oncology Medical Affairs, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151 8589, Japan.; Corporate Affairs, Health & Value, Pfizer Japan Inc., 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151 8589, Japan.; Clinical Study Support Inc., Daiei Bldg., 2F, 1-11-20, Nishiki, Naka-ku, Nagoya-shi, Aichi, 460 0003, Japan.",None
35305580,Experiences of family caregivers 3-months after stroke: results of the prospective trans-regional network for stroke intervention with telemedicine registry (TRANSIT-Stroke).,2022/Mar/19,"Wiedmann, Silke; von Nippold, Karin","Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Cardiology, Clincal Centre Helios Frankenwald, Kronach, Germany.",steffi.hillmann@uni-wuerzburg.de.
35305400,Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.,2022,"Bustillos, A; Fear, S; Ganta, S","Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",jtabernero@vhio.net.
35304405,Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.,2022,"Gupta, Saurabh; Yao, Jin; Han, Celine; Ammar, Ron; Papillon-Cavanagh, Simon; Saggi, Shruti S; McHenry, M Brent; Ross-Macdonald, Petra; Wind-Rotolo, Megan","Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.; Translational Medicine, Bristol Myers Squibb Co, Princeton, New Jersey, USA.",motzerr@mskcc.org.
35303508,Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.,2022,"Rearden, Jessica","QED Therapeutics, San Francisco, CA, USA.",matteo.fassan@unipd.it.
35303141,Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.,2022,"Hibma, Jennifer E; O'Gorman, Melissa; Pithavala, Yazdi K","Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA. Jennifer.e.hibma@pfizer.com.; Pfizer (Pharmacometrics Oncology), Groton, CT, USA.; Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA.",Jennifer.e.hibma@pfizer.com.
35302585,ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.,2022/Jun/13,"Lee, Patrice; Golden, Adele; Harney, Allison; Rothenberg, S Michael; Zhang, Yuanyuan","Pfizer Inc., Boulder, Colorado.; Pfizer Inc., Boulder, Colorado.; Pfizer Inc., Boulder, Colorado.; Pfizer Inc., Boulder, Colorado.; Pfizer Inc., Boulder, Colorado.",None
35302493,Effector membrane translocation biosensors reveal G protein and βarrestin coupling profiles of 100 therapeutically relevant GPCRs.,2022/Mar/18,"Mancini, Arturo; Breton, Billy; Normand, Claire; Gross, Florence; Morissette, Sandra; Schann, Stephan; Leroy, Xavier","Domain Therapeutics North America, Montréal, Canada.; Domain Therapeutics North America, Montréal, Canada.; Domain Therapeutics North America, Montréal, Canada.; Domain Therapeutics North America, Montréal, Canada.; Domain Therapeutics North America, Montréal, Canada.; Domain Therapeutics, Illkirch-Strasbourg, France.; Domain Therapeutics, Illkirch-Strasbourg, France.",None
35301134,Towards a more patient-centered clinical trial process: A systematic review of interventions incorporating health literacy best practices.,2022,"Bader, Mehnaz; Myers, Laurie","Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA. Electronic address: Mehnaz.Bader@pfizer.com.; Global Health Literacy and Oncology Health Equity, Merck & Co., Inc., Kenilworth, NJ, USA.",Mehnaz.Bader@pfizer.com.
35298698,"First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.",2022,"Ascierto, Paolo A","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS-Fondazione Pascale, Napoli, Italy.",emiliano.calvo@startmadrid.com.
35298559,A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex.,2022,"Dao, Tao; Mun, Sungsoo; Korontsvit, Tatyana; Klatt, Martin G; Scheinberg, David A","Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.",None
35298049,Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.,2022,"Bui, Cat N; Delgado, Alex; Duan, Yinghui; Guijarro, Belen Garbayo; Llamas, Cynthia","AbbVie, Inc., North Chicago, Illinois, USA.; AbbVie, Inc., Singapore City, Singapore.; AbbVie, Inc., North Chicago, Illinois, USA.; AbbVie, Inc., Madrid, Spain.; AbbVie, Inc., North Chicago, Illinois, USA.",None
35297649,Natural History of Human Epidermal Growth Factor Receptor 2-Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice.,2022,"Schröder, Carsten; Gower-Page, Craig; Reyes-Rivera, Irmarie; Patel, Arisha; Price, Richard; Sen, Shiraj; Davies, Jessica; Mhatre, Shivani K","F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, CA.",None
35296560,Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis.,2022,"Guizzetti, Leonardo; McFarlane, Stefanie C; MacDonald, John K; Feagan, Brian G; Jairath, Vipul","Alimentiv Inc, London, Ontario, Canada.; Alimentiv Inc, London, Ontario, Canada.; Alimentiv Inc, London, Ontario, Canada.; Alimentiv Inc, London, Ontario, Canada.; Alimentiv Inc, London, Ontario, Canada.",christopher.ma@ucalgary.ca.
35294767,The Predictive Individual Effect for Survival Data.,2022,"Neuenschwander, Beat; Roychoudhury, Satrajit; Wandel, Simon; Natarajan, Kannan; Zuber, Emmanuel","Novartis Pharma AG, Basel, Switzerland.; Pfizer Inc, New York, NY, 235 E 42nd St, 10017, USA. satrajit.roychoudhury@pfizer.com.; Novartis Pharma AG, Basel, Switzerland.; Pfizer Inc, New York, NY, 235 E 42nd St, 10017, USA.; Novartis Pharma AG, Basel, Switzerland.",satrajit.roychoudhury@pfizer.com.
35294525,Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.,2022/Jul/18,"Panowski, Siler H; Srinivasan, Surabhi; Tan, Nguyen; Tacheva-Grigorova, Silvia K; Smith, Bryan; Mak, Yvonne S L; Ning, Hongxiu; Villanueva, Jonathan; Wijewarnasuriya, Dinali; Lang, Shanshan; Melton, Zea; Ghosh, Adit; Van Blarcom, Thomas; Sasu, Barbra J","Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.; Allogene Therapeutics, South San Francisco, California.",None
35294522,Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.,2022/Jul/15,"Ascierto, Paolo A; Reddy, Micaela B; Harney, Allison S","Melanoma Unit, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy.; Pfizer Inc., New York, New York.; Pfizer Inc., New York, New York.",None
35294224,"Safety, Feasibility, and Merits of Longitudinal Molecular Testing of Multiple Metastatic Sites to Inform mTNBC Patient Treatment in the Intensive Trial of Omics in Cancer.",2022,"Ramirez, Arturo B; Spilman, Patricia; Ronen, Roy; Stilwell, Jackie; Kaldjian, Eric; Dutkowski, Janusz; Rabizadeh, Shahrooz","Rarecyte Inc, Seattle, WA.; ImmunityBio Inc, Culver City, CA.; Data4Cure Inc, La Jolla, CA.; Rarecyte Inc, Seattle, WA.; Rarecyte Inc, Seattle, WA.; Data4Cure Inc, La Jolla, CA.; ImmunityBio Inc, Culver City, CA.",None
35294223,Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.,2022,"Schweitzer, Brock L; Lawrence, O Rayne; Seitz, Robert S; Morris, Stephan W; Hout, David R","Oncocyte Corporation (formerly Insight Genetics), Nashville, TN.; Oncocyte Corporation (formerly Insight Genetics), Nashville, TN.; Oncocyte Corporation (formerly Insight Genetics), Nashville, TN.; Oncocyte Corporation (formerly Insight Genetics), Nashville, TN.; Oncocyte Corporation (formerly Insight Genetics), Nashville, TN.",None
35293030,"Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.",2022,"Aoyama, Junya; Hatayama, Tomoyoshi; Ito, Miku","Janssen Pharmaceutical K.K., Tokyo, Japan.; Janssen Pharmaceutical K.K., Tokyo, Japan.; Janssen Pharmaceutical K.K., Tokyo, Japan.",None
35292724,A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.,2022,"Humeniuk, Michael","Gibbs Cancer Center, Spartanburg Regional Healthcare System, Spartanburg, SC, USA.",andrew.armstrong@duke.edu.
35290915,ACCELERATE - Five years accelerating cancer drug development for children and adolescents.,2022,"Rousseau, Raphaël; Skolnik, Jeffrey; Barry, Elly; Kieran, Mark","Gritstone Oncology, Inc., Emeryville, USA.; INOVIO Pharmaceuticals, Inc. Plymouth Meeting, USA.; Day One Biopharmaceuticals, USA.; Day One Biopharmaceuticals, USA.",andy1pearson@btinternet.com.
35290407,Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.,2022,"Nakao, Takafumi; Tanaka, Shinji; Watanabe, Ayu","Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., Osaka, Japan.; Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",None
35290101,"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.",2022/Jul/01,"Bookman, Michael A","Director, Gynecologic Oncology Therapeutics, Kaiser Permanente Northern California, San Francisco, CA.",None
35289960,Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.,2022,"Pei, Jinglan; Raut, Pranil; Pedotti, Rosetta; Hawker, Kathleen; Raposo, Catarina; Priest, Jessica; Cabatingan, Mark; Winger, Ryan C","Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.; Genentech, Inc., South San Francisco, CA.",None
35288469,"Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.",2022,"Wang, Ben X; Gadalla, Ramy; Pugh, Trevor","Immune Profiling Team - Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Immune Profiling Team - Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Cancer Genomics Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",stephanie.lheureux@uhn.ca.
35288468,"Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.",2022,"Leopold, Lance; Geschwindt, Ryan; Ding, Kai; Smith, Michael","Immuno-Oncology, Incyte Corporation, Wilmington, Delaware, USA.; Immuno-Oncology, Incyte Corporation, Wilmington, Delaware, USA.; Biostatistics, Incyte Corporation, Wilmington, Delaware, USA.; Immuno-Oncology, Incyte Corporation, Wilmington, Delaware, USA.",anaing@mdanderson.org.
35288332,Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS).,2022,"Schroeter, Hagen","Mars Inc., 6885 Elm St, McLean, VA 22101, USA.",hsesso@bwh.harvard.edu.
35286137,Financial Toxicity Among Older Mexican Adults With Cancer and Their Families: A Mixed-Methods Study.,2022,"Flores-Estrada, Diana; Arrieta, Oscar","Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.; Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.",None
35285853,Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.,2022/Apr/05,"Gupta, Anil; Gonzalez-Rojas, Yaneicy; Zheng, Hanzhe; Cathcart, Andrea L; Parra, Sergio; Sager, Jennifer E; Alexander, Elizabeth; Yeh, Wendy W; Aldinger, Melissa","Albion Finch Medical, William Osler Health Centre, Toronto, Ontario, Canada.; Optimus U Corp, Miami, Florida.; Vir Biotechnology Inc, San Francisco, California.; Vir Biotechnology Inc, San Francisco, California.; Vir Biotechnology Inc, San Francisco, California.; Vir Biotechnology Inc, San Francisco, California.; Vir Biotechnology Inc, San Francisco, California.; Vir Biotechnology Inc, San Francisco, California.; Vir Biotechnology Inc, San Francisco, California.",None
35284808,"Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.",2022,"Narakorn, Piengthong; Surichan, Somchaiya; Prangpratanporn, Sumalee; Puksuriwong, Suttida; Kaweepornpoj, Ruangchai; Singchareon, Ratsamikorn; Suthepakul, Nava; Theerasurakarn, Sompone; Vilasmongkolchai, Thanakrit; Poopipatpol, Kittisak; Wirachwong, Ponthip","The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.; The Government Pharmaceutical Organization, 75/1 Rama VI Road, Ratchathewi, Bangkok 10400, Thailand.",None
35279527,"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.",2022,"Musso, E","AO Ospedali Riuniti PO Vincenzo Cervello, Palermo, Italy.",lpazaresr@seom.org.
35277454,Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis.,2022/Sep/26,"Sartini, Claudio; Ghoreishi, Narges; Suzart-Woischnik, Kiliana","Medical Affairs and Pharmacovigilance, Pharmaceuticals, Integrated Evidence Generation, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany.; Medical Affairs and Pharmacovigilance, Pharmaceuticals, Integrated Evidence Generation, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany.; Medical Affairs and Pharmacovigilance, Pharmaceuticals, Integrated Evidence Generation, Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany.",s.gill.5@bham.ac.uk.
38994514,Qualitative Analysis of Pain in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.,2022,"Shah, Sonali N; Hepp, Zsolt","Astellas Pharma, Inc., Northbrook, IL, USA.; Seagen Inc., Bothell, WA, USA.",None
35271694,Predictive Value of Isolated Symptoms for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children Tested During Peak Circulation of the Delta Variant.,2022/Sep/30,"Griffiths, Mark A; Rostad, Christina A; Vos, Miriam B; Welsh, Jean","Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Children's Healthcare of Atlanta, Atlanta, Georgia, USA.",None
35271306,Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.,2022/Jul/01,"Zweidler-McKay, Patrick","ImmunoGen, Inc, Waltham, MA.",None
35267638,"Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.",2022/Mar/04,"Xie, Yuran; Karol, Michael; Hitron, Matthew","Sumitomo Dainippon Pharma Oncology, 640 Memorial Drive, Cambridge, MA 02139, USA.; Sumitomo Dainippon Pharma Oncology, 640 Memorial Drive, Cambridge, MA 02139, USA.; Sumitomo Dainippon Pharma Oncology, 640 Memorial Drive, Cambridge, MA 02139, USA.",None
35267477,"Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.",2022/Feb/24,"Wei, Ran; Ferry, David; Gao, Ling; Oliveira, Joana M","Eli Lilly and Company, Indianapolis, IN 46225, USA.; Eli Lilly and Company, New York, NY 10016, USA.; Eli Lilly and Company, New York, NY 10016, USA.; Eli Lilly and Company, New York, NY 10016, USA.",None
35264433,PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.,2022,"Quigley, Michael","Research Biology, Gilead Sciences Inc, Foster City, California, USA.",nhaining@arsenalbio.com.
35263962,"Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis.",2023,"Togo, Kanae; Yoshii, Noritoshi; Hoshi, Masato; Arai, Shoko","Pfizer Japan Inc., Tokyo, Japan.; Pfizer Japan Inc., Tokyo, Japan.; Pfizer Japan Inc., Tokyo, Japan.; Pfizer Japan Inc., Tokyo, Japan.",None
35263495,Quality of life in a large multinational haemophilia B cohort (The B-Natural study) - Unmet needs remain.,2022,"LeBeau, Petra; Krouse, Rebecca","Rho, Inc., Durham, North Carolina, USA.; Rho, Inc., Durham, North Carolina, USA.",None
35263168,Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.,2022,"Fehringer, Gordon; Aushev, Vasily N; Kalashnikova, Ekaterina; Sharma, Shruti; Malhotra, Meenakshi; Demko, Zachary P; Aleshin, Alexey; Rodriguez, Angel; Billings, Paul R","Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.; Natera, Inc., Austin, TX.",None
35260027,"Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.",2022,"Lubiniecki, Gregory M; Dutcus, Corina; Smith, Alan D; Okpara, Chinyere E; Hussein, Ziad; Hayato, Seiichi; Tamai, Toshiyuki","Global Clinical Development, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.; Clinical Research, Eisai Inc., Nutley, NJ, USA.; Clinical Research, Eisai Inc., Nutley, NJ, USA.; Clinical Research, Eisai Inc., Nutley, NJ, USA.; Clinical Pharmacology Science, Eisai Europe Ltd, Hatfield, UK.; Clinical Pharmacology Science, Eisai Co., Ltd, Tokyo, Japan.; Clinical Research, Eisai Co., Ltd, Tokyo, Japan.",None
35258993,Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.,2022,"Mohan, Arathi; Raupp, Shelby; Pannecouk, Brittany; Ramnath, Nithya","Division of Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.; Division of Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.; Division of Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.; Division of Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI.",None
35254876,"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma.",2022/Jun/10,"Butler, Marcus O","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",None
35254550,"A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer.",2022,"Suna, Hideaki","Clinical Development Planning Division, Ono Pharmaceutical Co., Ltd., Osaka, Japan.",ykodera@med.nagoya-u.ac.jp.
35254415,"Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.",2022/Jun/01,"Morgan, Liza; Aregay, Mehreteab; Hurtado, Felipe K","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.",None
35251320,Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer.,2022,"Dionne, Pierre-Alexandre; Chandiwana, David; Pathak, Purnima; Lanoue, Brad","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",None
35248211,Global multi-stakeholder endorsement of the MAFLD definition.,2022,"Palmer, Melissa","Gannex-Ascletis Pharma, Beijing, China; Liver Consulting, New York, NY, USA.",mohammed.eslam@sydney.edu.au.
35247915,Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.,2022/May/13,"Frattini, Mark G","Cellectis Inc., New York, New York.",None
35247274,Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.,2022,"Zahir, Hamim; Greenberg, Jonathan; Hsu, Ching; Lasseter, Kenneth C; Xu, Li-An; LaCreta, Frank","Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.; Clinical Pharmacology of Miami, Miami, Florida, USA.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.",None
35245084,HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America.,2022,"Corona Cruz, Jose; Mena, Evelin; Menendez, Alvaro","Instituto Nacional de Cancerologia (INCan), Mexico City, Mexico.; Instituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic.; Hartford Healthcare, Hartford, CT.",None
35244350,A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.,2022,"Xu, Jianfeng; Liu, Dan; Li, Diange; Gallant, Maxime A; Roy, Dhruvajyoti; Taggart, David J","Helio Health, Inc.IrvineCaliforniaUSA.; Laboratory for Advanced Medicine, Inc.BeijingChina.; Guangzhou Youze Biological Pharmaceutical Technology Company LtdGuangzhouGuangdong ProvinceChina.; Helio Health, Inc.IrvineCaliforniaUSA.; Helio Health, Inc.IrvineCaliforniaUSA.; Helio Health, Inc.IrvineCaliforniaUSA.",None
35242633,"Smoking burden, MPOWER, future tobacco control and real-world challenges in China: reflections on the WHO report on the global tobacco epidemic 2021.",2022,"Zhang, Kaiping","Editorial Office, AME Publishing Company, Hong Kong, China.",None
35242629,A nomogram to predict the recurrence-free survival and analyze the utility of chemotherapy in stage IB non-small cell lung cancer.,2022,"Cai, Weijing","Shanghai Tongshu Biotechnology Co., Ltd., Shanghai, China.",None
35242510,Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.,2022,"Cadieux, Benoit; Jafarinasabian, Pegah","Amgen Inc., Thousand Oaks, CA, USA.; Amgen Inc., Thousand Oaks, CA, USA.",None
35240095,ROAR trial: which treatment is effective after progression? - Authors' reply.,2022,"Burgess, Paul; Ilankumaran, Palanichamy","Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals, Basel, Switzerland.; Global Drug Development, Oncology Development Unit, Novartis Pharma, East Hanover, NJ, USA.",patrick_wen@dfci.harvard.edu.
35238955,"Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].",2022,"Pong, Annpey","Merck & Co., Inc., Kenilworth, NJ, USA.",david.cherney@uhn.ca.
35238147,Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.,2022,"Gao, Seasea; Singh, Manmohan","Merck Pte. Ltd., Singapore, an affiliate of Merck KGaA.; Pfizer Corporation Hong Kong Ltd., Hong Kong.",None
35237053,Efficacy and Safety of Ceftaroline Fosamil in Hospitalized Patients with Community-Acquired Pneumonia in China: Subset Analysis of an International Phase 3 Randomized Controlled Trial.,2022,"Stone, Gregory G; Yan, Jean Li; Mohamed, Naglaa","Biopharmaceuticals Group, Pfizer Inc., Groton, CT, USA.; Biopharmaceuticals Group, Pfizer Inc., Cambridge, MA, USA.; Biopharmaceuticals Group, Pfizer Inc., New York, NY, USA.",None
35236002,Evaluation of pharmacokinetics and safety of talazoparib in patients with advanced cancer and varying degrees of hepatic impairment.,2022,"Guo, Cen; Yu, Yanke; Chakrabarti, Jayeta; Moroose, Rebecca; Shi, Haihong; Durairaj, Chandrasekar; Wang, Diane D","Pfizer Inc., La Jolla, California, USA.; Pfizer Inc., La Jolla, California, USA.; Pfizer Ltd., Surrey, UK.; Orlando Health Inc., Orlando, Florida, USA.; Pfizer Inc., Groton, Connecticut, USA.; Pfizer Inc., La Jolla, California, USA.; Pfizer Inc., La Jolla, California, USA.",None
35235189,Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.,2022,"Ono, Chiho","Pfizer Japan Inc, Tokyo, Japan.",naotot@doc.med.akita-u.ac.jp.
35235039,Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study.,2022,"Sabatelli, Lorenzo; Thunström, Daniel; Pfeiffer, Minja","Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110, Morges, Switzerland. lsabatelli@incyte.com.; Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110, Morges, Switzerland.; Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110, Morges, Switzerland.",lsabatelli@incyte.com.
35233056,Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.,2022/Mar/01,"Hovelson, D; Tomlins, S","Strata Oncology, Inc, Ann Arbor, MI, USA.; Strata Oncology, Inc, Ann Arbor, MI, USA.",Mansfield.aaron@mayo.edu.
35232230,Effectiveness of crizotinib versus entrectinib in ,2022,"Tremblay, Gabriel; Groff, Michael; Iadeluca, Laura; Daniele, Patrick; Wilner, Keith; Wiltshire, Robin; Bartolome, Lauren; Usari, Tiziana; Cappelleri, Joseph C","Cytel Inc. Health Economics & Outcomes Research (HEOR). 1050 Winter St no. 2700, Waltham, MA 02451, USA.; Cytel Inc. Health Economics & Outcomes Research (HEOR). 1050 Winter St no. 2700, Waltham, MA 02451, USA.; Pfizer Inc. Health Economics & Outcomes Research (HEOR). 235 East 42nd Street NY, NY 10017, USA.; Cytel Inc. Health Economics & Outcomes Research (HEOR). 1050 Winter St no. 2700, Waltham, MA 02451, USA.; Pfizer Inc. Health Economics & Outcomes Research (HEOR). 235 East 42nd Street NY, NY 10017, USA.; Pfizer Inc. Health Economics & Outcomes Research (HEOR). 235 East 42nd Street NY, NY 10017, USA.; Pfizer Inc. Health Economics & Outcomes Research (HEOR). 235 East 42nd Street NY, NY 10017, USA.; Pfizer Inc. Health Economics & Outcomes Research (HEOR). 235 East 42nd Street NY, NY 10017, USA.; Pfizer Inc. Health Economics & Outcomes Research (HEOR). 235 East 42nd Street NY, NY 10017, USA.",None
35228755,Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.,2022,"Takahashi, Motomichi; Oka, Kentaro; Higashi, Seiya","Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan.; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan.; Miyarisan Pharmaceuticals, Co., Ltd., Tokyo, Japan.",spal@coh.org.
35228264,"Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.",2022,"Eggleton, S Peter; Bajars, Marcis","Merck Serono Ltd, Feltham, London, UK, an affiliate of Merck KGaA.; Merck Healthcare KGaA, Darmstadt, Germany.",gulleyj@mail.nih.gov.
35227966,Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.,2022,"Duruisseaux, M","Unité de Recherche Commune en Oncologie Thoracique (URCOT), Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France; Service de Pneumologie, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France; Oncopharmacology Laboratory, Cancer Research Center of Lyon, Inserm 1052, CNRS 5286, Lyon, France; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.",nicolas.girard2@curie.fr.
35227895,"Proteogenomic Analysis of Breast Cancer Transcriptomic and Proteomic Data, Using De Novo Transcript Assembly: Genome-Wide Identification of Novel Peptides and Clinical Implications.",2022,"Tiwary, Shivani","Simulation and Modeling Sciences, Pfizer Pharma GmBH, Berlin, Germany.",ravisirdeshmukh@gmail.com.
35226243,Impact of time to distant recurrence on breast cancer-specific mortality in hormone receptor-positive breast cancer.,2022,"Cueto, Jenilee; Mitra, Debanjali; Law, Ernest H","Patient & Health Impact, Pfizer, Inc, New York, NY, US.; Patient & Health Impact, Pfizer, Inc, New York, NY, US.; Patient & Health Impact, Pfizer, Inc, New York, NY, US.",gcalip@uic.edu.
35223458,"Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.",2021,"Beeram, Muralidhar; Manuel, Allison M; Lithio, Andrew; Price, Gregory L; Chapman, Sonya C; Litchfield, Lacey M","South Texas Accelerated Research Therapeutics, San Antonio, TX, United States.; Eli Lilly and Company, Indianapolis, IN, United States.; Eli Lilly and Company, Indianapolis, IN, United States.; Eli Lilly and Company, Indianapolis, IN, United States.; Eli Lilly and Company, Indianapolis, IN, United States.; Eli Lilly and Company, Indianapolis, IN, United States.",None
35220402,Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.,2022,"Shetty, Jeevan K; Ito, Rodrigo; Zhang, George; Ha, Xianwei; Backstrom, Jay T","Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Acceleron Pharma, Cambridge, MA, USA.",Rami.Komrokji@moffitt.org.
35219776,The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.,2022,"Oza, A","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.",katherine.francis@sydney.edu.au.
35218887,Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.,2022,"Polito, L; Pal, N; Ton, T G N; Merritt, D; Morris, S","Product Development Data Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Data Sciences, Genentech, Inc, South San Francisco, USA.; Product Development Data Sciences, Genentech, Inc, South San Francisco, USA.; Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Medical Affairs, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",Rolf.Stahel@etop-eu.org.
35218313,Addressing unmet needs for people with cancer cachexia: recommendations from a multistakeholder workshop.,2022,"Birnbaum, Morris J","Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA.",None
35217573,"Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.",2022,"Albright, Andrew; Mogg, Robin; Ayers, Mark; Huang, Lingkang; Lunceford, Jared; Cristescu, Razvan; Cheng, Jonathan","Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.; Merck & Co., Inc, Kenilworth, New Jersey, USA.",Robert_Haddad@dfci.harvard.edu.
35214617,The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.,2022/Jan/21,"Hojo, Wataru; Sakai, Hironori","R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan.; R&D, Cellspect Co., Ltd., Morioka 020-0857, Japan.",None
35213669,Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.,2022,"Nelson, David R; Brown, Jacqueline; Method, Michael","Eli Lilly and Company, Indianapolis, IN, United States of America.; Eli Lilly and Company, Bracknell, Surrey, United Kingdom.; Eli Lilly and Company, Indianapolis, IN, United States of America.",None
35211674,Target 2035 - update on the quest for a probe for every protein.,2022/Jan/27,"Beck, Hartmut; Dreher, Jan; Hartung, Ingo V; Hillisch, Alexander; Kiefer, James R; Lindemann, Sven; Matsui, Hisanori; Saikatendu, Kumar Singh; Scholten, Cora","Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany.; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany.; Medicinal Chemistry, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany.; Research and Development, Bayer AG, Pharmaceuticals 42103 Wuppertal Germany.; Genentech, Inc. 1 DNA Way South San Francisco California 94080 USA.; Strategic Innovation, Global R&D, Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany.; Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited Fujisawa Kanagawa Japan.; Global Research Externalization, Takeda California, Inc. 9625 Towne Center Drive San Diego CA 92121 USA.; Research and Development, Bayer AG, Pharmaceuticals 13353 Berlin Germany.",Cheryl.Arrowsmith@uhnresearch.ca.
35210399,Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies.,2022/Feb/24,"Pacaud, Lida; Akram, Muhammad; Geng, Dong","Legend Biotech USA, Inc, Piscataway, NJ, USA.; Legend Biotech USA, Inc, Piscataway, NJ, USA.; Legend Biotech USA, Inc, Piscataway, NJ, USA.",sundar.jagannath@mountsinai.org.
35210307,Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.,2022,"Johansen, Jennifer L","US Medical Immunology & Fibrosis, Bristol Myers Squibb, Princeton, New Jersey, USA.",stykodi@fredhutch.org.
35205734,Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma.,2022/Feb/16,"Solas, Caroline","Assistance Publique-Hôpitaux de Marseille (APHM), Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, INSERM 1207, IRD 190, Unité des Virus Emergents, Aix-Marseille Université, 13005 Marseille, France.",None
35200588,Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network.,2022/Feb/12,"Mitra, Debanjali; Alfred, Tamuno; Emir, Birol; Liu, Xianchen; DiCristo, Caroline; Chen, Connie","Pfizer Inc., New York, NY 10017, USA.; Pfizer Inc., New York, NY 10017, USA.; Pfizer Inc., New York, NY 10017, USA.; Pfizer Inc., New York, NY 10017, USA.; Pfizer Inc., New York, NY 10017, USA.; Pfizer Inc., New York, NY 10017, USA.",None
35196866,Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.,2022,"Russell-Smith, T Alexander; Gurskyte, Laura; Muresan, Bogdan; Mamolo, Carla M; Gezin, Ana; Cappelleri, Joseph C; Heeg, Bart","Pfizer, Inc., New York, NY 10017, USA.; Ingress Health, a company of Cytel, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.; Ingress Health, a company of Cytel, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.; Pfizer, Inc., Groton, CT 06340, USA.; Ingress Health, a company of Cytel, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.; Pfizer, Inc., Groton, CT 06340, USA.; Ingress Health, a company of Cytel, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.",None
35195881,The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.,2022,"Piscitelli, Joseph; Chen, Joseph; LaBadie, Robert R; Salageanu, Joanne; Chung, Chin-Hee; Tan, Weiwei","Global Product Development, Clinical Pharmacology, Pfizer Inc., 10555 Science Center Drive, La Jolla, CA, 92121, USA. Joseph.Piscitelli@pfizer.com.; Global Product Development, Clinical Pharmacology, Pfizer Inc., San Francisco, CA, USA.; Global Product Development, Biostatistics, Pfizer Inc., Groton, CT, USA.; Global Product Development, Pharmacometrics, Pfizer Inc., Groton, CT, USA.; Global Product Development, Oncology Clinical, Pfizer Inc., New York, NY, USA.; Global Product Development, Clinical Pharmacology, Pfizer Inc., 10555 Science Center Drive, La Jolla, CA, 92121, USA.",Joseph.Piscitelli@pfizer.com.
35195274,"A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.",2022/May/15,"Takiguchi, Toru","Clinical Development Planning, Ono Pharmaceutical Co, Ltd, Osaka, Japan.",None
35193933,ISA101 and nivolumab for HPV-16,2022,"Melief, Cornelis J M","ISA Pharmaceuticals, Leiden, The Netherlands.",mcurran@mdanderson.org.
35192684,Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.,2022/Jun/16,"Laird, A Douglas","Pfizer Inc., La Jolla, CA.",None
35192404,A Novel Artificial Intelligence-Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers.,2022,"Randhawa, Ramandeep; Jain, Parag; Kummar, Shivaani; Wilding, George; Roy, Rajat","PathomIQ, Inc, Cupertino, CA.; PathomIQ, Inc, Cupertino, CA.; PathomIQ, Inc, Cupertino, CA.; PathomIQ, Inc, Cupertino, CA.; PathomIQ, Inc, Cupertino, CA.",None
35191170,Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments.,2022,"Huang, Bo","Pfizer Inc., Groton, Connecticut, USA.",None
35190653,Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).,2022,"Guo, Helen; Reeves, John; Jiao, XiaoLong; Sandström, Per","Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.",daniel.george@duke.edu.
35190375,Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in ,2022,"McCleland, Mark; Kim, Eugene; Morris, Stefanie; Zou, Wei; Shames, David; Das Thakur, Meghna; Shankar, Geetha","Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.; Genentech Inc, South San Francisco, California, USA.",jackwestmd@gmail.com.
35189624,Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.,2022,"Talarico, Carla A","Moderna, Inc, Cambridge, MA, USA.",hung-fu.x.tseng@kp.org.
35187516,Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.,2022,"Crowell, Jennifer; Dixon, Becky","St Elizabeth Healthcare, Edgewood, KY, USA.; St Elizabeth Healthcare, Edgewood, KY, USA.",None
35183775,Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.,2022,"Kherani, Jennifer F; Soldatenkova, Victoria; Olek, Elizabeth A; Muehlenbein, Catherine E","Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.; Eli Lilly and Company, Indianapolis, Indiana.; Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company, Stamford, Connecticut.; Eli Lilly and Company, Indianapolis, Indiana.",caroline.mccoach@ucsf.edu.
35183242,"IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET).",2022/Feb/19,"Chapman, Sonya C; Li, Thomas; Phillips, Keith G","Eli Lilly and Company, Arlington Square, Bracknell, UK.; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA, USA.; Neuroscience Next Generation Therapeutics, Eli Lilly and Company, Lilly Innovation Center, Cambridge, MA, USA.",finnerup@clin.au.dk.
35183043,Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.,2022,"Thomas, Z M; French, P; Lin, B K; Sashegyi, A","Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.",Ben.Solomon@petermac.org.
35182247,First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.,2022,"Li, Ang; Oukessou, Abderrahim","Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, USA.; Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, NJ, USA.",Tom.John@petermac.org.
35182224,Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.,2023,"Chitra, Surya; Nielsen, Tina G; Sellam, Gila","Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",topp_m@ukw.de.
35180010,Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.,2022/May/20,"Harb, Jason; Hutti, Jessica E; Holes, Leanne; Masud, Abdullah A; Nuthalapati, Silpa; Potluri, Jalaja","AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.; AbbVie Inc, North Chicago, IL.",None
35179784,Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.,2022,"Wojdyla, Matthew; Vredenburg, Michael","Dova Pharmaceuticals, a Sobi company, Durham, North Carolina, USA.; Dova Pharmaceuticals, a Sobi company, Durham, North Carolina, USA.",None
35179764,Systematic review and pooled analysis of survival outcomes in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia who have undergone haematopoietic stem cell transplant.,2022,"Russell-Smith, T A","Pfizer Inc, New York, NY, USA. schadda@genesisrg.com.",schadda@genesisrg.com.
35179585,Association of Prognostic Understanding With Health Care Use Among Older Adults With Advanced Cancer: A Secondary Analysis of a Cluster Randomized Clinical Trial.,2022/Feb/01,"O'Rourke, Mark A","NCORP of the Carolinas (Greenville Health System NCORP), Greenville, South Carolina.",None
35179251,"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.",2022/Jun/01,"Numerof, Robert; Tong, Sandra","Development and Medical Affairs, Rigel Pharmaceuticals, Inc, South San Francisco, California, USA.; Development and Medical Affairs, Rigel Pharmaceuticals, Inc, South San Francisco, California, USA.",None
35177936,"Identifying Valid Algorithms for Number of Lines of Anti-Neoplastic Therapy in the Danish National Patient Registry Among Patients with Advanced Ovarian, Gastric, Renal Cell, Urothelial, and Non-Small Cell Lung Cancer Attending a Danish University Hospital.",2022,"Oksen, Dina; Boutmy, Emmanuelle; Verpillat, Patrice","Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.; Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.",None
35176457,"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.",2022,"Féliz, L; Lihou, C F; Tian, C; Silverman, I M; Ji, T","Incyte Biosciences International Sàrl, Morges, Switzerland.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.; Incyte Corporation, Wilmington, USA.",VSubbiah@mdanderson.org.
35170759,Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.,2022,"Munugalavadla, Veerendra","Gilead Sciences, Inc., Foster City, CA, USA.",None
35169389,Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany.",None
35169388,Update Breast Cancer 2021 Part 4 - Prevention and Early Stages.,2022,"Lux, Michael P","Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Krankenhaus GmbH, Paderborn, Germany.",None
35168844,Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.,2022,"Campbell, Mary; Hepp, Zsolt; McKay, Caroline; Steinberg, Joyce","Seagen Inc., Bothell, WA, USA.; Seagen Inc., Bothell, WA, USA.; Astellas Pharma US, Inc., Northbrook, IL, USA.; Astellas Pharma US, Inc., Northbrook, IL, USA.",matthew.galsky@mssm.edu.
35167329,First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced ,2022/Aug/10,"Velastegui, Karen L; Cilliers, Cornelius; Christensen, James G; Yan, Xiaohong; Chao, Richard C","Mirati Therapeutics, Inc, San Diego, CA.; Mirati Therapeutics, Inc, San Diego, CA.; Mirati Therapeutics, Inc, San Diego, CA.; Mirati Therapeutics, Inc, San Diego, CA.; Mirati Therapeutics, Inc, San Diego, CA.",None
35166465,Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.,2022,"Khandelwal, Akash","The Healthcare Business of Merck KGaA, Darmstadt, Germany.",None
35163825,Inhibition of the Monocarboxylate Transporter 1 (MCT1) Promotes 3T3-L1 Adipocyte Proliferation and Enhances Insulin Sensitivity.,2022/Feb/08,"Nieto, Ainhoa","Primary Pharmacology Group, Discovery Sciences, Pfizer, Inc., 445 Eastern Point Rd, Groton, CT 06340, USA.",None
35159058,The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.,2022/Feb/04,"Kuruvilla, John; Xu, Jenny; Corona, Kelly; Chamoun, Kamal; Shah, Jatin","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.; Karyopharm Therapeutics, Newton, MA 02459, USA.; Karyopharm Therapeutics, Newton, MA 02459, USA.; Karyopharm Therapeutics, Newton, MA 02459, USA.; Karyopharm Therapeutics, Newton, MA 02459, USA.",None
35158207,First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.,2022,"Nathan, F E","Bristol Myers Squibb, Princeton, USA.",k.obyrne@qut.edu.au.
35158206,Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials.,2022,"Szeto, C W; Veerapaneni, S; Preble, A; Reddy, S K","NantHealth Inc, Santa Cruz, USA.; NantHealth Inc, Santa Cruz, USA.; NantHealth Inc, Santa Cruz, USA.; NantHealth Inc, Santa Cruz, USA.",jadashek@westernu.edu.
35157784,Pharmacokinetic Interaction Between the MEK1/MEK2 Inhibitor Trametinib and Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol in Female Patients With Solid Tumors.,2022,"Xu, Xiaoying; Nidamarthy, Prasanna Kumar; Ilankumaran, Palanichamy","Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Novartis Healthcare Pvt. Ltd., Hyderabad, India.; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.",None
35154495,Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.,2022,"Karanikas, Vaios; Cañamero, Marta; Klein, Christian; Umaña, Pablo; Bacac, Marina","Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.; Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.",None
35150356,Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.,2022,"Sponton, Laura; Jin, Hulin; Hering, Ursula; Cronier, Damien; Grinberg, Marianna; Seithel-Keuth, Annick","The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.",jordan.berlin@vumc.org.
35145071,Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).,2022/Feb/10,"Blackwell, Beth","The Emmes Company, Rockville, MD, USA.",dispenzieri.angela@mayo.edu.
35144713,Development of a model to predict psychotherapy response for depression among Veterans.,2023,"Leung, Lucinda B; Oslin, David W","Center for the Study of Healthcare Innovation, Implementation, and Policy, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.; VISN 4 Mental Illness Research, Education, and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.",None
35144482,Long-term avelumab in advanced non-small-cell lung cancer: summaries and ,2022,"Bajars, Marcis","Merck Healthcare KGaA, Darmstadt, Germany.",None
35141028,Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.,2022,"Potdar, Rushikesh; McGowan, Tracy","Medical Group Oncology, Janssen Pharmaceuticals Horsham, PA, USA.; Medical Group Oncology, Janssen Pharmaceuticals Horsham, PA, USA.",None
35138920,Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes.,2022,"Enke, Aaron; Hurley, Sabrina; Lin, Kevin K; Habeck, Jenn; Giordano, Heidi","Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.; Clovis Oncology Inc, Boulder, CO.",None
35138918,Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.,2022,"Mattar, Marissa; de Stanchina, Elisa","Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.",None
35138529,"Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.",2022,"Pemberton, Karine; Sadrolhefazi, Behbood; Jin, Xidong","Boehringer Ingelheim Ltd, Bracknell, UK.; Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada.; Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.",tamas.hickish@rbch.nhs.uk.
35134084,A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy.,2022,"Corti, Davide","Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.",None
35133982,Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy.,2022/Mar/22,"Huehnchen, Petra; Schinke, Christian; Dordevic, Adam D; Kern, Johannes; Maierhof, Smilla K; Hew, Lois; Nolte, Luca; Körtvelyessy, Peter; Ruprecht, Klemens; Blohmer, Jens-Uwe; Sehouli, Jalid; Endres, Matthias; Boehmerle, Wolfgang","Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik für Gynäkologie mit Brustkrebszentrum, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, Berlin, Germany.",None
35133617,"Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.",2022,"Tajima, Kentaro","Pfizer Japan Inc., Tokyo, Japan.",Rubikli@yahoo.com.
35131863,Soluble PD-L1 as an early marker of progressive disease on nivolumab.,2022,"Ross-Macdonald, Petra; Song, Linan; Veras, Eliseo; Wind-Rotolo, Megan","Bristol-Myers Squibb Co, Princeton, New Jersey, USA.; Quanterix Corporation, Billerica, Massachusetts, USA.; Quanterix Corporation, Billerica, Massachusetts, USA.; Bristol-Myers Squibb Co, Princeton, New Jersey, USA.",kmmah5@bidmc.harvard.edu.
35131452,Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF,2022,"Caro, I; Shah, K; Yan, Y; McArthur, G A","Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.; Genentech, Inc., South San Francisco, USA.; Melanoma and Skin Service and Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Australia.",caroline.robert@gustaveroussy.fr.
35131133,Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.,2022/Mar/01,"Lockhart, Stephen P; Hariharan, Subramanian; Kitchin, Nicholas; Bailey, Ruth; Liau, Katherine; Koury, Kenneth; Dychter, Samuel S; Lu, Claire; Gruber, William C","Pfizer Inc., Horizon Honey Lane, Maidenhead SL6 6RJ, UK. Electronic address: Stephen.P.Lockhart@pfizer.com.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA. Electronic address: s.hariharan@pfizer.com.; Pfizer Inc., Horizon Honey Lane, Maidenhead SL6 6RJ, UK. Electronic address: Nicholas.Kitchin@pfizer.com.; Pfizer Inc., Horizon Honey Lane, Maidenhead SL6 6RJ, UK. Electronic address: Ruth.Bailey@pfizer.com.; Pfizer Inc., 10555 Science Center Drive, San Diego, CA 92121, USA. Electronic address: Katherine.F.Liau@pfizer.com.; Pfizer Inc., 401 N. Middletown Rd, Pearl River, NY 10965, USA. Electronic address: Kenneth.Koury@pfizer.com.; Pfizer Inc., 10555 Science Center Drive, San Diego, CA 92121, USA. Electronic address: Samuel.Dychter@pfizer.com.; Pfizer Inc., 401 N. Middletown Rd, Pearl River, NY 10965, USA. Electronic address: Claire.Lu@pfizer.com.; Pfizer Inc., 401 N. Middletown Rd, Pearl River, NY 10965, USA. Electronic address: Bill.Gruber@pfizer.com.",Bill.Gruber@pfizer.com.
35128970,Bayesian basket trial design with false-discovery rate control.,2022,"Roychoudhury, Satrajit","Pfizer Inc., New York, NY, USA.",None
35124183,First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.,2022,"Zhang, X; Hu, N; Balli, D","Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA.; Biostatistics, Bristol Myers Squibb, Princeton, USA.; Translational Medicine, Bristol Myers Squibb, Princeton, USA.",solange.peters@chuv.ch.
35122924,Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.,2022/Apr/20,"Lobos-González, Lorena; Guevara, Francisca","Centro De Medicina Regenerativa, Facultad de Medicina - Clínica Alemana, Universidad Del Desarrollo, Av. Las Condes 12496, Santiago, Chile; Fundación Ciencia & Vida - Andes Biotechnologies S.A., Av. Zanartu 1482, Santiago, Chile.; Fundación Ciencia & Vida - Andes Biotechnologies S.A., Av. Zanartu 1482, Santiago, Chile.",rarmisen@udd.cl.
35121597,Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study.,2022/Feb/04,"Soriano-Gabarró, Montse","Epidemiology, Bayer Pharma AG, Berlin, Germany.",ewchan@hku.hk.
35121370,Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.,2022,"Vormoor-Bürger, Britta","Princess Ma´xima Center for Pediatric Oncology, Utrecht, the Netherlands.",c.m.zwaan@prinsesmaximacentrum.nl.
35118821,Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.,2022,"Poondru, Srinivasu; Khosravan, Reza; Manchandani, Pooja; Heo, Nakyo; Moy, Selina; Wojtkowski, Tomasz; Patton, Melanie; Haas, Gabriel P","Astellas Pharma Inc., Northbrook, Illinois, USA.; Pfizer Inc., San Diego, California, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.; Astellas Pharma Inc., Northbrook, Illinois, USA.",None
35115180,Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.,2022,"Oza, Amit","Princess Margaret Cancer Centre, Toronto, Canada.",Fabian.Trillsch@med.uni-muenchen.de.
35114152,Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.,2022,"Anaissie, Elias","CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA.",nraje@mgh.harvard.edu.
35112424,The shared uncertainty experience of older adults with advanced cancer and their caregivers.,2022,"Bradley, Thomas P","Northwell Health NCORP, New Hyde Park, New York, USA.",None
35112331,Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.,2022,"Huang, Min; Haiderali, Amin","Merck & Co., Inc., Kenilworth, NJ, USA. Min_Huang@merck.com.; Merck & Co., Inc., Kenilworth, NJ, USA.",Min_Huang@merck.com.
35109927,Co-creating with patients an impact framework across the medicine's life cycle: a qualitative study exploring patients' experiences of involvement in and perceptions of impact measures.,2022/Feb/02,"Kolarova, Teodora","International Neuroendocrine Cancer Alliance (INCA), Boston, USA.",sandeep@medipace.com.
35106125,Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning.,2022,"Mas, José Manuel","Anaxomics Biotech, Barcelona, Spain.",None
35103790,Evaluation of Adiposity and Cognitive Function in Adults.,2022/Feb/01,"Poirier, Paul","Faculté de Pharmacie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Quebec, Canada.",None
35103571,Factors influencing HPV knowledge and vaccine acceptability in parents of adolescent children: results from a survey-based study (KAPPAS study).,2022/Dec/31,"Vergés, Edelmiro; Suárez Vicent, Eva; Sánchez, Almudena; Panizo-Santos, María Belén; Garcés-Sánchez, María; Montesdeoca, Abián","Binissalem Healthcare Center, Illes Balears, Spain.; Burriana II Healthcare Center, Valencia, Spain.; Les Hortes Healthcare Center, Barcelona, Spain.; Pediatrician at Illescas Healthcare Center, Toledo, Spain.; Nazaret Healthcare Center, Valencia, Spain.; Primary Care Pediatrician in Guanarteme Healthcare Center, Las Palmas and Member of the Vaccine Advisory Committee of the Spanish Association of Pediatrics.",None
35101943,Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.,2022,"Budde, Griffin; Krainock, Michael; Aushev, Vasily N; Koyen Malashevich, Allyson; Malhotra, Meenakshi; Olshan, Perry; Billings, Paul R; Aleshin, Alexey","Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Scientific Affairs, Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.; Natera Inc, San Carlos, California, USA.",pashtoon-kasi@uiowa.edu.
35100459,Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria.,2022,"Liu, Peng; Sierra, J Rafael","Alexion Pharmaceuticals, Inc., Boston, Massachusetts, USA.; Alexion Pharmaceuticals, Inc., Boston, Massachusetts, USA.",None
35098723,Real-world multi-country study of ,2022,"Lux, Michael P; Niyazov, Alexander","Kooperatives Brustzentrum Paderborn, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen- und Kinderklinik St. Louise, St. Vincenz-Kliniken, Husener Strasse 81, Paderborn 33098, Germany.; Patient Health Impact, Pfizer Inc., New York, NY 10071, USA.",None
35094366,Delivery Strategies for mRNA Vaccines.,2022,"Satapathy, Soumya Ranjan; Dutta, Tathagata","DFE Pharma India Pvt Ltd, Bangalore, 560066, India.; Jodas Expoim Pvt Ltd, Hyderabad, 500072, India.",sivakumar.ramachandran@gmail.com.
35093516,"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.",2022,"Maag, D; Dunbar, M","AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.",cgeyer@houstonmethodist.org.
35091441,"Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.",2022/Apr/01,"Laird, A Douglas; Chen, Ying; Lanzalone, Silvana; Chelliserry, Jijumon; Czibere, Akos; Hopkins, Julia F; Albacker, Lee A","Pfizer Inc., La Jolla, California.; Pfizer Inc., La Jolla, California.; Pfizer Inc., Milan, Italy.; Pfizer Inc., La Jolla, California.; Pfizer Inc., Cambridge, Massachusetts.; Foundation Medicine Inc., Cambridge, Massachusetts.; Foundation Medicine Inc., Cambridge, Massachusetts.",None
35090960,Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.,2022,"Chng, Elaine; Ren, Yayun","HistoIndex Pte Ltd, Singapore.; HistoIndex Pte Ltd, Singapore.",quentin.anstee@newcastle.ac.uk.
35090638,"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.",2022,"Shi, Jiayuan","TechData Service Company, King of Prussia, PA, USA.",saranya.sridhar@sanofi.com.
35089812,"Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.",2022/Apr/20,"Kamradt, Jeffrey","Hartford Healthcare Medical Group, Hartford, CT.",None
35089317,"APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.",2022/Apr/01,"Hung, Adriana M; Shah, Shailja C; Ho, Yuk-Lam; Gaziano, J Michael; Huffman, Jennifer E; Chang, Kyong-Mi; Casas, Juan P; O'Donnell, Christopher J; Cho, Kelly; Tuteja, Sony","Tennessee Valley Healthcare System, Nashville Campus, Nashville.; GI Section, VA San Diego Healthcare System, San Diego, California.; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.; Center for Population Genomics, Massachusetts Veterans Epidemiology Research & Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts.; The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.; Cardiology, VA Boston Healthcare System, Boston, Massachusetts.; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.; The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.",None
35087199,Precision cancer genome testing needs proficiency testing involving all stakeholders.,2022/Jan/27,"Yamasaki, Tadashi","Development of Clinical Genomics, BML Inc., Kawagoe, Japan.",mmaekawa@hama-med.ac.jp.
35086949,Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.,2022,"Polaske, Nathan; Fields, Paul A","Adaptive Biotechnologies Corp, Seattle, Washington, USA.; Adaptive Biotechnologies Corp, Seattle, Washington, USA.",david.page2@providence.org.
35086926,Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.,2022/Jun/06,"Oza, Amit M","Princess Margaret Consortium (PMHC), Toronto, Ontario, Canada.",m.friedlander@unsw.edu.au.
35085735,Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of LAG-3: a transcriptomic analysis of a retrospective cohort.,2022,"Mallardo, D; Capone, M; Madonna, G; Simeone, E; Ascierto, P A","Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.; Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy. Electronic address: paolo.ascierto@gmail.com.",paolo.ascierto@gmail.com.
35085008,Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing.,2022,"Hehir-Kwa, Jayne Y; Koudijs, Marco J; Verwiel, Eugene T P; Kester, Lennart A; van Tuil, Marc; Strengman, Eric; Kranendonk, Mariëtte E G; Hiemcke-Jiwa, Laura S; de Haas, Valerie; van de Geer, Ellen; van der Lugt, Jasper; Lijnzaad, Philip; Holstege, Frank C P; Kemmeren, Patrick; Tops, Bastiaan B J","Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.",None
35085007,Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.,2022,"Dima, Laura; Brega, Nicoletta","Bayer HealthCare Pharmaceuticals, Inc, Basel, Switzerland.; Bayer HealthCare Pharmaceuticals, Whippany, NJ.",None
35083149,Targeting KRAS in Non-Small Cell Lung Cancer.,2021,"Corral de la Fuente, Elena","Early Phase Clinical Drug Development in Oncology, South Texas Accelerated Research Therapeutics (START) Madrid-Centro Integral Oncológico Clara Campal (CIOCC), Centro Integral Oncológico Clara Campal, Madrid, Spain.",None
35080190,Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.,2022,"Paccagnella, Maria Luisa; Santo, Nicola Di; Elmeliegy, Mohamed; Lin, Xun; Czibere, Akos","Pfizer Inc., Global Product Development, Groton, CT 06340, USA.; Pfizer Inc., Global Product Development, Durham, NC 27707, USA.; Pfizer Inc., Global Product Development, La Jolla, CA 92121, USA.; Pfizer Inc., Global Product Development, La Jolla, CA 92121, USA.; Pfizer Inc., Cambridge, MA, USA.",None
35078840,Effectiveness of tobacco cessation interventions for different groups of tobacco users in Sweden: a study protocol for a national prospective cohort study.,2022/Jan/25,"Björk-Eriksson, Thomas","Regional Cancer Centre West, Western Sweden Healthcare Region, Goteborg, Sweden.",mette.rasmussen@med.lu.se.
35075109,"Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase﻿ 2 trial.",2022/Jan/24,"Vorog, Alexander; Labotka, Richard; Du, Jichang; Darif, Mohamed","Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.",mdimop@med.uoa.gr.
35074903,Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.,2022,"Chen, Richard O","Personalis Inc, Menlo Park, California, USA.",friedmac@mskcc.org.
35070991,Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.,2021,"Lu, Brian; Zarotiadou, Angeliki; Connarn, Jamie N; Le Bruchec, Yvan; Dumitru, Calin Dan","Bristol Myers Squibb, Princeton, NJ, United States.; Celgene Research S.L.U., a Bristol-Myers Squibb Company, Boudry, Switzerland.; Bristol Myers Squibb, Princeton, NJ, United States.; Bristol Myers Squibb, Princeton, NJ, United States.; Bristol Myers Squibb, Princeton, NJ, United States.",None
35070951,Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.,2021,"Jacobs, Ira; Baumfeld Andre, Elodie; Lee, Lauren J; Beaupre, Darrin","Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.; Pfizer Inc., New York, NY, United States.",None
35068186,Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study.,2022,"Kirchhoff, Carol F","Pfizer Inc., Chesterfield, MO 63017, USA.",None
35065058,"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.",2022,"Fiaschi, Nathalie; Gupta, Namita T; Deering, Raquel; Wang, Wei; Wang, Fang; Thanigaimani, Pradeep; Mani, Jayakumar; Kou, Baijun; Li, Siyu; Jankovic, Vladimir; James, Nicola; Hamon, Sara C; Cheung, Hung Kam; Sims, Jennifer S; Miller, Elizabeth; Thurston, Gavin; Lowy, Israel","Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.; Regeneron Pharmaceuticals, Tarrytown, NY, USA.",thomas.marron@mssm.edu.
35062760,"Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines.",2022/Jan/10,"Jarkiewicz-Tretyn, Joanna; Sandomierz, Dorota; Jarkiewicz-Tretyn, Aleksander; Dejewska, Joanna; Ciechanowska, Karolina","Cancer Genetics Laboratory Ltd., 87-100 Torun, Poland.; Cancer Genetics Laboratory Ltd., 87-100 Torun, Poland.; Cancer Genetics Laboratory Ltd., 87-100 Torun, Poland.; Cancer Genetics Laboratory Ltd., 87-100 Torun, Poland.; Cancer Genetics Laboratory Ltd., 87-100 Torun, Poland.",None
35058882,Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.,2021,"Moraitis, Andreas G","Drug Research and Development, Corcept Therapeutics, Menlo Park, CA, United States.",None
35058326,"Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.",2022,"Lépine, Lucie","Pharmacokinetics, Excelya on behalf of Sanofi, Alfortville, France.",Johann.de-Bono@icr.ac.uk.
35055387,Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.,2022/Jan/08,"Thomas, Marlene; Ujupan, Sonia","F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.; Eli Lilly and Company, Rue du Marquis 1, Markiesstraat, 1000 Brussels, Belgium.",None
35052829,"Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas.",2022/Jan/11,"Trojaniello, Claudia; Vitale, Maria Grazia; Simeone, Ester; Ascierto, Paolo Antonio","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy.; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy.; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy.; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy.",None
35050320,Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.,2022/Mar/01,"Goldmacher, Gregory V","Merck & Co, Inc, Kenilworth, New Jersey.",None
35047649,Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers.,2022,"Pollett, Simon D; Davies, Julian; Illinik, Luca; Maiolatesi, Santina E; Ortega, Orlando; Parmelee, Edward; Powers, John H","Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Clinical Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.",None
35046678,Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR).,2022,"Musat, Mihaela Georgiana; Kwon, Christina Soeun; Forsythe, Anna","Evidence Generation, Purple Squirrel Economics, a Wholly Owned Subsidiary of Cytel, Inc., Waltham, MA, USA.; Evidence Generation, Purple Squirrel Economics, a Wholly Owned Subsidiary of Cytel, Inc., Waltham, MA, USA.; Value and Access, Purple Squirrel Economics, a Wholly Owned Subsidiary of Cytel, Inc., Waltham, MA, USA.",None
35046520,Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.,2022,"Price, Kristin S; Nagy, Rebecca","Guardant Health, Inc, Redwood City, CA, USA.; Guardant Health, Inc, Redwood City, CA, USA.",bmf9003@med.cornell.edu.
36860696,Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.,2022,"Siu, Lillian L","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",None
35044810,CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.,2022/Apr/20,"Parker, Joel S","Life Edit Therapeutics, RTP, NC.",None
35043428,Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.,2022,"Brackman, Deanna; Eckert, Doerthe; Menon, Rajeev; Salem, Ahmed Hamed; Potluri, Jalaja; Hayslip, John; Miles, Dale; Mensing, Sven; Gopalakrishnan, Sathej; Zha, Jiuhong","Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH Co. KG, Ludwigshafen, Germany.; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.; Oncology Development, AbbVie Inc., North Chicago, Illinois, USA.; Oncology Development, AbbVie Inc., North Chicago, Illinois, USA.; Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH Co. KG, Ludwigshafen, Germany.; Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH Co. KG, Ludwigshafen, Germany.; Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, Illinois, USA.",None
35042152,"Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.",2022,"Chlistalla, M; Cardona, A; Ruf, T; Trunzer, K; Smoljanovic, V","F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.; F. Hoffmann-La Roche Ltd., Basel, Switzerland.",silvia.novello@unito.it.
35042070,Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.,2022,"Miranda, Flora; Banerjee, Hiya; Lau, Mike","Clinical Operations, Global Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Analytics, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.; Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland.",victoria.atkinson@health.qld.gov.au.
35040887,Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.,2022/Jan/18,"Atassi, Bassel","OSF Little Company of Mary Medical Center, Evergreen Park, Illinois.",None
35040698,CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.,2022,"Peterfy, Charles; Chen, Yan; Countryman, Peter; Qian, Meng; Sterba, Mike; Hsu, Henry H; Tong-Starksen, Sandra","Spire Sciences, Inc., Boca Raton, FL, USA.; Spire Sciences, Inc., Boca Raton, FL, USA.; Spire Sciences, Inc., Boca Raton, FL, USA.; Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA.; Plexxikon Inc., South San Francisco, CA 94080, USA.; Plexxikon Inc., South San Francisco, CA 94080, USA.; Plexxikon Inc., South San Francisco, CA 94080, USA.",None
35039606,Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.,2022,"Ramaswamy, Krishnan; Mardekian, Jack; Schultz, Neil M; Lechpammer, Stanislav","Pfizer Inc., New York, NY, USA. krishnan.ramaswamy@pfizer.com.; Pfizer Inc., New York, NY, USA.; Astellas Pharma Inc., Northbrook, IL, USA.; Pfizer Inc., San Francisco, CA, USA.",krishnan.ramaswamy@pfizer.com.
35038429,"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.",2022,"Cui, Na; Wang, Jingru; Wang, Qiang; Zhang, Ran; Yang, Jason","CStone Pharmaceuticals Suzhou, Shanghai, China.; CStone Pharmaceuticals Suzhou, Shanghai, China.; CStone Pharmaceuticals Suzhou, Shanghai, China.; CStone Pharmaceuticals Suzhou, Shanghai, China.; CStone Pharmaceuticals Suzhou, Shanghai, China.",syylwu@live.cn.
35036860,Optical genome mapping identifies rare structural variations as predisposition factors associated with severe COVID-19.,2022/Feb/18,"Jill Lai, Chi-Yu; Hastie, Alex","Bionano Genomics, Inc., San Diego, CA 92121, USA.; Bionano Genomics, Inc., San Diego, CA 92121, USA.",None
35035535,Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.,2022,"Card, Paul B","Kaleidoscope Strategic, Inc., Toronto, ON, Canada.",None
35032437,"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.",2022,"Blum, Steven I; Ejzykowicz, Flavia; Hamilton, Melissa; Simsek, Burcin; Zhang, Joshua","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",d-cella@northwestern.edu.
35030011,Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for ,2022/May/01,"Brase, Jan C; Green, Steven; Haas, Tomas; Masood, Aisha; Gasal, Eduard","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",None
35029629,Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.,2022/Feb/01,"O'Brien, Meagan P; Forleo-Neto, Eduardo; Sarkar, Neena; Isa, Flonza; Hou, Peijie; Chan, Kuo-Chen; Musser, Bret J; Heirman, Ingeborg; Davis, John D; Turner, Kenneth C; Ramesh, Divya; Mahmood, Adnan; Hooper, Andrea T; Hamilton, Jennifer D; Kim, Yunji; Purcell, Lisa A; Baum, Alina; Kyratsous, Christos A; Kowal, Bari; DiCioccio, A Thomas; Geba, Gregory P; Stahl, Neil; Lipsich, Leah; Braunstein, Ned; Herman, Gary; Yancopoulos, George D; Weinreich, David M","Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.; Regeneron Pharmaceuticals Inc, Tarrytown, New York.",None
35026412,"Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.",2022,"Fagniez, N","Pharmacokinetics, Dynamics and Metabolism, Sanofi, Chilly-Mazarin, France.",Anas.gazzah@gustaveroussy.fr.
35026411,Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.,2022,"Boran, A; Ilankumaran, P; Burgess, P; Romero Salas, T","Novartis Pharmaceuticals Corporation, East Hanover, USA.; Novartis Pharmaceuticals Corporation, East Hanover, USA.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, USA.",bhumsuk@snu.ac.kr.
35026019,Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.,2022/May/09,"Golmakani, Marzieh K","Pfizer Inc, San Diego, CA, USA.",None
35025065,Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow.,2022,"Khurana, Aditi; Bischoff, Farideh Zamaniyan; Moore, Mathew; Cotter, Philip","Research Dx Inc., Irvine, CA, USA.; Menarini Silicon Biosystems Inc., Huntingdon Valley, USA.; Research Dx Inc., Irvine, CA, USA.; Research Dx Inc., Irvine, CA, USA.",sabine.kasimir-bauer@uk-essen.de.
35022192,"Immuno-oncology trends: preclinical models, biomarkers, and clinical development.",2022,"Franklin, Maryland Rosenfeld; Platero, Suso; Saini, Kamal S; Anderson, Steven","Labcorp Drug Development Inc, Princeton, New Jersey, USA.; Labcorp Drug Development Inc, Princeton, New Jersey, USA.; Labcorp Drug Development Inc, Princeton, New Jersey, USA.; Labcorp Drug Development Inc, Princeton, New Jersey, USA.",giuseppe.curigliano@ieo.it.
35020119,"A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.",2022,"Tian, Yahui; Xue, Zhiyi","Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.; Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.",syylwu@live.cn.
35018553,"A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.",2022,"Lin, Swan; Gong, Jason; Canas, George C; Pelletier, Kathleen; LaBadie, Robert R; Ginman, Katherine; Pithavala, Yazdi K","Pfizer Inc., Global Product Development, San Diego, CA, USA. swandlin@gmail.com.; Pfizer Inc., Global Product Development, New York, NY, USA.; Prism Research Inc., Prism Clinical Research, St. Paul, MN, USA.; Pfizer Inc., Global Product Development, Groton, CT, USA.; Pfizer Inc., Global Product Development, Groton, CT, USA.; Pfizer Inc., Global Product Development, Groton, CT, USA.; Pfizer Inc., Global Product Development, San Diego, CA, USA.",swandlin@gmail.com.
35015566,Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups.,2022/May/01,"Beach, Gillian C","Emmes Company, New York, NY.",None
35012962,Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.,2022,"Lopez-Martin, Jose A; Fudio, Salvador; Pontes, Maria Jose; de Rivas, Beatriz; Giron de Velasco, Patricia; Nieto, Antonio; Gomez, Javier; Aviles, Pablo; Lubomirov, Rubin; Belgrano, Alvaro; Sopesen, Belen; Fernandez-Sousa, Jose M; Jimeno, Jose M","Virology and Inflammation Unit, PharmaMar, SA, Madrid, Spain.; Clinical Pharmacology Unit, PharmaMar, Madrid, Spain.; Medical Affairs, PharmaMar, Madrid, Spain.; Medical Affairs, PharmaMar, Madrid, Spain.; Virology and Inflammation Unit, PharmaMar, SA, Madrid, Spain.; Bio Statistics Unit, PharmaMar, Madrid, Spain.; Bio Statistics Unit, PharmaMar, Madrid, Spain.; Preclinical Unit, Pharmamar, Madrid, Spain.; Clinical Pharmacology Unit, PharmaMar, Madrid, Spain.; Bio Statistics Unit, PharmaMar, Madrid, Spain.; Virology and Inflammation Unit, PharmaMar, SA, Madrid, Spain.; Pharmamar, Madrid, Spain.; Virology and Inflammation Unit, PharmaMar, SA, Madrid, Spain.",jfvarona@hmhospitales.com.
35008087,Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes.,2022,"Yu, Jingbo; Scherber, Robyn M; Paranagama, Dilan; Visaria, Jay; Singhal, Mukul","Incyte Corporation, Wilmington, Delaware, USA, jyu@incyte.com.; Incyte Corporation, Wilmington, Delaware, USA.; Incyte Corporation, Wilmington, Delaware, USA.; HealthCore, Inc., Wilmington, Delaware, USA.; HealthCore, Inc., Wilmington, Delaware, USA.",jyu@incyte.com.
35001472,Risk of major depressive disorder in adolescent and young adult cancer patients in Japan.,2022,"Mishiro, Izumi; Fujimoto, Shinji","Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.; Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.",None
34997449,Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).,2022,"Pericay, Carles; Makris, Lukas; Benhadji, Karim A","Medical Oncology, Corporación Sanitaria Parc Tauli, Barcelona, Spain.; Stathmi, Inc., New Hope, PA, USA.; Clinical Development, Taiho Oncology, Inc., Princeton, NJ, USA.",kshitara@east.ncc.go.jp.
34995105,Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).,2022/Feb/10,"Theall, Kathy Puyana; Lu, Dongrui Ray","Pfizer, Inc, Cambridge, MA.; Pfizer, Inc, La Jolla, CA.",None
34995081,Building Sustainable Practice Transformation Through Payment Reform Initiatives.,2022,"Miller, Harold","Center for Healthcare Quality and Payment Reform, Pittsburgh, PA.",None
34992090,Role of Fcγ receptors in HER2-targeted breast cancer therapy.,2022,"Nordstrom, Jeffrey L; Rock, Edwin P; Arnaldez, Fernanda","MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.; MacroGenics, Inc, Rockville, Maryland, USA.",mpegram@stanford.edu.
34991679,Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee.,2022/Jan/06,"Xu, Jing; Hall, Tracey; Srivastava, Shouryadeep; Naranjo, Daniel","Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.",JJANUZZI@PARTNERS.ORG.
34991158,G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL.,2022/Jun/14,"Laird, A Douglas","Pfizer, Inc., La Jolla, CA.",None
34990895,Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.,2022,"Parker, Joel S","Life Edit Therapeutics, North Carolina, USA.",alprat@clinic.cat.
34990208,Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.,2022/Mar/01,"Hansen, Aaron R; Xu, Lei; Jin, Fan; Norwood, Kevin","Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.; Merck & Co, Inc, Kenilworth, NJ.",None
34984540,"Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.",2022,"Xia, Hongqiang; Qi, Qinzhou; Dai, Hangjun; Shi, Qingmei; Yang, Jianxin","CStone Pharmaceuticals (Suzhou) Co., Ltd, Suzhou, China.; CStone Pharmaceuticals (Suzhou) Co., Ltd, Suzhou, China.; CStone Pharmaceuticals (Suzhou) Co., Ltd, Suzhou, China.; CStone Pharmaceuticals (Suzhou) Co., Ltd, Suzhou, China.; CStone Pharmaceuticals (Suzhou) Co., Ltd, Suzhou, China.",shenlin@bjmu.edu.cn.
34983073,Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France.,2022,"Mokgokong, Ruth","Pfizer Ltd, Health Economics and Outcomes Research, Tadworth, United Kingdom.",None
34983046,Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases.,2022,"Udagawa, Eri","Japan Medical Office, Takeda Pharmaceutical Company Limited, Chuo-ku, Japan.",None
34982158,Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.,2022/Jan/04,"Flora, Daniel B; Lewis, Mark A; Rhodes, Terence D","St Elizabeth Healthcare, Edgewood, Kentucky.; Intermountain Healthcare, Salt Lake City, Utah.; Intermountain Healthcare, Salt Lake City, Utah.",None
34973512,Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma.,2022,"Rosales, M K","MacroGenics Inc., Rockville, USA.",dcatenac@bsd.uchicago.edu.
39296726,Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study.,2022,"Murray, Suzanne; Péloquin, Sophie; Lazure, Patrice","AXDEV Group Inc, Brossard, Quebec, Canada.; AXDEV Group Inc, Brossard, Quebec, Canada.; AXDEV Group Inc, Brossard, Quebec, Canada.",None
34971577,"Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.",2022,"Morariu-Zamfir, Rodica; Arbushites, Michael; Lakshminarayanan, Mani; Barbour, April M","Incyte, Wilmington, DE, USA.; Incyte, Wilmington, DE, USA.; Incyte, Wilmington, DE, USA.; Incyte, Wilmington, DE, USA.",ychen6@partners.org.
34971492,Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab.,2022,"Khandelwal, Akash; von Heydebreck, Anja","The healthcare business of Merck KGaA, Darmstadt, Germany.; The healthcare business of Merck KGaA, Darmstadt, Germany.",None
34965953,Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).,2022/Jul/01,"Febbo, Phillip G","Illumina Inc., Redwood City, California.",None
34965947,The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.,2022/Mar/01,"Duggan, William T","Pfizer Inc., Groton, Connecticut.",None
34964940,Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.,2022,"Waterhouse, David; Iadeluca, Laura; Wilner, Keith; Emir, Birol; Bartolome, Lauren","Oncology Hematology Care, The US Oncology Network, Cincinnati, OH, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA. lauren.bartolome@pfizer.com.",lauren.bartolome@pfizer.com.
34958894,COVID-19 vaccination and breakthrough infections in patients with cancer.,2022,"Daher, A","Hartford HealthCare Medical Group, Hartford, USA.",Toni_Choueiri@dfci.harvard.edu.
34954044,Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.,2022,"Ramos, J; Feng, W","Seagen Inc., Bothell, USA.; Seagen Inc., Bothell, USA.",giuseppe.curigliano@ieo.it.
34953531,"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.",2022,"Gilgun-Sherki, Yossi; Patou, Gary; Haviv, Asi","Chiasma Inc, Needham, MA, USA, acquired by Amryt Pharmaceuticals DAC, Dublin, Ireland as of August, 2021.; Chiasma Inc, Needham, MA, USA, acquired by Amryt Pharmaceuticals DAC, Dublin, Ireland as of August, 2021.; Chiasma Inc, Needham, MA, USA, acquired by Amryt Pharmaceuticals DAC, Dublin, Ireland as of August, 2021.",fleseriu@ohsu.edu.
34953400,Results of a single-arm pilot study of ,2022,"Young, E","Southern Star Research Pty Ltd, Gordon, Australia.",paul.ross@gstt.nhs.uk.
34952480,Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.,2022,"Smith, Jessica L; Carlino, Matteo S","Crown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia. Electronic address: JessicaLouise.Smith@health.nsw.gov.au.; Crown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia. Electronic address: matteo.carlino@sydney.edu.au.",alexander.menzies@sydney.edu.au.
34950969,[,2022,"Leeuwenkamp, Oscar","Advanced Accelerator Applications/A Novartis Company, Geneva, Switzerland.",sergio.baldari@unime.it.
34949788,"CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.",2022,"Esplin, Edward D; Hatchell, Kathryn; Nielsen, Sarah M","Invitae Corporation, San Francisco, CA, USA.; Invitae Corporation, San Francisco, CA, USA.; Invitae Corporation, San Francisco, CA, USA.",GuruP_Sonpavde@dfci.harvard.edu.
34940781,"Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.",2022/Feb/01,"Banchereau, Romain; Hamidi, Habib; Khan, Omara; Craine, Veronica; Huseni, Mahrukh; Flinn, Nick; Dubey, Sarita","Genentech Inc, South San Francisco, California.; Genentech Inc, South San Francisco, California.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, California.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Genentech Inc, South San Francisco, California.",None
34937730,Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.,2022,"Budimir, Natalija; Thomas, Graham D; Dolina, Joseph S; Salek-Ardakani, Shahram","Cancer Immunology Discovery, Pfizer Inc., San Diego, California. ssalekardakani@gmail.com natalija.budimir@gmail.com graham.thomas@pfizer.com.; Cancer Immunology Discovery, Pfizer Inc., San Diego, California. ssalekardakani@gmail.com natalija.budimir@gmail.com graham.thomas@pfizer.com.; Cancer Immunology Discovery, Pfizer Inc., San Diego, California.; Cancer Immunology Discovery, Pfizer Inc., San Diego, California. ssalekardakani@gmail.com natalija.budimir@gmail.com graham.thomas@pfizer.com.",ssalekardakani@gmail.com
34936379,Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.,2022/Mar/10,"Hantel, Alex","Edward Elmhurst Healthcare, Naperville, IL.",None
34935522,"LPS induces rapid increase in GDF15 levels in mice, rats, and humans but is not required for anorexia in mice.",2022/Feb/01,"Bezy, Olivier","Was Internal Medicine Research Unit, Pfizer Inc., Cambridge, Massachusetts.",None
34935177,Robust group sequential designs for trials with survival endpoints and delayed response.,2022,"Ghosh, Pranab; Mehta, Cyrus","Pfizer Corporation, Cambridge, MA, USA.; Cytel Inc., Cambridge, MA, USA.",None
34932938,"Rare coding variants in 35 genes associate with circulating lipid levels-A multi-ancestry analysis of 170,000 exomes.",2022/Jan/06,"Choi, Won Jung; Kim, Ryan W; Lee, Seonwook; Park, Cheol Joo; Seo, Daekwan; Seo, Jeong-Sun; Viaud Martinez, Karine A","Psomagen, Inc. (formerly Macrogen USA), 1330 Piccard Drive Ste 103, Rockville, MD 20850, USA.; Psomagen, Inc. (formerly Macrogen USA), 1330 Piccard Drive Ste 103, Rockville, MD 20850, USA.; Psomagen, Inc. (formerly Macrogen USA), 1330 Piccard Drive Ste 103, Rockville, MD 20850, USA.; Psomagen, Inc. (formerly Macrogen USA), 1330 Piccard Drive Ste 103, Rockville, MD 20850, USA.; Psomagen, Inc. (formerly Macrogen USA), 1330 Piccard Drive Ste 103, Rockville, MD 20850, USA.; Psomagen, Inc. (formerly Macrogen USA), 1330 Piccard Drive Ste 103, Rockville, MD 20850, USA.; Illumina Laboratory Services, Illumina Inc., San Diego, CA 92122, USA.",gpeloso@bu.edu.
34932394,Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.,2022/Mar/01,"Neffa, Maryna; Ortuzar Feliu, Waldo; Ancukiewicz, Marek","CI of Healthcare Regional Clinical Specialized Dispensary of the Radiation Protection, Kharvik, Ukraine.; Agenus Inc, Waltham, MA.; Agenus Inc, Waltham, MA.",None
34932393,Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.,2022/Feb/10,"Redjal, Navid","Capital Health Medical Center - Hopewell Campus, Princeton, NJ.",None
34929616,Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial.,2022,"Kurt, M; Moshyk, A","Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, USA.; Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, USA.",Sebastien.branchoux@bms.com.
34929613,Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.,2022,"Rudolph, Marion; Silvertown, Josh; Wierzbinska, Justyna; Shen, Kui; Nogai, Hendrik","Bayer AG Pharmaceuticals, Berlin, Germany.; Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA.; Bayer AG Pharmaceuticals, Berlin, Germany.; Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA.; Bayer HealthCare Pharmaceuticals, Inc., Basel, Switzerland.",erin.rudzinski@seattlechildrens.org.
34928709,"Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).",2022/Apr/01,"Eton, Omar","Hartford Healthcare, Hartford, CT.",None
34928484,"RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.",2022,"Frimodt-Moller, Bente; Barrett, Emily; Lipkovich, Olga","Eli Lilly and Company, Copenhagen, Denmark.; Eli Lilly and Company, Bracknell, UK.; Eli Lilly and Company, Indianapolis, IN, USA.",esnadal@iconcologia.net.
34922298,"Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).",2022,"Hsu, K; Lindmark, B; McIntyre, N; Firth, C","ASLAN Pharmaceuticals, Singapore, Singapore.; ASLAN Pharmaceuticals, Singapore, Singapore.; ASLAN Pharmaceuticals, Singapore, Singapore.; ASLAN Pharmaceuticals, Singapore, Singapore.",mjavle@mdanderson.org.
34921960,"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.",2022,"Miao, H; Bunn, V; Fenton, K; Fanale, M; Puhlmann, M","Millennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; Millennium Pharmaceuticals, Inc, Cambridge, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.; Seagen Inc., Bothell, USA.; Seagen Inc., Bothell, USA.; Seagen Inc., Bothell, USA.",horwitzs@mskcc.org.
34921525,What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.,2022,"Wang, Yingbo","Novartis Pharma AG, Basel, Switzerland.",None
34921021,Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.,2022/Apr/01,"Grisic, Ana-Marija; Zheng, Jenny; Khandelwal, Akash","the healthcare business of Merck KGaA, Darmstadt, Germany.; Pfizer, Inc., La Jolla, California.; the healthcare business of Merck KGaA, Darmstadt, Germany.",None
34918546,Encorafenib plus binimetinib in patients with ,2022,"Wilner, Keith D","Clinical Development and Operations, Pfizer Inc., San Diego, CA 92121, USA.",None
34915592,Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.,2022,"Stern, Jennifer C; Prathikanti, Radha; Wu, Kenneth; Novotny, William; Huang, Jane","BeiGene USA, Inc, San Mateo, CA, USA.; BeiGene USA, Inc, San Mateo, CA, USA.; BeiGene USA, Inc, San Mateo, CA, USA.; BeiGene USA, Inc, San Mateo, CA, USA.; BeiGene USA, Inc, San Mateo, CA, USA.",None
34914889,"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.",2022,"Begic, Damir; Chen, Gong; Neely, Jaclyn; Wisniewski, Tami; Tschaika, Marina","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",the@netvigator.com.
34914545,Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.,2022/Feb/10,"O'Hear, Carol; Kwan, Antonia; Li, Chi-Chung; Piccione, Emily C; Wei, Michael C; Yin, Shen","Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",None
34910556,Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.,2022/Mar/10,"Zhou, Ying; Dail, Monique; Chyla, Brenda; Potluri, Jalaja","AbbVie Inc., North Chicago, IL.; Genentech Inc., South San Francisco, CA.; AbbVie Inc., North Chicago, IL.; AbbVie Inc., North Chicago, IL.",None
34910554,"BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.",2022/Feb/01,"Blaya, Marcelo; Cooper, Maureen E; Pavlick, Dean C; Albacker, Lee A; Gregg, Jeffrey","Memorial Healthcare System, Hollywood, FL.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.; Foundation Medicine Inc, Cambridge, MA.",None
34908235,Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.,2022,"Lu, Dongrui Ray; Kim, Sindy","Pfizer Inc, San Diego, California, USA.; Pfizer Inc, San Diego, California, USA.",None
34903481,Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies.,2022,"Chang, Jane","Pfizer Inc, New York, NY.",pgrivas@uw.edu.
34902530,Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.,2022,"Verret, Wendy; Ma, Ning; Nicholas, Alan","Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.; Product Development Safety, Genentech, Inc., South San Francisco, CA, USA.; Product Development Biostatistics, Genentech, Inc., South San Francisco, CA, USA.",RFinn@mednet.ucla.edu.
34896693,A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer.,2022,"Miller, Kristen","MedStar Health National Center for Human Factors in Healthcare, Washington, DC, USA.",jcj74@georgetown.edu.
34895487,"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.",2022,"Rossi, John M; Goyal, Lovely; Plaks, Vicki; Yang, Yin; Vezan, Remus; Avanzi, Mauro P","Kite Pharma, Santa Monica, CA, USA.; Kite Pharma, Santa Monica, CA, USA.; Kite Pharma, Santa Monica, CA, USA.; Kite Pharma, Santa Monica, CA, USA.; Kite Pharma, Santa Monica, CA, USA.; Kite Pharma, Santa Monica, CA, USA.",caron_jacobson@dfci.harvard.edu.
34890214,Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.,2022/Feb/10,"Shah, Jigna; Liu, Haiying; Trask, Peter; Song, Chunyan","Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",None
34882500,Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.,2022/Feb/01,"Hill, Matthew L","Medical Oncology and Hematology Associates-Des Moines, Des Moines, IA accrual under Iowa-Wide Oncology Research Coalition NCORP.",None
34878659,"Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.",2022/Mar/01,"Shih, Chie-Schin","Merck & Co., Inc., Kenilworth, New Jersey.",None
34876673,Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.,2022,"Schatz, Christoph; Zitzmann-Kolbe, Sabine; Sommer, Anette","Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.; Bayer AG, Pharmaceuticals, Berlin, Germany.",gig4001@med.cornell.edu.
34871104,Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.,2022/Feb/01,"Gillies, Stephen D","Provenance Biopharmaceuticals, Carlisle, MA.",None
34870845,Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations.,2022,"Yang, Derek Z; Alhadab, Ali; Parivar, Kourosh; Wang, Diane D; Elmeliegy, Mohamed","Global Product Development, Pfizer Inc, San Diego, California, USA.; Global Product Development, Pfizer Inc, San Diego, California, USA.; Global Product Development, Pfizer Inc, San Diego, California, USA.; Global Product Development, Pfizer Inc, San Diego, California, USA.; Global Product Development, Pfizer Inc, San Diego, California, USA.",None
34866317,Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.,2022,"Sero, Valeria","Menarini Silicon Biosystems, Inc., San Diego, CA, USA.",None
34865212,Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.,2022,"Li, Jianling; Krigsfeld, Gabriel; Dean, James P","Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.",None
34864947,Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry.,2022/Jul/14,"de Francisco, Ruth","H.U. Central de Asturias and Instituto de Investigación Biosanitaria del principado de Asturias (ISPA), Oviedo, Spain.",None
34864943,Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.,2022/Sep/10,"Wu, Jingyang; Sundberg, Aimee K; Fournier, Martha","Biostatistics, Takeda Development Center Americas, Inc, Lexington, Massachusetts, USA.; Clinical Sciences, Takeda Development Center Americas, Inc, Lexington, Massachusetts, USA.; Clinical Sciences, Takeda Development Center Americas, Inc, Lexington, Massachusetts, USA.",None
34861374,Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.,2022,"Bach, B A; Kundu, M G; Khandelwal, N; Feng, D; Bhattacharya, S; Maag, D; Ratajczak, C K","AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.; AbbVie Inc., North Chicago, USA.",hyo.han@moffitt.org.
34860318,Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.,2022,"Lian, Qinshu; Reilly, Sarah-Jayne; Hinton, Heather; Wongchenko, Matthew J; Mani, Aruna","Biostatistics, Genentech, Inc, South San Francisco, CA, USA.; Pharma Development, Roche Products Ltd, Welwyn Garden City, UK.; Product Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA, USA.; Product Development Oncology, Genentech, Inc, South San Francisco, CA, USA.",Nick.Turner@icr.ac.uk.
34855460,Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.,2022/Feb/01,"Wu, Juan; Mendizabal, Adam","Emmes Company, Rockville, MD.; Emmes Company, Rockville, MD.",None
34855329,Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors.,2022/Feb/01,"Stwalley, Brian; Ritchings, Corey","Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey.; Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey.",None
34854921,Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study.,2022/Feb/01,"Wu, Julie Tsu-Yu; La, Jennifer; Branch-Elliman, Westyn; Huhmann, Linden B; Tuck, David P; Brophy, Mary T; Do, Nhan V; Lin, Albert Y; Fillmore, Nathanael R","VA Palo Alto Healthcare System, Palo Alto, California.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts.; VA Boston Healthcare System, Section of Infectious Diseases, Boston, Massachusetts.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts.; VA Boston Healthcare System, Hematology/Oncology Service, Boston, Massachusetts.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts.; VA Palo Alto Healthcare System, Palo Alto, California.; VA Cooperative Studies Program, VA Boston Healthcare System, Boston, Massachusetts.",None
34854733,Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.,2022,"Beachler, Daniel C; Dinh, Jade; Jamal-Allial, Aziza; Lamy, Francois-Xavier","HealthCore Inc., Wilmington, DE.; HealthCore Inc., Wilmington, DE.; HealthCore Inc., Wilmington, DE.; the healthcare business of Merck KGaA, Darmstadt, Germany.",None
34854095,"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.",2022,"Modesto, Irene","Pfizer Inc, New York, NY, USA.",None
34853914,Oncology care providers' awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: a nationwide cross-sectional web-based survey.,2022,"Sakurai, Naomi","Cancer Solutions Inc, Tokyo, Japan.",matsuoka-psy@umin.ac.jp.
34851366,Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology: CLEAR Derm Consensus Guidelines From the International Skin Imaging Collaboration Artificial Intelligence Working Group.,2022/Jan/01,"Helba, Brian","Kitware, Inc, Clifton Park, New York.",None
34848822,Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.,2022,"Duggan, William; Sugg, Jennifer; Haas, Gabriel P","Global Product Development, Pfizer Inc., Groton, CT, USA.; Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA.; Global Development, Astellas Pharma, Inc., Northbrook, IL, USA.",david.penson@vumc.org.
34846775,Application of artificial intelligence to overcome clinical information overload in urological cancer.,2022,"Ghith, Jenny","Pfizer, Inc., New York, NY, USA.",None
34844255,Estimating Long-Term Survival Outcomes for Tumor-Agnostic Therapies: Larotrectinib Case Study.,2022,"Paracha, Noman; Upton, Alexander","Bayer Pharmaceuticals, Basel, Switzerland.; Bayer Pharmaceuticals, Whippany, New Jersey, USA.",katherine.rosettie@iqvia.com.
34843406,Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).,2022/Jan/20,"Li, Ju","Bristol Myers Squibb Company, Princeton, NJ.",None
34843401,Poziotinib in Non-Small-Cell Lung Cancer Harboring ,2022/Mar/01,"Leu, Szu-Yun; Bhat, Gajanan; Lebel, Francois","Research and Development, Spectrum Pharmaceuticals, Irvine, CA.; Research and Development, Spectrum Pharmaceuticals, Irvine, CA.; Research and Development, Spectrum Pharmaceuticals, Irvine, CA.",None
34843044,A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies.,2022,"Yanai, Tomoko; Faller, Douglas V; Dobler, Lwona; Gupta, Neeraj; Sedarati, Farhad","Takeda Pharmaceutical Company Limited, Osaka, Japan.; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.",tosshimi@ncc.go.jp.
34842454,Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study.,2022,"Zhan, Lin; Mitra, Debanjali","Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA.; Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA.",None
34840026,Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.,2022,"Ricafort, Rosanna; Cohen, Sarah Beaussant; Horak, Ivan D; Masouleh, Behzad K; Matloub, Yousif; Pieters, Rob; Quintás-Cardama, Alfonso; Sersch, Martina A","Bristol Myers Squibb Company/Celgene, a BMS Company, USA.; CRISPR Therapeutics, Switzerland.; Tessa Therapeutics, Singapore.; Kite, a Gilead Company, USA.; Takeda Pharmaceuticals International, USA.; Princess Maxima Center for Pediatric Oncology, Netherlands.; TCR(2) Therapeutics, USA.; Gracellbiotechnologies Inc, China.",andy1pearson@btinternet.com.
34838325,Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.,2022,"Cruz-Guilloty, Fernando; Jin, Liming; Zhang, Ying; Anderson, Abraham","Amgen Inc, Thousand Oaks, CA, USA. Electronic address: fcruzgui@amgen.com.; Amgen Inc, Thousand Oaks, CA, USA. Electronic address: limingj@amgen.com.; Amgen Inc, Thousand Oaks, CA, USA. Electronic address: yizhang@amgen.com.; Amgen Inc, Thousand Oaks, CA, USA. Electronic address: anderso@amgen.com.",fskoulidis@mdanderson.org.
34838156,Dabrafenib plus trametinib in patients with BRAF,2022,"Boran, Aislyn; Burgess, Paul; Ilankumaran, Palanichamy; Gasal, Eduard","Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Global Drug Development, Oncology Development Unit, Novartis Pharma AG, Basel, Switzerland.; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Global Drug Development, Oncology Development Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.",patrick_wen@dfci.harvard.edu.
34826108,An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma.,2022,"Takahara-Matsubara, Mariko; Sugimoto, Saori","Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.; Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.",nishikor@kuhp.kyoto-u.ac.jp.
34822128,"Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.",2022,"Nair, Sandhya; Diels, Joris; Nesheiwat, Tonia; Garrett, Ashraf","Health Economics Design & Analytics, Janssen Pharmaceutica NV, Beerse, Belgium.; Market Access Analytics and Health Economics, Janssen Pharmaceutica NV, Beerse, Belgium.; Medical Affairs, Cell Therapy, Legend Biotech USA, Inc, Piscataway, NJ, USA.; Medical Affairs, Cell Therapy, Legend Biotech USA, Inc, Piscataway, NJ, USA.",k.weisel@uke.de.
34821081,"Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.",2022,"Prakash, Prashanth Srirangapattana","Medical Affairs, AstraZeneca Pharma India Limited, Bangalore, India.",None
34818112,Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.,2022/Jan/10,"Butler, Marcus O; Bas, Tuba; Ritchings, Corey","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",None
34813053,Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis.,2022,"Bennetts, Margherita; Nickens, Dana J; Brinkmann, Julia; Kayser, Antonin; Moran, Michael","Pfizer R&D UK Ltd., Sandwich, UK.; Pfizer Inc., La Jolla, CA, USA.; Pfizer Pharma GmbH, Berlin, Germany.; Pfizer Pharma GmbH, Berlin, Germany.; Pfizer Pharma GmbH, Berlin, Germany.",BMelosky@bccancer.bc.ca.
34811954,Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.,2022,"Oger, Emmanuel","Pharmacologie Clinique et CIC-IP 1414, CHU Rennes et Université Rennes-1, Rennes, France.",None
34801354,KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.,2022,"Ascierto, Paolo A","Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS ""Fondazione G. Pascale"", Via Mariano Semmola, Naples 80131, Italy. Electronic address: paolo.ascierto@gmail.com.",ohamid@theangelesclinic.or.
34801197,Challenges in the Methodology for Health Disparities Research in Thoracic Surgery.,2022,"Litle, Virginia R","Intermountain Healthcare, 5169 So. Cottonwood Street, Suite 640, Murray, UT 84107, USA.",cherie.erkmen@tuhs.temple.edu.
34800678,"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer",2022,"Chartash, E; Lala, M; Chen, Q; Healy, J A","Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.; OED-QP2IO, Merck & Co., Inc., Kenilworth, NJ, USA.; BARDS, Merck & Co., Inc., Kenilworth, NJ, USA.; Oncology Early Development, Merck & Co., Inc., Kenilworth, NJ, USA.",jiaxin.niu@bannerhealth.com.
34800178,"Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.",2022,"Chen, Mei","Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ, 07033, USA.",satoshitamada@osaka.med.or.jp.
34799418,"Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.",2022,"McKenzie, Jodi; Lee, John J","Eisai Inc, Woodcliff Lake, New Jersey, USA.; Merck & Co Inc, Kenilworth, New Jersey, USA.",Christian.marth@tirol-kliniken.at.
34798201,Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.,2022,"Yang, Ya-Wen; Papp, Kim A","Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania.; K Papp Clinical Research and Probity Research, Inc, Waterloo, Ontario, Canada.",ablauvelt@oregonmedicalresearch.com.
34795408,"Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.",2022,"Zhang, Kathy; Zhang, Maggie; Tang, Zhiyu","BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene USA, Inc., San Mateo, CA, USA.; BeiGene USA, Inc., San Mateo, CA, USA.",michael.millward@uwa.edu.au.
34789563,Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.,2022,"Kim, Nam Doo","VORONOI BIO Inc., Incheon, Republic of Korea.",pasi_jänne@dfci.harvard.edu.
34784056,Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.,2022/Mar/01,"Zhang, Joshua; Johansen, Jennifer L; Leung, David K","Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.; Bristol Myers Squibb, Princeton, New Jersey.",None
34782346,BET Inhibition Enhances TNF-Mediated Antitumor Immunity.,2022,"Wellinger, Lisa C; Friess, Thomas; Geiss, Daniela; Bacac, Marina; Fauti, Tanja; Marbach, Daniel; Jarassier, Laura; Paehler, Axel; Rohle, Daniel","Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Zurich, Schlieren, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland.; Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland. drohle@ridgelinediscovery.com ricky.johnstone@petermac.org.",drohle@ridgelinediscovery.com
34782240,Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.,2022,"Drusbosky, Leylah M; Dada, Hiba; Raymond, Victoria M; Dix, Daniel; Odegaard, Justin I; Lanman, Richard B; Papadimitrakopoulou, Vassiliki A; Leighl, Natasha B","Guardant Health, Inc, Redwood City, CA. Electronic address: ldrusbosky@gmail.com.; Guardant Health, Inc, Redwood City, CA.; Guardant Health, Inc, Redwood City, CA.; Guardant Health, Inc, Redwood City, CA.; Guardant Health, Inc, Redwood City, CA.; Guardant Health, Inc, Redwood City, CA.; U of Texas, MD Anderson Cancer Center, Houston, TX; Pfizer, Inc, New York, NY.; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",ldrusbosky@gmail.com.
34779028,Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.,2022/Feb/01,"Popovic, Relja; Dunbar, Fengjiao; Lu, Charles; Robinson, Kenneth; Quarless, Danjuma; Warder, Scott E; Mukherjee, Nabanita; Pesko, John; Souers, Andrew J; Waring, Jeffrey F; Ross, Jeremy A; Leverson, Joel D; Kim, Su Young; Chyla, Brenda J","AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.; AbbVie Inc, North Chicago, Illinois, USA.",None
34773474,"A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.",2022,"Kawashima, Jun; Kong, Shengchun; Kowalski, Mark","Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.; Gilead Sciences, Inc., Foster City, CA, USA.",sukhmani.padda@cshs.org.
34767747,MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function.,2022/Jan/11,"Cameron, Alanna M; Foerch, Patrik; Bourne, Tim","Sitryx Therapeutics Limited, Magdalen Centre, Oxford Science Park, Oxford, UK.; Sitryx Therapeutics Limited, Magdalen Centre, Oxford Science Park, Oxford, UK.; Sitryx Therapeutics Limited, Magdalen Centre, Oxford Science Park, Oxford, UK.",jeff.rathmell@vumc.org.
34761486,Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.,2022,"Hale, Sarah A; Oladapo, Abiola","Baxalta US Inc., a, Takeda company, Cambridge, Massachusetts, USA.; Baxalta US Inc., a, Takeda company, Cambridge, Massachusetts, USA.",None
34761368,Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide.,2022,"Brown, Ailsa","Healthcare Improvement Scotland, Glasgow, UK.",dikshyanta.rana@glasgow.ac.uk.
34756989,Letter to the Editor for 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study'.,2022,"Shahir, A","Eli Lilly and Company, Indianapolis, USA.",Nadia.Harbeck@med.uni-muenchen.de.
34756500,"Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128].",2022,"Gollerkeri, Ashwin","At Time of Research: Pfizer Inc., Boulder, CO, USA.",helgogas@gmail.com.
34754095,Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.,2022,"Gerritsmann, Hanno","Novartis Pharma GmbH, Jakov-Lind-Straße 5, 1020, Vienna, Austria.",marija.balic@medunigraz.at.
34750637,"Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.",2022,"Patnaik, Amita; Rasco, Drew W; Beeram, Murali; McEachern, Kristen","South Texas Accelerated Research Therapeutics, San Antonio, TX, USA. Amita.Patnaik@startsa.com.; South Texas Accelerated Research Therapeutics, San Antonio, TX, USA.; South Texas Accelerated Research Therapeutics, San Antonio, TX, USA.; Ribon Therapeutics, Cambridge, MA, USA.",Amita.Patnaik@startsa.com.
34740768,Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).,2022/Apr/01,"Beyer, David","Cancer Centers of Northern Arizona Healthcare, Flagstaff, Arizona.",jcrook@bccancer.bc.ca.
34740705,EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.,2022,"Denham, Douglas; Goodwin, Bryan; Ahmad, Alaa; Adda, Nathalie","Clinical Trials of Texas, Inc., San Antonio, TX, United States.; Enanta Pharmaceuticals, Inc, Watertown, MA, United States.; Enanta Pharmaceuticals, Inc, Watertown, MA, United States.; Enanta Pharmaceuticals, Inc, Watertown, MA, United States. Electronic address: nadda@enanta.com.",nadda@enanta.com.
34737207,Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with ,2022,"Papadopoulos, Nickolas; Peters, Ulrike","Ludwig Center for Cancer Genetics and Therapeutics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland.; Public Health Sciences Division, Fred Hutchinson Cancer Research Centre, Seattle, Washington. upeters@fredhutch.org vincent.ferretti.hsj@ssss.gouv.qc.ca.",upeters@fredhutch.org
34737197,SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.,2022,"Jensen-Pergakes, Kristen; Tatlock, John; Maegley, Karen A; McAlpine, Indrawan J; McTigue, Michele; Xie, Tao; Dillon, Christopher P; Wang, Yuli; Yamazaki, Shinji; Spiegel, Noah; Shi, Manli; Nemeth, Amy; Miller, Natalie; Hendrickson, Eleanore; Lam, Hieu; Sherrill, John; Chung, Chi-Yeh; McMillan, Elizabeth A; Bryant, Shannon Karlicek; Palde, Prakash; Braganza, John; Brooun, Alexei; Deng, Ya-Li; Goshtasbi, Vesta; Kephart, Susan E; Kumpf, Robert A; Liu, Wei; Patman, Ryan L; Rui, Eugene; Scales, Stephanie; Tran-Dube, Michelle; Wang, Fen; Wythes, Martin; Paul, Thomas A","Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc.; San Diego, California.; Oncology Research Division, Pfizer Inc.; San Diego, California. Thomas.A.Paul@pfizer.com.",Thomas.A.Paul@pfizer.com.
34734980,Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.,2022/Jan/01,"Huang, Bo","Pfizer Inc, Groton, Connecticut.",None
34732856,Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.,2022,"Ramaswamy, Krishnan; Russell, David; Mardekian, Jack; Schultz, Neil M","Pfizer Inc., New York, NY, USA.; Pfizer Inc., New York, NY, USA.; Pfizer Inc., New York, NY, USA.; Astellas Pharma, Inc, Northbrook, IL, USA.",daniel.george@duke.edu.
34716541,Future care for long-term cancer survivors: towards a new model.,2022,"López, A","Pharmacy, Navarra Health Service-Osasunbidea, Navarra, Spain.",mariano.provencio@salud.madrid.org.
34710571,Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.,2022,"Jensen, E; Leiby, M A; Ibrahim, N","Merck & Co., Inc., Kenilworth, NJ, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.; Merck & Co., Inc., Kenilworth, NJ, USA.",georgina.long@sydney.edu.au.
34706874,Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.,2022,"Deberdt, Walter; Issa, Maher; Terres, Jorge Ross; Bello, Natalia","Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.; Eli Lilly and Company, Indianapolis, Indiana, USA.",peter.taylor@kennedy.ox.ac.uk.
34698901,Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.,2022,"Hibma, Jennifer E; O'Gorman, Melissa; Pithavala, Yazdi K","Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA. Jennifer.e.hibma@pfizer.com.; Pfizer (Pharmacometrics Oncology), Groton, CT, USA.; Pfizer (Clinical Pharmacology Oncology), La Jolla, 10555 Science Center Drive, CB10-2727, San Diego, CA, 92121, USA.",Jennifer.e.hibma@pfizer.com.
34694907,Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry.,2022,"Clayton, Eric J; Waterhouse, David; Jazieh, Abdul-Rahman","OHC, Cincinnati OH/an Affiliate of US Oncology, Cincinnati, OH.; OHC, Cincinnati OH/an Affiliate of US Oncology, Cincinnati, OH.; Cincinnati Cancer Advisors, Cincinnati, OH.",None
34694168,The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review.,2022,"Sertkaya, Aylin","Eastern Research Group, Inc., Lexington, MA, USA.",None
34677647,"Efficacy and safety of Wilms' tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial.",2022,"Masui, Koichi; Ihara, Yuichiro; Hirota, Masao; Shimofurutani, Naoko","Otsuka Pharmaceutical Co., Ltd, Osaka, Japan.; Otsuka Pharmaceutical Co., Ltd, Tokushima, Japan.; Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan.; Otsuka Pharmaceutical Co., Ltd, Osaka, Japan.",kiguchi-t@umin.ac.jp.
34672933,Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.,2022,"Stundzia, Audrius","Tomographix IP Ltd, Toronto, ON, Canada.",None
34668577,Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men.,2022,"Kraus, Albert L; Yu-Kite, Michelle; Mardekian, Jack; Cotter, Matthew J; Kim, Sindy; Decembrino, Jaclyn; Snow, Tamara; Carson, Kenneth R; Motyl Rockland, Jillian; Gossai, Anala; Wilner, Keith; Wang, Diane D; Oharu, Norihiko; Schnell, Patrick; VanArsdale, Todd; Lu, Dongrui R","Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, San Diego, California, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, San Diego, California, USA.; IQVIA Inc, Plymouth Meeting, Pennsylvania, USA.; Flatiron Health, Inc, New York, New York, USA.; Flatiron Health, Inc, New York, New York, USA.; Flatiron Health, Inc, New York, New York, USA.; Flatiron Health, Inc, New York, New York, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, San Diego, California, USA.; Pfizer Inc, Groton, Connecticut, USA.; Pfizer Inc, New York, New York, USA.; Pfizer Inc, San Diego, California, USA.; Pfizer Inc, San Diego, California, USA.",None
34667027,Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.,2022/Jan/01,"Duh, Mei Sheng; Bhak, Rachel H; DerSarkissian, Maral; Huynh, Lynn; Wang, Kelsey; Wojciehowski, John; Wu, Melody; Niyazov, Alexander","Analysis Group, Inc., Boston, Massachusetts.; Analysis Group, Inc., Boston, Massachusetts.; Analysis Group, Inc., Boston, Massachusetts.; Analysis Group, Inc., Boston, Massachusetts.; Analysis Group, Inc., Boston, Massachusetts.; Analysis Group, Inc., Boston, Massachusetts.; Analysis Group, Inc., Boston, Massachusetts.; Pfizer, Inc, New York City, New York.",Bhakti.Arondekar@pfizer.com.
34661821,"Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.",2022,"van der Walt, Jan-Stefan","Eli Lilly and Company, Berkshire, UK.",toi@kuhp.kyoto-u.ac.jp.
34655734,"Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges.",2022,"Saini, K S","Labcorp Drug Development Inc., Princeton, USA.",fabrice.andre@gustaveroussy.fr.
34648657,"A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.",2022/Mar/01,"Baron, Benoit; Duran, Aurea; Pranzo, Alessandra; Serikoff, Alexis","Astellas Pharma Inc, Leiden, The Netherlands.; Astellas Pharma Europe Ltd, Weybridge, UK.; Astellas Pharma Europe Ltd, Weybridge, UK.; Astellas Pharma, Levallois-Perret, France.",None
34637336,First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.,2022/Jan/10,"Abdullaev, Sandzhar; Gricar, Joseph; Ledeine, Jean-Marie","Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.; Bristol Myers Squibb, Princeton, NJ.",None
34632569,Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.,2022,"Matsutani, Takaji","Osaka laboratory, Repertoire Genesis Incorporation, Ibaraki, Osaka, Japan.",None
34628472,Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.,2022,"Yang, Xiaoqin; Marinello, Patricia; Raut, Monika","Merck & Co., Inc, Kenilworth, NJ, USA.; Merck & Co., Inc, Kenilworth, NJ, USA.; Merck & Co., Inc, Kenilworth, NJ, USA.",bastian.vontresckow@uk-essen.de.
34626429,Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.,2022,"Modesto, Irene; Kwok, Kenneth K; Koram, Nana","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.",None
34621044,Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.,2022,"Youkstetter, Jillian; Hazra, Saswati; Sen, Suvajit","Exelixis, Inc, Alameda, CA, USA.; Exelixis, Inc, Alameda, CA, USA.; Exelixis, Inc, Alameda, CA, USA.",katie.kelley@ucsf.edu.
34621011,Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.,2022,"Duggan, William; Sugg, Jennifer; Haas, Gabriel P","Global Product Development, Pfizer Inc., Groton, CT, USA.; Biostatistics, Astellas Pharma, Inc., Northbrook, IL, USA.; Global Development, Astellas Pharma, Inc., Northbrook, IL, USA.",david.penson@vumc.org.
34612846,Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.,2022/Mar/01,"Qamra, Aditi; Summers, David; Stubbings, William","Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Roche Products Ltd, Welwyn Garden City, United Kingdom.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",None
34608844,Comparative analysis of infectious complications with outpatient ,2022,"Hartley, Garrett A; Welch, Verna L","Pfizer Inc, New York, NY, USA.; Pfizer Inc, New York, NY, USA.",None
34606378,Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.,2022/Jan/01,"Ping, Jerry; Hauns, Bernhard; Arango-Hisijara, Israel","Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.",None
34599413,Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.,2022,"Fukuda, Natsuko; Sumitani, Tokuhito; Sumi, Hiroyuki; Shimizu, Shinji; Kakurai, Yasuyuki; Yoshikawa, Kenji","Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.; Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.; Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.; Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.; Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.; Daiichi Sankyo Co., Ltd, 1-2-58, Hiromachi, Shinagawa, Tokyo, 140-8710, Japan.",kato.koji.429@m.kyushu-u.ac.jp.
34595671,Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.,2022,"Masters, Elizabeth","Pfizer Inc., New York, NY, USA.",xinke.zhang@emdserono.com.
34582343,Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma.,2022,"Malone, Eoghan R; Sim, Hao-Wen; Stundzia, Audrius; Sacher, Adrian G; Sridhar, Srikala S; Hansen, Aaron R","Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.; Tomographix IP Ltd., Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, UHN, Toronto, ON, Canada.",None
34582105,Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).,2022,"Bernaards, Coen A; Ballinger, Marcus; Bruno, René; Quarmby, Valerie; Ruppel, Jane; Vilimovskij, Alexandr; Sternheim, Nitzan","Product Development Biometrics, Genentech, Inc, South San Francisco, California, USA.; Product Development Oncology, Genentech, Inc, South San Francisco, California, USA.; Clinical Pharmacology, Genentech-Roche, Marseille, France.; BioAnalytical Sciences, Genentech Inc, South San Francisco, California, USA.; BioAnalytical Sciences, Genentech Inc, South San Francisco, California, USA.; Product Development Safety, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Product Development Regulatory, Genentech Inc, South San Francisco, California, USA.",None
34581902,Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study.,2022,"Tanaka, Shinji; Akamatsu, Ayumi","Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd, Osaka, Japan.; Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd, Osaka, Japan.",kensei.yamaguchi@jfcr.or.jp.
34562230,"Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.",2022,"Shah, Jatin",", Karyopharm Therapeutics, Newton, MA, USA.",theink@ohsu.edu.
34558113,Healthy volunteers in first-in-human oncology drug development for small molecules.,2022,"de Las Heras, Begoña; Bouyoucef-Cherchalli, Dalila; Reeve, Lesley; Reichl, Andreas; Mandarino, Debra; Flach, Stephen; Vidal, Laura","Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.; Labcorp Drug Development Inc., headquarters in Burlington, North Carolina, USA.",None
34554830,Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer.,2022,"Lewis, Mark A","Intermountain Healthcare, Murray, UT.",None
34554584,Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer.,2022,"Yu, Yanke; Sun, Wan; Wang, Diane","Pfizer, Clinical Pharmacology, San Diego, California, USA.; Vertex, Clinical Pharmacology, Boston, Massachusetts, USA.; Pfizer, Clinical Pharmacology, San Diego, California, USA.",None
34549834,A single-arm pilot of a web-based intervention to improve itch-related quality of life.,2022,"Riley, M","Metronic Inc., Denver, CO, USA.",None
34535037,Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.,2022,"Chapelle, Céline","Unité de Recherche Clinique Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France.",None
34534511,"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.",2022,"Diallo, Alpha; Lê, Minh-Patrick; Peytavin, Gilles","Pharmacovigilance, ANRS-MIE, Paris, France.; Laboratoire de Pharmacologie-Toxicologie, AP-HP, Hôpital Bichat Claude Bernard, Paris, France; Université de Paris, INSERM, UMRS 1144, Paris, France.; Université de Paris, IAME, INSERM, Paris, France; Laboratoire de Pharmacologie-Toxicologie, AP-HP, Hôpital Bichat Claude Bernard, Paris, France.",florence.ader@chu-lyon.fr.
34518652,Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.,2022,"Ganguli, Arijit; Ramaswamy, Krishnan; Bhadauria, Hemant; Holmstrom, Stefan","HEOR, Astellas Pharma Inc, Northbrook, IL, USA.; HEOR, Pfizer Inc, New York, NY, USA.; Medical Affairs, Astellas Pharma Inc., Northbrook, IL, USA.; HEOR, Astellas Pharma Inc., Leiden, the Netherlands.",fred.saad@umontreal.ca.
34483079,Life expectancy in older adults with advanced cancer: Evaluation of a geriatric assessment-based prognostic model.,2022,"Giguere, Jeffrey K; Burnette, Brian L","NCORP of the Carolinas (Greenville Health System NCORP), Greenville, SC, USA.; Cancer Research of Wisconsin and Northern Michigan (CROWN) NCORP, Grand Rapids, MI, USA.",jennifer.lund@unc.edu.
34480657,Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.,2022,"Sameshima, Hiroki","Medical Affairs, Ono Pharmaceutical, Co. Ltd., Osaka, Japan.",ykkang@amc.seoul.kr.
34480094,NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.,2022,"Eshaghian, Shahrooz","James R. Berenson, MD, Inc., West Hollywood, CA, USA.",christian.rolfo@mssm.edu.
34467476,Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study.,2022,"Dalvi, Tapashi","AstraZeneca Pharmaceuticals, Gaithersburg, USA.",sujinkoh@uuh.ulsan.kr.
34458977,Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study.,2022,"Stankovic, Miona; Maier, Joan","Novartis Pharma AG, Basel, Switzerland.; Novartis Pharma AG, Basel, Switzerland.",None
34456145,Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.,2022,"Bene-Tchaleu, Fabiola; Zhu, Jing; Zhang, Xiaosong; Cha, Edward","F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.; Genentech, Inc, South San Francisco, CA.",DeWong@mednet.ucla.edu.
34420037,"Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.",2022,"Rosbrook, Brad; Lee, Ho-Jin; Haas, Gabriel P","Pfizer Inc., San Diego, CA, USA.; Astellas Pharma Inc., Northbrook, IL, USA.; Astellas Pharma Inc., Northbrook, IL, USA.",andrew.armstrong@duke.edu.
34417224,PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by ,2022,"Oyer, Jon A","Pfizer Inc., Oncology Research and Development, San Diego, California.",jdlicht@ufl.edu.
34406606,"A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic ""first wave"" in a German tertiary care hospital.",2022,"Jeck, Julia; Jakobs, Florian; Kron, Anna; Kron, Florian","VITIS Healthcare Group, Cologne, Germany.; VITIS Healthcare Group, Cologne, Germany.; VITIS Healthcare Group, Cologne, Germany.; VITIS Healthcare Group, Cologne, Germany. florian.kron@fom.de.",florian.kron@fom.de.
34389552,Cardiorespiratory fitness in breast cancer survivors: a randomised controlled trial of home-based smartphone supported high intensity interval training.,2022,"Ueno, Taro","SUSMED Inc, Chuo-ku, Tokyo, Japan.",matsuoka-psy@umin.ac.jp
34379148,Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients.,2022,"Burke, Natasha; Oliveira, Thiago; Slatkovska, Lubomira","Amgen Canada Inc., Mississauga, ON, Canada.; Amgen Canada Inc., Mississauga, ON, Canada.; Amgen Canada Inc., Mississauga, ON, Canada. lslatkov@amgen.com.",lslatkov@amgen.com.
34366169,COVID-19 Vaccine Guidance for Patients with Cancer in Mexico: Report From the Working Group of the Mexican Society of Oncology.,2022,"Soto-Perez-de-Celis, Enrique","Departamento de Geriatría. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México. Electronic address: enrique.sotop@incmnsz.mx.",enrique.sotop@incmnsz.mx.
34364796,A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.,2022,"Mardekian, Jack; Borham, Azah","Pfizer Inc, New York, NY.; Pfizer Inc, New York, NY.",costello.brian@mayo.edu.
34316017,Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.,2022,"Du, Ling; Gathmann, Insa; Pallaud, Celine","Novartis Pharmaceuticals, Cambridge, MA, USA.; Novartis Pharmaceuticals, Basel, Switzerland.; Novartis Pharmaceuticals, Basel, Switzerland.",konstanze.doehner@uniklinik-ulm.de.
34282533,Receipt of Tobacco Treatment and One-Year Smoking Cessation Rates Following Lung Cancer Screening in the Veterans Health Administration.,2022,"Krebs, Paul","VA San Diego Healthcare System, San Diego, CA, USA.",jheffner@fhcrc.org.
34272632,Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale.,2022,"Brannan, Christine","Lynda Jackson Macmillan Centre, East & North Hertfordshire NHS Trust Incorporating Mount Vernon Cancer Centre, Northwood, UK.",singers@uni-mainz.de.
34260265,Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.,2022/Apr/20,"Bohac, G Chet; Yurasov, Sergey; Yakovich, Adam; Lu, Hailing; Chen, Michael","Immune Design Corp, South San Francisco, CA.; Immune Design Corp, South San Francisco, CA.; Immune Design Corp, South San Francisco, CA.; Immune Design Corp, South San Francisco, CA.; Immune Design Corp, South San Francisco, CA.",None
34257408,"Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.",2022,"Lauer, Peter; Brockstedt, Dirk","Aduro Biotech, Berkeley, CA, USA.; Aduro Biotech, Berkeley, CA, USA.",cdrake2@its.jnj.com.
34231930,Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings.,2022,"Weldon, Christine B","Center for Business Models in Healthcare, Glencoe, IL, USA.",None
34228510,Using Geriatric Assessment to Guide Conversations Regarding Comorbidities Among Older Patients With Advanced Cancer.,2022,"Vogelzang, Nicholas J","Nevada Cancer Research Foundation NCORP, Las Vegas, NV.",None
34226144,Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.,2022,"Zou, Wei; Bhatia, Namrata; Koeppen, Hartmut; Paul, Sarah M; Shames, David; Yi, Jing; Matheny, Christina; Ballinger, Marcus; McCleland, Mark","Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.; Genentech Inc, South San Francisco, CA, USA.",sgadgee1@hfhs.org.
34216247,"First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.",2022,"Lambert, Stacie; Parikh, Apurvasena; Afar, Daniel E; Vosganian, Gregory","AbbVie Inc, Redwood City, CA, USA.; AbbVie Inc, Redwood City, CA, USA.; AbbVie Inc, Redwood City, CA, USA.; AbbVie Inc, Redwood City, CA, USA.",katriina.peltola@hus.fi.
34185953,Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.,2022,"Tran, Qui; Morris, Joan; Franklin, Janet","Amgen Inc., Thousand Oaks, California, USA.; Amgen Inc., Thousand Oaks, California, USA.; Amgen Inc., Thousand Oaks, California, USA.",None
34168284,A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis.,2022,"Berg, Deborah; Liu, Guohui; Kumar, Arun; Faller, Douglas V","Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.",gmerlini@unipv.it.
34158245,A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.,2022,"Kurland, Brenda","eResearch Technologies, Inc., Pittsburgh, PA.",jspecht@uw.edu.
33940581,Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.,2022,"Kassler-Taub, Kenneth B; Binder, Polina; Banks, Phillip; Lapuerta, Pablo","Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.",None
33939839,Nonhomogeneous Markov chain for estimating the cumulative risk of multiple false positive screening tests.,2022,"Golmakani, Marzieh K","Pfizer Inc., San Diego, California, USA.",None
33742652,Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.,2022/Feb/01,"Mundayat, Rajiv","*Pfizer Inc, New York, New York, USA.",None
32680895,Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden.,2022,"Romani, Claudio","UO Ematologia e Centro TMO, Ospedale Armando Businco, Cagliari, Italy.",f.efficace@gimema.it.
